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Background: Atopic Eczema (AE) is a common skin disease that results from a complex 
interplay between genetic and environmental factors.  It may be associated with other 
atopic phenotypes including; asthma, hayfever and food allergy.  The onset, typically in 
early childhood, can affect any part of the body but often occurs in the flexures of the 
elbows and knees.   
 
Aim and hypothesis: The aim of this thesis was to investigate the genetics of AE in the 
Bangladeshi families of East London to identify possible positive association with AE or 
other atopic diseases.  This involved investigating previously associated genes and also 
novel genes mapping to regions showing suggestive linkage from a microsatellite genome 
scan and data from a haplotype tagging SNP based Illumina based Array genotyping.  
  
Methods: A total of 70 families (n=384) individuals were recruited via the Paediatric 
dermatology Clinic at the Royal London Hospital.  Three genes; FOXP3, SPINK5 and TNC 
were assessed for genetic association with AE and other atopic phenotypes using a 
combination of techniques, such as PCR, dHPLC, sequencing, and Taqman SNP assays.  
FBAT software was used for statistical analysis.   
 
Results and future work: Suggestive associations with AE and other allergic disorders 
were identified in all genes examined however, none of these results remained significant 
(p-value<0.05) after correcting for multiple testing. As part of this project, several novel 
genes have been identified including TNC, JAK3 and KYNU.  To follow up these promising 
findings, replication studies could be conducted in other populations with AE in particular 
by large case-control analyses. In addition, with the development of high throughput SNP 
genotyping and, in particular, exome sequencing, the larger Bangladeshi families with 
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1. Overview of the skin  
 
The skin is the largest organ in the human body with a total surface area exceeding 2m² and 
accounts for about 15% of the total adult body weight (Odland, 1991).  It covers the whole 
external surface of the body and it is the main site of interaction with the surrounding 
environment.  Skin is composed of two distinct layers resting on a fatty subcutaneous layer; 
the outer layer is the epidermis, and the inner layer is the dermis (Eckert, 1989).  The 
epidermis is a stratified and continually renewing epithelium that differentiates in a basal to 
superficial direction to produce an effective barrier.  The dermis is a dense fibroelastic 
connective tissue mass that provides much of the elasticity and tensile strength.  The main 
functions of the dermis consist of protection from mechanical injury, and thermal 
regulation as well as containing receptors of sensory stimuli.  The lower most layer is the 
hypodermis or subcutaneous tissue, which act as a reserve energy supply, cushioning and 
protecting the skin in order to maintain its mobility over the underlying structures (Freinkel 
and Woodley, 2001).  The fine structure of the skin shows considerable regional variations 
concerning its thickness; skin is thickest on the palms and soles, where friction is needed 
for gripping, while the thinnest skin is found on the eyelids, which must be light and 
flexible (Odland, 1991). 
 
Skin and underlying tissue start to proliferate and differentiate as early as the fourth week 
of embryonic development.  Later in life, skin proceeds toward maturation and 
differentiation to more specialized structures.  Specialized structures formed by the skin 
include hair, teeth, nails, sebaceous glands, mammary glands, apocrine and sweat glands 




1.1.1 Structure and ultra-structure 
 
The epidermis is a stratified keratinizing epithelium, that renews itself continuously, in 
which desquamation is balanced by cell proliferation in the lower epidermis (Bouwstra et 
al., 2003).  It serves as a protective barrier against the invasion of harmful organisms and 
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foreign exogenous substances (Presland and Jurevic, 2002).  The epidermis is made of 
various cell types such as keratinocytes, melanocytes, Langerhans’ cell and Merkel cells.   
Keratinocytes are the major cell type making up 80% of the total epidermal cellular 
component, which moves continuously from epidermal basement membrane upwards to 
skin surface, forming several well-defined layers.  Morphologically, the viable epidermis 
consists of four continuous layers (from bottom to top) (Figure 1.1): stratum basal, stratum 
spinosum (5-15 layers), stratum granulosum (1-3 layers) and stratum corneum (5-10 
layers).  Two specialised epithelial structures found in the epidermis; the superficial part of 
sweat glands and hair follicles are connected to the epidermis but are located within the 

















Figure 1.1: A schematic representation of epidermal layers and cellular component.  
Morphologically, epidermis consists of four distinct layers that rest on the dermal 
epidermal junction (from bottom to top): basal layer, spinous layer, granular layer and 
cornified layer.  The major cell types of the epidermis are keratinocytes as well as other 
types such as melanocytes and Langerhans cells.  Adapted from (Eckert, 1989). 
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The stratum basale is usually described as only one cell thick layer which contains small 
and cuboidal (10-14nm) basal cells with large prominent nuclei, ribosome rich cytoplasm 
and tonofilament bundles.  The basal cell layer contains stem cells within this proliferative 
compartment, which is responsible for the epidermal regeneration (Kanitakis, 2002). 
Directly above this basal cell layer, the epibasal keratinocytes enlarge to form the spinous-
cell layer or stratum spinosum, which contains cells with numerous desmosomal plaques, 
helping to stabilize adjacent cells (Eady et al., 1998).  Desmosomes are specialized cell 
junctions that anchor keratin intermediate filaments and link neighbouring cells in order to 
provide structural strength for the epidermal layer (Kitajima, 2002). 
 
The Stratum granulosum or granular layer is located above the stratum spinosum layer; 
contains keratinohyalin granules, which are made of an assembly of histidin-rich proteins 
(mainly profilaggrin) and keratin (Eckert, 1989).  The keratinocytes of the upper spinous 
layer and granular cell layer contain smaller lamellated granules, which are known as 
lamellar bodies, contain ceramides, cholesterol and fatty acids (Landmann, 1988).  These 
granules play a major role in the process of desquamation and the formation of a lipidic 
envelope, which is essential for normal barrier function (Jackson et al., 1993).  Prior to 
terminal differentiation, the lamellated granules in the keratinocyte migrate toward the 
periphery.  These granules discharge their contents into the intercellular space, which  play 
a major role in barrier function formation of skin (Landmann, 1988). 
 
The outermost layer of epidermis is the stratum corneum or horny layer made of 
corneocytes.  These flattened cells have lost their nuclei and cyto-plasmic organelles and 
are eventually shed from the skin surface.  Corneocytes are made of a dense keratin 
filament matrix and a thick cornified envelope consisting of cross-linked proteins such as 
loricrin and involucrin (Ishida-Yamamoto et al., 1998). 
 
1.1.2 Cellular component of the epidermis 
 
The keratinocyte is the principle cell type in the skin, which varies in morphology 
according to their position in the epidermal layers.  Basal keratinocytes are columnar in 
shape; possess a basophilic cytoplasm and a large nucleus.  They are situated perpendicular 
to the basement membrane, to which they are attached via hemidesmosomes (Kanitakis, 
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2002).  Electronmicroscopically, small bridges can be visualized connecting keratinocytes 
to adjacent cells known as desmosomes as well as other types of intercellular junctions such 
as gap junctions and adherens junctions.  Keratins are the major proteins found within 
keratinocytes, belonging to the family of intermediate filament proteins which form the 
cytoskeleton of keratinocytes and provide strength to the epidermis (Denning, 2004).  
Matured keratinocytes are able to synthesize keratohyaline granules that secrete different 
proteins such as loricrin, filaggerin (FLG) and involucrin as well as participating in the 
final stages of epidermal differentiation (Kalinin et al., 2002). 
 
There are several other cell populations within the epidermal layer, namely melanocytes, 
Langerhans cells and Merkel cells.  Melanocytes are dendritic, pigment-producing cells 
distributed regularly among basal keratinocytes and originated from neural crest (Vancoillie 
et al., 1999).  The histological structure of melanocytes is recognized by their pale-staining 
cytoplasm, ovoid nucleus, and the pigment-containing organelles known as melanosomes 
which are membrane-bound structures within which a series of reactions produce melanin.  
Mature melanosomes are transported along the dendritic processes of melanocytes to the 
surrounding keratinocytes (Chu et al., 2003) where melanin plays an important protective 
role against ultraviolet radiation that is the main cause of skin cancer.  It functions by 
absorbing and scattering potentially harmful radiation, thereby minimizing 
deoxyribonucleic acid (DNA) absorption (Agar and Young, 2005). 
 
Merkel cells are specialized intraepithelial cells of skin and some parts of mucous 
membranes.  They function as slow adapting, type I mechanoreceptors located at sites of 
high tactile sensitivity mainly palmoplanter skin.  They are large oval cells found in the 
basal layer of the epidermis, most often associated with adjacent keratinocytes by 
desmosomal junctions (Halata et al., 2003).  Merkel cells are localized mainly in the basal 
layer of the epidermis and the epithelial sheath of hair follicles (Lacour et al., 1991). 
 
Langerhans cells (LCs) are mobile epidermal cells responsible for the recognition, uptake, 
and presentation of soluble antigen to sensitized T lymphocytes, thus, they generate an 
immune response against pathogens.  They are a special type of dendritic cells (DCs) 
randomly distributed in all epidermal layers, showing a preference for the suprabasal region 
(Romani et al., 2003).  The characteristic histological feature of Langerhan’s cells are the 
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presence of unique racket-shaped structures called Birbeck granules, which are special 
phagosomes present in Langerhan’s cells (Thorbecke et al., 1980).  
 
1.2 The dermis 
 
The dermis is a supportive and elastic structure lying between the epidermis and the 
adipose-containing hypodermis.  It contains a complex network of blood vessels and nerves 
important for the response to external stimuli (Freinkel and Woodley, 2001).  It consists of 
two layers: the more superficial papillary dermis and the deeper reticular dermis.  Papillary 
dermis forms upward projections alternating with epidermal rete ridges, allowing better 
adhesion between both layers.  It is composed of loose connective tissue of collagen and 
elastic fibers, vessels and nerve endings as well as different types of cells such as 
fibroblasts, mast cells and dermal dendrocytes (Kanitakis, 2002).  The reticular dermis 
consists of dense collagen bundles, thick elastic fibers and larger blood vessels arranged in 
layers parallel to the skin surface.  The majority of dermal fibers are made of collagen 
responsible for the mechanical support of the skin.  Fibroblasts are spindle-shaped cells, 
considered as the most abundant cell type in the dermal layer and most connective tissues, 
synthesizing various types of fibers, collagen (Kanitakis, 2002) and extracellular matrix 
(Bertolami and Bronson, 1990).  The dermo-epidermal junction undulates along the rete 
ridges of the epidermis and project into the dermis to provide support and serve as a barrier 
against exchange of cells and molecules (Freinkel and Woodley, 2001).  
 
1.3 Functions of the skin 
 
Skin exhibits different functions; the most important function is to provide a protective 
barrier against different environmental insults.  The stratum corneum is the main barrier of 
the skin, consists of conrneocytes embedded in lipid lamellar regions (Bouwstra et al., 
2003).  Its intact integrity acts as a two way barrier to control the inward and the outward 
passages of waste and electrolyte.  Injuries to skin as well as skin diseases may facilitate the 
entry of bacteria, viruses and fungi (Lee et al., 2006).  Furthermore, skin is a vital 
contributor in the process of body’s temperature regulation system.  It regulates body 
temperature by providing a sensory perception to thermoregulation and functions to permit 
heat loss or conservation via two types of thermo-receptor cells; cold and warm sensitive 
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receptors (Archer, 1998).  Heat may be lost throughout the skin surface in several ways 
such as convection, radiation and evaporation.  Skin optimizes such function through its 
rich blood supply which is vast beyond its biological nutritional requirements.  
Furthermore, it has mechanical properties designed to respond to mechanical forces.  It has 
a degree of mechanical strength to resist damage and repair itself if injured, and the dermis 
provides elasticity in response to mechanical trauma (Archer, 1998).  The immunological 
function of the skin relies on both: the cells in the epidermis and those in the dermis.  T 
lymphocytes are able to recognize antigens in association with products of the major 
histocompatibility complex (MHC) gene region of the antigen presenting cells (APCs).  In 
humans, most T cells are found in the dermal layer, usually grouped around venules and 
appendages (Archer, 1998).  Langerhan’s cells act as professional APCs in skin and other 
mucous membranes (Girolomoni et al., 2002). 
 
Studies have been conducted to address both genetic and phenotypic differences among 
different ethnic groups (Halder and Nootheti, 2003; Hsu et al., 2009; Yang et al., 2004a).  
In general, pigment-related conditions have been encountered more frequently among 
coloured skin than Caucasians especially in Asians.  Several studies showed that Asian skin 
may be more sensitive to chemicals due to a thinner stratum corneum and higher sweat 
gland density (Rawlings, 2006).  The stratum corneum barrier function against chemical or 
physical challenges is found to be more effective in individuals with darker skin (Reed et 






Atopy is defined as a prolonged increased production of Immunoglobulin E (IgE) in 
response to specific allergens exposure.  Atopy is indicated by a raised level of specific 
serum level of IgE to common environmental allergens and the individual is said to be 
sensitised to that allergen (Feijen et al., 2000).  Specific IgE antibodies are measured by the 
skin prick test or radioallergosorbent testing (RAST).  Atopic diseases include atopic 
eczema (AE), allergic rhinitis or hay fever and asthma, each defined by a group of 
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symptoms and signs.  Food allergy is another disorder which is strongly associated with 
specific allergic diseases such as AE and asthma (Gustafsson et al., 2000; Rhodes et al., 
2001; Rhodes et al., 2002).  It might be an IgE-mediated or non-IgE mediated 
hypersensitivity (Sicherer and Sampson, 2006).  Both genetic and environmental factors are 
responsible for allergic immune dysregulation and the development of different atopic 
diseases (Gold and Kemp, 2005).  Evidence from twin and family studies imply that there 
is a strong genetic component in the pathogenesis of AE and other atopic disorders such as 
asthma and hayfever (Hunter and Herd, 1994; Larsen et al., 1986).  However, 
environmental influence is also a curcial determinant of atopic diseases.  Several studies 
showed an increase in prevalence of atopic diseases worldwide and regional differences in 
disease incidence (ISSAC, 1998; Sanchez-Lerma et al., 2009; Stipic-Markovic et al., 2003; 
Williams et al., 1999).  It is likely that children who have inherited the ‘atopy gene(s)’ are 
more likely to get sensitised and develop atopic disease when subjected to a specific 
environmental trigger (Halapi and Hakonarson, 2004; Nickel et al., 2002). 
 
2.2 Immunological aspects of atopy and atopic eczema (AE) 
 
Atopic diseases begin when the immune system is dysregulated, leading to allergic 
inflammation and atopic symptoms (Gold and Kemp, 2005).  The immune system consists 
of two different components: the innate ‘non-specific’ and adaptive ‘specific’ immune 
systems (Clark and Kupper, 2005). 
 
2.2.1 Innate immune system 
 
The innate immune system is the first line of defense against environmental pathogens.  It 
senses microbes through a group of pattern recognition receptors (PRRs) (Janeway and 
Medzhitov, 2002) such as toll-like receptors (TLR) and nucleotide binding oligomerization 
domain (NOD) receptors.  Activation of these receptors results in the production of 
chemokines and cytokines, as well as activation of immune cells including natural killers 
(NKs), neutrophils (PMNs), and dendritic cells (DCs) (De Benedetto et al., 2009).  These 
responses occur rapidly to kill pathogens and minimize tissue damage.  In addition, the 
innate immune system controls the magnitude and the outcome of the adaptive immune 
response which provides immunological memory (Hammad and Lambrecht, 2008).  Skin 
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innate immune system consists of three main components: physical barrier, cellular and 
secretory elements (De Benedetto et al., 2009).  Recently, evidence suggests that there are a 
variety of defects both genetic and acquired in the innate immune system that account for 
the development and severity of AE.  These defects include: abnormalities in the epithelial 
barrier and decreased capacity to recruit innate immune cells such as NKs, PMNs and 
plasmacytoid dendritic cells (pDCs).  Also, reduction in antimicrobial peptides (AMPs) 
such as human B-defensins (HBDs) and cathelicidin (LL37) as well as dysfunction in PRRs 
such as TLR2/9 and NOD1/2 (Hata and Gallo, 2008) as shown in (Table 1.1). 
 
Table 1.1: Skin innate immunity and related defects identified in patients with AE.  
There are three main compartments of skin innate immunity system including: physical 
barrier, cellular and secretory elements, adapted from (De Benedetto et al., 2009). 
 
 
2.2.2 Adaptive immune system 
 
The adaptive immunity is antigen and pathogen specific.  This is a much stronger response 
although it often takes some time from infection to response which is why the innate 
immunity is crucial (Clark and Kupper, 2005).  Stimulation of the adaptive immune system 
requires antigen presentation which is when antigens are captured and presented to T-cells 
for recognition as non-self.  T-cells and B-cells are the main response cells of the adaptive 
34 
immune response.  Also, immune memory is produced through the adaptive immune 
response so that responses can be mounted quicker (Clark and Kupper, 2005) 
 
2.2.3 Initial mechanisms in the development of AE 
 
Initial events that induce atopic skin inflammation involve skin barrier disruption which 
might be pruritis-induced scratching.  This releases proinflammatory mediators such as IL-
1α, IL-1β, TNF-α and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Homey et al., 2006).  These cytokines bind to receptors on the vascular endothelium, 
which initiate the mechanism of adhesion to the endothelium, tethering and transmigration 
of inflammatory cells.  T-cell-endothelial cell interaction and the release of chemokines are 
important in acute phase of AE (Steinhoff et al., 2006).  In response to infection or injury, 
several mediators produced which play an important role in defining the nature of the 
immune response in AE (Maintz and Novak, 2007).  One example is IL-16 secreted by LCs 
which helps in the recruitment of T cells and has been found in lesional skin (Reich et al., 
2002).  Other chemokines have been reported to be upregulated in AE which may support 
leukocyte recruitment.  Of note, thymus and activation-regulated cytokine (CCL17), 
cutaneous T-cell-attracting chemokine (CCL27), macrophage-derived chemokine (CCL22) 
and others (Homey et al., 2006). 
 
2.2.4 A biphasic T-cell-mediated disease 
 
Inflammation in AE is biphasic: an initial phase predominated by Th2 cytokines that 
switches to a chronic Th1-dominated eczematous phase as shown in (Figure 1.2) (Novak et 
al., 2003).  Patients with AE have increased number of activated circulating T cells, mainly 
CD4+cells.  However, CD8+ cells are also of relevance in this disease (Werfel, 2009).  The 
role of CD8+ T-cells in AE is still not well known.  It has been reported that the number of 
CD8+ T-lymphocytes in AE patients is significantly higher than healthy controls in acute 
psychological stress usually accompanied patients with AE (Schmid-Ott et al., 2001a).  A 
study reported a positive association between the frequency of Der p1-specific CD8+ T-
cells and AE activity (Seneviratne et al., 2002).   
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Recruitment of T cells into the skin is regulated by various mediators which contribute to 
inflammation found in AE.  The acute phase of AE is strongly controlled by Th2 cytokines, 
especially IL-4, IL-5 and IL-13 (Romagnani, 1992).  IL-4 stimulates the differentiation of 
Th2 cells from CD+4precursors, also, together with IL-13 facilitates the IgE isotype 
switching in B cells and makes LCs more efficient in handling naïve proteins (Elbe-Burger 
et al., 2002).  Furthermore IL-4 induces the expression of the high-affinity receptor for IgE 
(FcεRI) (Geiger et al., 2000) and downregulates INF-γ-dependent macrophages responses.  
The second cytokine is IL-5 which activates the proliferation, differentiation and survival 
of eosinophils.  This leads to peripheral eosinophilia and increased IgE levels found in most 
of AE patients (Maintz and Novak, 2007).  IL-31 has been found to be highly expressed in 
the acute phase of AE (Neis et al., 2006).  Several evidences suggest that IL-31 may be an 
itch-causing cytokine in patients with AE and may correlate with the severity of the disease 
(Raap et al., 2008; Sonkoly et al., 2006).   
 
Expression of Th1 cytokines such as IFN-γ and IL-12 were not significantly detectable in 
acute phase of AE, whereas these cytokines in addition to GM-CSF could be found in 
chronic phase (Hamid et al., 1994).  IL-12 plays a major role in cell-mediated innate 
immune reaction to intracellular pathogens.  Both IL-12 and IL-18 induce the IFN-γ 
production of natural killer (NK) and T cells; enhance cytolytic activity of NK cells and the 
production of Th1 cells.  IFN-γ also increases microbiocidal function of macrophages, 
expression of class I and II MHC molecules and stimulation of APCs, Th1 cell 
differentiation and suppresses the proliferation of Th2 cells (Hamid et al., 1994).   
 
T regulatory (Treg) cells play a key role in AE.  These cells control the activation of 
autoreactive and T-effector cells and are fundamental for the control of peripheral tolerance 
to self-antigens.  There are two main groups of these cells including: CD4+ Foxp3+ Treg 
cells known as ‘naturally occurring’ Treg cells and adaptive Treg cells, which are produced 
upon activation.  Adaptive cells characterized by the secretion of high levels of IL-10 with 
or without transforming growth factor (TGF) (Akdis et al., 2005).  Foxp3 is a nuclear factor 
expressed in natural Treg cells and a group of adaptive Treg cells.  Mutation of Foxp3 results 
in immune dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) 




Figure 1.2:  Biphasic nature of AE.  The acute phase is initiated by activation of LCs 
which binds allergens by means of specific IgE and FcεRI which results in the production 
of monocyte chemotactic protein1 (MCP-1) and IL-16.  Allergen-derived peptides are 
presented to T cells by LCs which intiate a Th2 immune response.  The recruited 
monocytes differentiate into IDEC after migration into the skin and secrete IL-1, IL-6 and 
TNF-α.  The secretion of IL-12 and IL-18 facilitates the switch from Th2 to Th1/Th0 
immune response and results in the chronic phase of AE, adapted from (Bieber, 2008). 
 
2.2.5 Dendritic cells 
 
Dendritic cells are special cells found in lymphoid tissues and in other peripheral tissues 
such as the skin.  These cells act as antigen-presenting cells and consist of two major 
subtypes which have been found to play a crucial role in the pathophysiology of AE: 
myloid DCs and plasmacytoid DCs (Novak et al., 2007).  Myeloid DCs can be further 
divided into two populations: LCs and inflammatory dendritic epidermal cells (IDECs).  
Both subtypes have been found in lesional skin of patients with AE and express FcεRI 
(Bieber, 2007), however, they play different roles in AE.  In the early stage of AE, LCs 
predominate with initiation of the allergic immune response and transformation of naïve T 
cells into T cells of the Th2 type that produce IL-4 (Novak et al., 2004).  The aggregation 
of FcεRI on the surface of LCs facilitate the production of chemotactic factors such as 
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CCL2, CCL22, CCL17 and IL-16 as well as allergen presentation to T cells (Maintz and 
Novak, 2007).  The second type of myeloid DCs are IDECs which express Fc receptors for 
IgE and are more prominent in chronic AE lesions.  These cells induce Th1 cytokine 
production from T cells in comparison to LCs (Werfel, 2009).  In the peripheral blood of 
patients with AE, IgE bearing FcεRI+pDCs have been detected.  These cells promote Th2 
type immune response (Novak et al., 2007).  However, pDCs are not common in lesional 
skin of AE patients (Wollenberg et al., 2002), which contribute to the high susceptibility of 
AE patients to viral infections (Werfel, 2009). 
 
2.2.6 The contribution of mast cells, eosinophils and keratinocytes to AE 
 
Mast cells (MCs) are key effector cells in allergic response and innate immunity to bacteria 
which are found in large numbers in skin (Weber et al., 2003).  During the acute phase of 
AE, the number of mast cells is increased (Alenius et al., 2002).  These cells are involved 
in pruritus and the inflammatory process of AE via production of histamine, mast cell 
chymase (MCC) and tryptase.  Histamine release initiates pruritus by binding to histamine 
receptors on periphery sensory nerves as well as stimulating keratinocytes (KCs) to 
increase the production of different inflammatory mediators including nerve growth factor 
(NGF) (Kanda and Watanabe, 2003), IL-8 and IL-6 (Kohda et al., 2002).  Variants in the 
MCC gene (CMA1) have been associated with AE in many reports (Iwanaga et al., 2004; 
Mao et al., 1998; Mao et al., 1996), which suggest a contribution of this gene to skin 
inflammation and pruritus in AE (Rukwied et al., 2000). 
 
There are several reports supporting KCs as inducer cells of the inflammatory reaction in 
AE (Holgate, 2007; Wittmann and Werfel, 2006).  KCs have been known as an important 
cellular source of chemokines, which attract T cells of various groups (Wittmann and 
Werfel, 2006).  These include chemokine (C-X-C motif) receptor 3 (CXCR3) ligands such 
as chemokine (C-X-C motif) ligand 10 (CXCL10), which attract Th1 cells (Albanesi et al., 
2001) CCL17 and CCL22 that mainly attract Th2 cells by binding to CCR4 (Purwar et al., 
2006).  Also, KCs play a major role in innate immune response by expressing TLRs and 
secreting antimicrobial peptides after exposure to microbes (De Benedetto et al., 2009; 
McGirt and Beck, 2006).  Furthermore, these cells produce a special profile of mediators in 
response to proinflammatory cytokines, keratinocyte-derived thymic stromal lymphopoietin 
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(TSLP), may be of importance in AE (Homey et al., 2006; Soumelis and Liu, 2004).  This 
protein is believed to be involved in triggering the differentiation of inflammatory Th2 cells 
(Ito et al., 2005).  KCs respond to cytokines from T cells, among them, IFN-γ which is a 
potent keratinocyte-activating factor.  It activates surface molecules such as intercellular 
adhesion molecule 1 (ICAM-1), CD40 and MHC class I, chemokines such as CCL4, CCL5, 
CCL22 and CCL18 as well as several cytokines such as IL-1, IL-6 and TGF-β (Werfel, 
2009).   
 
Eosiophils are detected in high numbers in both lesional skin and peripheral blood of 
patients with AE (Kapp, 1993; Leiferman et al., 1985; Simon et al., 2004).  Suppression of 
eosinophil apoptosis in patients with AE, mediated by IL-5 and GM-CSF, results in 
eosinophil accumulation (Wedi et al., 1999).  Also, acute psychological stress in AE 
patients can lead to further increase in eosinophil numbers as shown in some studies 
(Schmid-Ott et al., 2001a; Schmid-Ott et al., 2001b). 
 
2.3 Prevalence of atopic diseases 
 
Prevalence of a disease is the percentage of the cases present in the population at a 
particular time (Kramer, 1988).  The International Study of Asthma and Allergies in 
Childhood (ISSAC) reported a significant variation in the prevalence of atopic diseases 
worldwide (ISSAC, 1998).  The prevalence of atopic conditions in Swedish school children 
such as AE, asthma and allergic rhinitis was; 10-20 %, ,10–20% and  20% respectively 
(Aberg et al., 1995).  A recent report on Australian preschool children showed a twelve 
month period prevalence of reported AE, asthma, and allergic rhinitis being; 18.8%, 23.7% 
and 20.8% respectively (Tai et al., 2009).  A large cohort study conducted in the United 
Kingdom (UK) to establish the prevalence of allergic diseases in a complete 18-years 
follow up period, showed AE had the highest prevalence at 36.5%, followed by asthma 
22.9% and allergic rhinitis 11.4% in children (Punekar and Sheikh, 2009).  Food allergy 
affects approximately 5% to 8% of children. It has increased substantially over the last 
decade in similar pattern to that previously seen for other atopic conditions (Hong et al., 
2009).  Most of these reports concluded that atopic diseases are increasing in developed 
countries.  Such increase cannot be explained easily by genetic factors only because it has 
occurred within one or two generations.  Thus, the environmental factors such as paternal 
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or maternal smoking, indoor heating system, allergens exposure and Western life-style are 
playing a major role in the clinical expression of atopic disease (Cogswell, 2000). 
 
2.4 Clinical manifestation of atopic diseases 
 
Atopic eczema (AE) is the cutaneous manifestation of a systemic disorder which can also 
give rise to allergic rhinitis and asthma (Leung and Bieber, 2003; Spergel and Paller, 2003).  
AE usually begins in early infancy and considered as the initial step in the “atopic march” 
that leads to asthma and allergic hayfever in most cases (Wuthrich et al., 2007).  
Experimentally, induction of allergic skin inflammation by epi-cutaneous application of 
allergens has been found to initiate systemic allergic reaction and airway hyper-
responsiveness which is the hallmark feature of asthma (Beck and Leung, 2000). 
 
Diagnosis of atopic diseases is difficult to define, although these diseases are characterized 
by a collection of symptoms and signs.  Asthma characterised by signs and symptoms of 
intrathoracic airway tract obstruction after exposure to specific factors such as viral 
infection, allergens and exercise.  The British Thoracic Society (BTS) and the Scottish 
Intercollegiate Guidelines Network (SIGN), provide updates and guidelines of diagnosis 
and managemet of asthma.  The diagnosis of asthma depends mainly on clinical history and 
subsequent findings.  Clinical features that increase the probability of asthma including 
more than one of the following symptoms: Wheezing, difficulty in breathing, chest 
tightness and cough (Levy et al., 2009).  Allergic rhinitis or hay fever characterised by 
cold-like symptoms including: nasal congestion, nasal and eye itch and excessive sneezing.  
The cause is likely to be allergic when these symptoms occur seasonally but sometimes 
non-allergic causes need to be considered in the diagnosis as approximately half of children 
have symptoms at all seasons of the year (Gold and Kemp, 2005). 
 
Food-induced allergic reactions are manifested in several symptoms involving skin, 
respiratory tract and digestive system.  Currently, various methods used to diagnose food 
allergy consists of systematic history and physical examination, followed by laboratory 
tests such as prick skin tests (PSTs) and measurement of specific IgE levels.  After that, 
elimination diets and usually food challenges to confirm the diagnosis (Sicherer and 
Sampson, 2006).  IgE-mediated reactivity to food, as diagnosed by different methods 
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including: double-blind, placebo-controlled oral food challenge (DBPCFC), and/or serum 
levels of specific IgE ≥0.7 kIUa/L on CAP System fluorescein-enzyme immuno-assay 
testing, has been identified in 37% of children with moderate to severe AE (Eigenmann et 
al., 1998).  The DBPCFC used to be the best measurement for the diagnosis of food 
allergy, which has been known to correlate with clinical improvement on food restriction 
(Sampson, 1997).  On the other hand, the combination of other methods such as patch 
testing and the measurement of food-specific IgE levels has been found to have a high 
predictive value of 94% for hen’s egg and 100% for cow’s milk (Roehr et al., 2001; 
Sampson, 2001)  Atopic eczema will be discussed in more details in the following section. 
 




Atopic eczema is an itchy chronic inflammatory skin condition with onset typically in early 
infancy and childhood and it may persist or start in adulthood as well (Breuer et al., 2006).  
The manifestations of AE are the product of complex interactions between environmental 
factors, susceptibility genes, skin barrier dysfunction and various immunological responses 
(Leung et al., 2004).  There are two types of eczema: the allergic or ‘extrinsic’ type and the 
non-allergic or ‘intrinsic’ form.  The extrinsic form affects approximately 70% to 80% of 
adult patients with AE.  It accompanied by sensitisation toward common environmental 
allergens and elevated serum IgE levels.  However, the second type is characterised by low 
IgE serum levels and absence of any other signs of allergen sensitisation (Novak et al., 
2003). 
 
3.2 Clinical features 
 
Atopic eczema is characterised by varying degrees of dry skin (xerosis) and intense 
itchiness (pruritis).  Pruritis leads to scratching which results in different morphological 
changes such as excoriation, lichenification and disruption of skin barrier.  The 
combination of both dry and scratched skin predispose to bacterial infections such as 
Staphylococcus aureus (S. aureus) (Correale et al., 1999). 
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Atopic eczema is a chronic dermatosis, characterised by exacerbation and remissions.  The 
clinical manifestations of AE vary with age; three stages can often be identified.  The first 
stage is the infantile stage that is up to two years of age (Rudikoff and Lebwohl, 1998). 
This stage characterised be severe pruritis, red, scaly, crusted and some times weeping 
plaques on the cheeks, neck area and trunk and on the extensor surfaces of the lower limbs 
(Figure 1.3).  The nasal and diaper areas are usually spared.  Pruritis is the predominant 
symptom, which may cause sleep disturbance and infants often rub themselves against any 
hard object to feel relieve (Rudikoff and Lebwohl, 1998).  Onset is typically within the first 
six months of age, with 80% of cases presented within the first year of life (Oranje and de 
Waard-van der Spek, 2002).  In childhood stage, which is from two to twelve years of age, 
the previously mentioned clinical features occur in the flexural areas, mainly in front of the 
elbow (antecubital) and posterior region of the knee (popliteal fossae) shown in (Figure 1.3) 
and the volar region of the ankles, neck and wrists.  Thickened lesions show lichenification 
and excoriation due to constant scratching (Rudikoff and Lebwohl, 1998).  Finally, the 
adult phase begins at puberty and usually continues through adulthood. It is characterized 
by lichenification involving flexural areas, face and neck, dorsa of hands, feet, fingers and 
ankles.  The hands wrist, feet, ankles and finger are also commonly involved. The eruption 
typified by dry, scaly papules and plaques that lichnified due to lesion chronicity (Akdis et 
al., 2006). 
 
Acute and subacute skin lesions are often seen in children, characterised by severe pruritis 
erythematous papules associated with excoriation and serous exudates secondary to 
scratching.  Chronic lesions have the same features, with the addition of alopecia and 











A)                                                                           B)           
                     
Figure 1.3: Clinical presentation of childhood atopic eczema A) weeping plaques on 
infant’s cheeks B) Acute (left) and chronic (right) lesions at the posterior region of the 
knee.  Adapted from (Leung and Bieber, 2003; Rudikoff and Lebwohl, 1998).   
 
3.3 Diagnosis and diagnostic criteria  
 
Atopic eczema is difficult to precisely define due to its intermittent course and variable 
clinical presentations.  Several sets of diagnostic criteria have been proposed (Williams, 
2005).  The diagnostic criteria for the main clinical presentation of AE was proposed by 
Hanifin, Lobitz and Raijka in 1980, which listed the main clinical features of AE (Hanifin 
and Raijka, 1980).  However, they were found to often be unrepeatable and complex.  As a 
result, they were used as a basis for the UK working party’s Diagnostic criteria for AE 
which is a refinement of the original Hanifin and Rajka diagnostic criteria, explained by 
Williams et al.  It requires an itchy skin condition in the last twelve months plus three or 
more of the following: family or personal history of atopy, typical pattern of flexural 
distribution, history of other atopic diseases, onset below the age of two years and history 
of a generally dry skin (Williams, 2000; Williams et al., 1994a; Williams et al., 1994b; 
Williams et al., 1994c).  These guidelines have now been rigorously validated by several 
groups and in many different ethnic groups and have become the standard method of 
evaluating AE. 
 
In the diagnosis of the severity of AE there are three main systems.  The Scoring Atopic 
Dermatitis (SCORAD) (Oranje et al., 2007; Sprikkelman et al., 1997).  The Eczema Area 
and Severity Index (EASI) (Barbier et al., 2004; Hanifin et al., 2001) and the Six Area, Six 
Sign Atopic Dermatitis (SASSAD) (Berth-Jones, 1996; Charman et al., 2002)  systems are 
all in use.  The SCORAD system was developed by the European Task Force on Atopic 
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Dermatitis in 1993 and the most widely used to determine the extent and severity of AE.  
The severity part of this index comprises the scoring of AE on six clinical signs of the 
disease with a score ranging from 0-3 for each sign.  The extent of AE is assessed using the 
rule of nines which calculates the affected areas as a percentage of the whole body area 
(Oranje et al., 2007).  Added to this is a score for itch and sleep loss.  It is often then 
interpreted as mild if the score is less than 15, moderate if the score is 15 to 40 and severe 
disease if more than 40 (Kunz et al., 1997).  The other index, SASSAD proved to be an 
effective method for assessing disease activity in AE patients.  The maximum score is 108 
obtained by grading 6 signs; exudation, excoriation, redness, dryness, lichenification and 
fissuring.  Each parameter was placed on a scale of zero (absent), one (mild), two 
(moderate) and three (severe) at each of the six body sites; legs, feet, head, arms, neck and 




Most patients with AE are colonized with S. aureus, which is a frequent cause of 
exacerbation and secondary infection of their skin disease.  More than 90% of atopic 
individuals compared with 5% non-atopic harbour S. aureus in their lesions.  Pruritis can 
cause excessive itching, resulting in damages, erosions and excoriation, leading to impetigo 
which needs antimicrobial treatment (Leung and Bieber, 2003). 
 
There is increasing evidence that patients with AE have a higher propensity toward 
disseminated viral infections such as Herpes simplex infection which may cause eczema 
herpiticum or eczema vaccinatum and may progress to generalized disseminated herpes 
infection (Howell et al., 2006).  In addition to the physical morbidity, AE can cause social, 
emotional, and financial stress in a family looking after a child with moderate to severe 
eczema (Kemp, 1999). 
 
3.5 Epidemiology  
 
Epidemiology is the study of diseases, consists of analyzing the occurrence and distribution 
of diseases and the factors responsible for their spread (Kramer, 1988).  There is wide 
variation in the epidemiology of allergic diseases worldwide and the prevalence rates of AE 
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and other allergic diseases differ substantially among different Asian populations (Asher et 
al., 2006).  Variations in environmental and ethnic background in Asians may provide 
insights on the environmental and genetic determinants of AE and allergy.  This could be 
looked at as two main broad topics, prevalence and social and ethnic variation.  
 
3.5.1 Prevalence of AE 
 
Prevalence of AE has increased over the last few years in developed countries; hence 
remain much lower in agricultural regions such as Eastern Europe, China and Africa.  
Higher prevalence has been reported in urban areas than in rural areas of developed 
countries and the disease is more frequent in higher socio-economic groups (Grize et al., 
2006; Schmid-Grendelmeier et al., 2001; Taylor et al., 1984).  This suggests a link to the 
"hygiene hypothesis", which indicates that the absence of early childhood exposure to 
different infections increase susceptibility to allergic conditions (Strachan, 1989).  Several 
studies revealed that children raised up in farms and exposed to different environmental 
exposures including animal sheds, certain foods and hay lofts have lower prevalence of 
atopic disorders (Braun-Fahrlander et al., 1999; Kilpelainen et al., 2000; Riedler et al., 
2000; Von Ehrenstein et al., 2000).  Usually AE starts early in infancy, a total of 45% of all 
cases begins within the first six months of age, 60% starts during the first year, and 85% 
begin before the fifth year of life.  More than half of children, who are affected early do not 
have any signs of IgE sensitization, but they develop IgE sensitization later on (Illi et al., 
2004). 
 
A number of studies have reported an increased prevalence of AE worldwide.  In 2000, the 
prevalence of AE in Oregon in the United State school children to be as high as 17% 
(Laughter et al., 2000).  A retrospective chart review of 320 children born in 1994 from a 
well baby clinic in Finland reported that the prevalence of AE is 16% during the first 5 
years of age, 49% of them diagnosed between the ages of 6–24 months (Lehtonen et al., 
2003).  Williams stated that the cumulative prevalence of AE average from 10% to 15% in 
developed countries (McNally et al., 2001).  Ninan and Russel’s  study of Scottish school 
children aged from 8-13 years showed an increase in the prevalence from 5.3% in 1964 to 
12% in 1989 (Ninan and Russell, 1992).  Results of comparative studies in former West 
and East Germany confirmed the association of environmental and life style role in the 
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expression of AE and other atopic diseases (Schafer et al., 2000).  A study conducted 
among British children (n=1104) showed that AE developed in the first year of life in 60% 
of them, three quarters of these children developed AE in the first six month of life.  
Furthermore, 20% of children between 3–11 years of age were reported to have AE (Kay et 
al., 1994).  These studies indicated that the prevalence of AE is increasing worldwide, 
mainly in industrialized countries. 
 
3.5.2 Social and ethnic variation 
 
There is strong evidence that prevalence of AE is higher in developed countries.  People 
who move to industrialized areas may become more vulnerable than the local people (Ben-
Gashir et al., 2004).  A survey was undertaken to investigate a possible ethnic differences 
among 693 junior school children in London suggested that children of black Caribbean 
origin born in London have been at higher risk of AE when compared with their white 
counterparts; the prevalence was 16.3% and 8.7% respectively (Williams et al., 1995).  A 
surveys conducted in 188 patients and more than 2000 family members, suggested that AE 
occurs more frequently in females than males by a ratio of 1.5:1 (Kuster et al., 1990).  
 
There is a significant association between AE and high socioeconomic class measured by 
household conditions, family size, and parent’s occupation.  It suggests that environmental 
factors that correlate with a life style of the West may play a major role in AE prevalence 
variation (von Mutius et al., 1998).  The influence of social class could be manifested in a 
number of different ways related to high maternal education status including: frequent 
consultations, increased demand to prescribed medicines especially corticosteroid that 
might lead to increase chronicity or reoccurrence of AE (McNally et al., 1998). 
 
Approximately half of the world population lives in Asia.  The current prevalence of AE 
and other atopic phenotypes such as asthma in Asia is still relatively low compared with 
that noticed in Europe and USA. There is a lack of reports highlighting the role of 
environmental and genetic factors which may be important in the pathogenesis of AE and 
other atopic diseases in the Bangladeshi population.  In great part, this relies on evidence 
from the Caucasian population, but very little data is provided about AE in the Bangladeshi 
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population.  The present thesis is the first to study AE in an Indian subcontinent population, 
the Bangladeshi population residing in the East London area of the U.K.  Epidemiological 
data were collected using questionnaires covering a wide range of information related to 
probands and their first degree relatives.  This will be discussed in more details in the 
general methods. 
 
3.6 Aetiology and risk factors 
 
The aetiology of AE is unknown, although many lines of evidence indicate that it is a 
multi-factorial disorder caused by interactions between environmental and genetic factors 
(Purvis et al., 2005).  The rapid acceleration in the prevalence of AE has been reported in 
several studies.  These results can not be explained entirely by a change in the genetic 
make-up of individuals, which indicates that environmental factors may affect the 
genetically susceptible individuals (McNally et al., 1998). Studies conducted after the 
reunification of West and East Germany supported the major role of environment in the 
pathogenesis of AE and other atopic disorders.  These studies revealed that the East 
German population had a lower prevalence of atopic disease compared with their Western 
counterparts, but after reunification, the prevalence of atopic diseases including AE with 
the adoption of the new western life style in the east has increased (von Mutius et al., 1994; 
von Mutius et al., 1998).  Several environmental factors such as aeroallergens, infection 
and diet habits have been suggested to have an important role in the development of atopic 
diseases and AE exacerbations (Williams, 2000). 
 
3.6.1 The hygiene hypothesis 
 
An increased prevalence rate of allergic disease could be related to the reduction of early 
childhood infectious disease through increased use of antibiotics and widespread use of  
vaccination, which is known as the “hygiene hypothesis” (Gern and Weiss, 2000).  This 
hypothesis suggests that a more hygienic environment and fewer childhood infections in 
Western countries may be blamed for the increase in atopic prevalence over the last several 
decades (Renz et al., 2006).  In support of this hypothesis, the frequency of several atopic 
diseases has been found to be inversely associated with early childhood exposure to 
infections through presence of older siblings at home, day care attendance and farm 
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residence (Kramer et al., 1999; Riedler et al., 2001).  On the other hand, different studies 
failed to find a protective role of early childhood infections on AE (McKeever et al., 2002).  
Another study was conducted to determine the role of childhood infection on AE revealed 
that some hygiene-related factors such as day care attendance, family size, antibiotics use 
and pet ownership do not appear to have a protective role against allergic diseases (Benn et 
al., 2004).  Therefore, evidences demonstrated by these studies are inconsistent. 
 
3.6.2 Triggering factors of AE 
 
Environmental and external factors have been shown to play a crucial role in atopic 
diseases and AE.  Certain factors are associated with initiation and/or exacerbations of 
atopic diseases are referred to triggering factors.  These triggering factors include low 
humidity and low temperatures, aeroallergen exposure, smoke, different foods, contact with 
animals and exposure to other irritants (Wuthrich et al., 2007).  House dust mites (HDMs) 
act as aeroallergen substances that are common inhabitants in homes in warm climates.  
There are two main groups of allergens derived from mite, Dermatophagoides (Der 1) and 
(Der 2) allergens, are found in more than 90% mite-sensitized patients (Kramer et al., 
2006).  Several studies support the role of HDMs as a powerful immunogens which have 
been shown to initiate IgE and IgG antibody response (Smith et al., 1998).  The 
relationship between dust mite exposure and eczema is far more complex and controversial.  
Few studies showed that homes of patients with AE have higher numbers of mites than 
homes of healthy people (Colloff, 1992).  In other studies, reduction of environmental 
exposure to dust mites resulted in significant clinical improvement (Sanda et al., 1992; Tan 
et al., 1996).  Although, in other controlled trial no overall disease improvement was 
observed in adult patients with AE after undertaking a year of HDMs avoidance measures 
that resulted in reduced exposure to specific allergen (Gutgesell et al., 2001).  Moreover, 
the effect of specific immunotherapy (SIT) on AE is not known yet, although some studies 
revealed promising results in the treatment of this chronic condition (Nahm et al., 2008; 
Werfel et al., 2006). 
 
Staphylococcus aureus, found in approximately 90% of AE skin lesions (Leyden et al., 
1974), produces toxins which can penetrate the damaged epithelium and may activate 
inflammatory immune respose (Leung, 1999).  Several defects in human immune defense 
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account for the increased incidence of skin infections in atopic patients.  These defects 
consist of abnormalities in the physical barrier of the epidermis, changes in microbial PRRs 
such as TLRs and NOD receptors, and a diminished ability to increase the expression of 
AMPs during inflammation.  Also, cathelicidin, human-β defensin 2 and 3 (HBD-2), 
(HBD-3) lower in lesional skin of atopic patients compared to normal skin or other 
inflammatory skin diseases (De Benedetto et al., 2009).  Approximately 75% of patients 
with AE produce IgE against S. aureus exotoxins which correlates with the severity of AE 
(Leung et al., 1993; Ruzicka, 1998).   Persistence of these bacteria on the skin may result in 
continuous activation of T-cells and release of pro-inflammatory mediators which leads to 
chronic inflammation (Eedy, 2001).  Furthermore, other defects in the immune defence 
barrier of atopics include deficiency in plasmacytoid dendritic cells, which are thought to 
play an important role in antiviral immune response.  Understanding the cause of these 
defects may permit therapeutic intervention to control cutaneous infection in atopic 
individuals and potentially reduce the severity of this disorder (Hata and Gallo, 2008). 
 
There is major confusion and controversy in the literature over the contribution of food 
allergy in the etiology of AE.  Several reports over the last ten years demonstrate a 
prevalence of food allergy in children with AE that ranges from 33% to 63% (Anderson 
and Dinulos, 2009).  Laboratory and clinical investigations have identified that food allergy 
plays an important role in children with AE.  The most common foods allergens were egg, 
milk, shellfish, cornstarch, soybeans, peanuts and fish.  Approximately 40% of infants and 
young children with moderate or severe forms of AE have food allergy.  All symptoms 
resolved when the causal food allergen were withdrawn from the patient’s diet but might be 
encountered again if the food re-introduced (Sicherer and Sampson, 1999).  A recent report 
by Bath-Hextall et al., (2008) showed that 75% of parents have used the exclusion of foods 
in their children in an attempt to control their disease.  The study concluded that there is a 
potential benefit to recommend an egg-free diet in children with positive specific IgE to 
eggs.  Although, no evidence supports the use of such method in children with AE without 
prior IgE testing (Bath-Hextall et al., 2008).  However, dietary restriction is difficult 
because approximately 35% of children with AE have positive prick-test results to different 
types of food (Kusunoki et al., 1998).  Also, the most common foods cause allergies are 
foods that are widely-used in the food supply such as peanuts, milk, eggs and wheat (van 
Reijsen et al., 1998).  Well-designed studies investigating the exclusion of foods in children 
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with positive IgE sensitivity to foods have not been completed (Anderson and Dinulos, 
2009). 
 
Other factors suggested to play a role in AE development such as maternal and infant 
allergen avoidance (Hide et al., 1994; Hide et al., 1996; Host et al., 2008) and breast 
feeding (Bergmann et al., 2002; Kull et al., 2004; Kull et al., 2005). 
 
4. Strategies in analysis of the genetic component of multifactorial 
diseases 
 
4.1 An Overview of the International HapMap Project 
 
The International HapMap Project was started in 2002 to provide a public resource to 
facilitate medical genetic research (International HapMap Consortium 2005).  The goal was 
to map and understand the patterns of common genetic variation in the human genome  
(Bentley, 2000; Thorisson et al., 2005).  These include: detecting polymorphisms, their 
frequency in different populations, and haplotype structure in order to facilitate the search 
for the genetic causes of human disease (Healy, 2006).  The first phase of the project was 
the genotyping of more than one million single nucleotide polymorphisms (SNPs) in 269 
individuals across four populations: Han Chinese, Japanese, Caucasian and Yourba 
(Nigeria) (International HapMap Consortium 2005) (Altshuler et al., 2005). This was 
followed by more than 3 million SNPs being genotyped in the second phase of the project 
(International HapMap Consortium 2007).  The most recent release is the third phase of 
HapMap project which contains genotype data from 1115 individuals from eleven 
populations (http://www.hapmap.org).  
 
The HapMap Web site at http://www.hapmap.org is one of the primary source of genetic 
data for geneticist, all data available was produced as part of the International Haplotype 
Map Project. The HapMap Web site provides a number of tools that allow easier access and 
analysis of data as well as download data.  These tools consist of instructions for retrieving 
genotype and frequency data, viewing haplotypes graphically, examining linkage 
disequilibrium (LD) patterns, and picking tag SNPs for association studies (Thorisson et 
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al., 2005).  Tag SNPs are representative SNPs in a specific region of the genome with 
strong LD to other variants and they can define common haplotypes.  Two SNPs that are 
totally correlated have an r-squared (r2) equal to 1, so each one perfectly ‘tag’ the other.  
Selecting one SNP from a group of SNPs in LD reduce genotyping requirements by 
excluding redundancy in the information obtained by the SNPs (Manolio et al., 2008; 
Stram, 2004). 
 
The discovery of functionally significant genetic variation lies at the centre of these efforts, 
and there has been an extensive progress in understanding the common patterns of SNPs in 
humans.  These are the most abundant variation type with estimated 10-15 million common 
human SNPs reported in the public database (Altshuler et al., 2005; Hinds et al., 2005). 
 
4.2 Genetic variants 
 
There are approximately 3.3 billion bases of DNA sequence now freely available for use in 
medical and scientific researches.  A very high percentage of genome sequence was found 
to be exactly the same in all subjects sequenced, addressing the relatively small proportion 
of genomic variation among individuals (Burton et al., 2005).  In that small variable 
proportion, are thought to be found the factors that result in disease susceptibility and 
variation in complex diseases present in populations (Burton et al., 2005; Feuk et al., 
2006).  There are two hypotheses: the ‘common disease common variant’ hypothesis and 
‘multiple rare-variant’ hypothesis (Healy, 2006).  The first hypothesis suggests that a few 
common polymorphisms of small effect found in the genome may cause disease in affected 
individuals (Pritchard and Cox, 2002), while the multiple rare-variant proposes that 
affected individuals carry rare genetic variants that differ from case to case (Healy, 2006). 
 
Genomic variation falls into different categories.  These include: variable number of 
tandem repeat (VNTR) (Nakamura et al., 1987), short tandem repeat or microsatellite 
(STR) (Weber and May, 1989), single-nucleotide polymorphisms (SNPs), and copy 
number-variation (CNV) (Dhami et al., 2005; Sharp et al., 2005; Tuzun et al., 2005) . 
Some of these variants discussed below. 
 
51 
4.2.1 Microsatellite Markers 
 
Microsatellites are short tandem repeats (STRs) contain repetitive sequence of two or more 
basepairs (bps) (Litt and Luty, 1989; Weber and May, 1989).  microsatellites have been 
used widely in linkage analysis and population genetic studies (Nakamura, 2009).  They 
have higher heterozygosities and are more informative for most studies than biallelic 
markers (Kidd et al., 2004).  Microsatellites are highly polymorphic between individuals 
resulting in their extensive use for genetic mapping.  Changes in the lengths of 
microsatellites also is linked to number of genetic disorders and global instability of 
microsatellites is associated with different types of cancer (Bayliss et al., 2004).  
 
4.2.2 Single nucleotide polymorphisms (SNPs)  
 
 Single Nucleotide Polymorphisms or SNPs are the most abundant genetic polymorphisms 
and are defined as a single base difference at a specific location of the genome (Kim and 
Misra, 2007).  For a variation to be considered as a SNP instead of mutation, it must occur 
in at least 1% of the general population.  They make up to 90% of all human sequence 
variants and occur, an average, every several hundred bases along the human genome 
(Brookes, 1999).  Generally, SNPs occur much less frequently in coding regions of the 
genome than noncoding regions.  Within coding regions the nucleotide diversity is 
approximately four-fold lower with about 50% resulting in nonsynonymous codon changes 
(Li and Sadler, 1991; Nickerson et al., 1998).  SNPs in protein-coding sequence are either 
synonymous or non-synonymous.  Nonsynonymous SNPs change the amino acid sequence 
and also known as coding SNPs, while the synonymous SNPs do not result in any change 
in amino acid sequence (Brookes, 1999).  SNPs found in noncoding regions, although they 
do not change encoded proteins, serve important genetic markers for comparative genetic 
studies.  Also, SNPs present in regulatory regions of a gene can affect rates of transcription 
causing alterations in the production of encoded protein (Kim and Misra, 2007).  They are 
considered as excellent genetic markers for identifying candidate genes involved in disease 





4.2.3 Copy-number variants (CNVs) 
 
Copy number variants (CNVs) may be defined as a form of genomic structural variation 
involving a segment of DNA that is present at a variable copy number, when compared to 
the reference genome.  These segments can be deleted, translocated, inverted, or duplicated 
and when variants involve segments of DNA greater or equal than 50kb, they known as 
large-scale copy-number variants (Feuk et al., 2006).  CNVs are thought to affect gene 
expression level in two ways: directly by altering the actual dosage of a particular gene that 
affects quantity of the gene products or an in indirect way by affecting gene transcriptional 
regulatory element.  For example, a deletion of a repressor segment may lead to high 
transcriptional levels of the associated gene (Rodriguez-Revenga et al., 2007).  Several 
reports showed associations between some CNVs with common diseases, including 
reduced numbers of CNV of  Fc receptor, IgG, low affinity III (Fcgr3) with 
glomerulonephritis in rats and humans (Aitman et al., 2006) and increased numbers of 
CNVs of chemokine (c-c motif) ligand 3-likes 1 (CCL3L1) with human immunodeficiency 
virus-type 1 (HIV-1) susceptibility (Gonzalez et al., 2005).  
 
 4.3 Linkage Disequilibrium (LD) 
 
Linkage disequilibrium is the non-random (more often than would occur by chance) 
association between SNPs of different loci when they are found together on the same 
haplotype (series of alleles at linked loci along a single chromosome).  That is due to the 
physical proximity on the same chromosome and a shared evolutionary history (Healy, 
2006).  When two loci have a high level of LD between them, the genotype of one of them 
will predict the genotype of the other one; this forms the basis of haplotype tagging (Healy, 
2006; Johnson et al., 2001).  Knowledge of the common haplotypes and the SNPs that tag 
them may be used to identify the complex patterns of LD between adjacent markers, thus 
reducing the number of SNPs that should be genotyped.  This due to the fact that careful 
chosen SNPs in the region will provide enough data to predict much of the information 
about the adjacent SNPs in that region (Johnson et al., 2001).  LD play an important role in 
fine mapping of genes involved in complex disease (Horikawa et al., 2000) and in 
suggested genomewide association studies (Risch and Merikangas, 1996). 
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Different measures have been proposed for evaluating the strength of LD.  Most of them 
capture the strength of association between two SNPs.  There are two important pairwise 
measures of LD including: (r2) and (D').  In both measures, 0 indicates to no 
disequilibrium, while 1 corresponds to complete disequilibrium, although the interpretation 
is slightly different (Devlin and Risch, 1995; Pritchard and Przeworski, 2001).  D' is equal 
to 1 if just two or three of the possible haplotypes are present, and it is <1 if all four 
possible haplotypes are present.  When D' is <1 this indicates that historical recombination 
has occurred between two sites.  Also, D' is not reliable if the minor allele frequency 
(MAF) is low for one SNP.  Recurrent mutation can cause D' to be <1, however, for SNPs 
this is considered as being less likely than recombination.  The parameter r2 acts as the 
statistical correlation between two sites, and it equals 1 if two haplotypes are present (Wall 
and Pritchard, 2003). 
 
4.4 Search for susceptibility genes for complex traits 
 
4.4.1 The genetic architecture of common complex traits 
 
The most effective approaches used in the search for genetic variants that predispose to 
common diseases depend on the the underlying genetic model which is usually unknown.  
In monogenic diseases the genetic model can be dominant which caused by a single 
mutated gene or recessive where two copies of the mutated genes are required.  These 
models show a specific inheritance patterns in families that allow the single highly 
penetrant causual mutations to be identified using linkage studies (Lango and Weedon, 
2008).  In contrast, polygenic disease can be inherited in families, but does not show a 
simple inheritance pattern.   This might be due to many of common genetic variants which 
have  only a modest effect on disease risk (affecting relative risk by <50%) which known as 
the common disease/common variant hypothesis (CDCV) (Reich and Lander, 2001).  
Relative risk (RR) is the risk of developing a disease relative to exposure (Sistrom and 
Garvan, 2004).  However, several research groups suggested that rare and modest-risk 
alleles may explain a large number of the variation in susceptibility to common diseases 
(Pritchard and Cox, 2002; Pritchard et al., 1995; Terwilliger et al., 2002).  This indicates 
that both common and rare alleles are important in polygenic diseases. 
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4.4.2 Methods for gene identification in common complex traits 
 
Over the last decade, the two main approaches that have been used to identify causative 
genes for complex traits are positional cloning using genome-wide linkage scans and 
candidate gene association studies.  Linkage approach has been successful in identifying 
genes following Mendelian pattern inheritance, but less successful with polygenic 
inheritance pattern (Altmuller et al., 2001).  A paper by Risch and Merikangas in 1996 
explained that genetic association strategy is more powerful than linkage strategy in 
identifying common variants of modest effects (Risch and Merikangas, 1996).  Following 
the sequencing of human genomes and cost-effective high throuput genotyping of 
thousands of SNP in hundreds and thousands of DNA samples, association studies have 
become the main approach for identifying common variants predisposing to disease. 
 
Apart from monogenic diseases, there is a set of complex diseases in which several genes 
interact in complex ways with each other and with multiple environmental factors (Elston, 
1995).  Having obtained evidence of possible genetic component in the cause of a complex 
disease, the next step is to locate and identify any obvious candidate genes (see section on 
association studies).  However, for most complex diseases there are so many candidates and 
function of most genes not known.  Attempts to localise regions of the genome that are 
aetiologically relevant usually precede the search for genes which may predispose to 
disease known as a linkage study (Burton et al., 2005).  This describes regions of genetic 
variation which are inherited in affected individuals more often than would occur by chance 
and usually tens of centimorgans in length (Teare and Barrett, 2005).  However, linkage 
studies do not give full information about location of prospective disease genes or alleles 
involved, therefore, once a chromosomal region has been located by this method, there are 
two approaches to follow.  The first approach aims to reduce the size of the genomic region 
of interest by fine mapping of that region where hundreds of SNPs are genotyped in order 
to find any association.  The other strategy is to search for any candidate genes within the 
linked region which contribute in disease pathogenesis (Hirschhorn and Daly, 2005).  In 
complex disease, its difficult to narrow down the field of candidate genes, many of them 
have unknown function, therefore can not be dismissed.  On the other hand, when the 
function of the gene is known, it is relatively easy to hypothesize its possible role in the 
disease (Teare and Barrett, 2005). 
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Once the region has been narrowed to include one or few genes, a dense set of SNPs can be 
genotyped in a candidate gene association study.  These types of studies aim to identify the 
association between one or more genetic variants and a trait, which might be of some 
quantitative characteristic or a specific attribute.  The main difference between association 
and linkage studies is that the same alleles are associated with trait in a similar pattern 
among the whole population, whereas linkage allows various alleles to be associated with 
the trait in different families (Cordell and Clayton, 2005).  Association analysis is a useful 
tool for studying complex diseases because it has a greater statistical power than linkage 
analysis when there is locus heterogeneity.  It is a comparison of unrelated affected and 
unaffected individuals.  A specific allele at a gene of interest is believed to be associated 
with the presentation with that condition if it occurs at increased frequency among affected 
individuals than control group (Lander and Schork, 1994).  Prior to high-throughput SNP 
genotyping, most associated studies with polygenic complex trait have been conducted as 
candidate-gene studies.  The candidate genes are usually selected based on their possible 
biological function in the pathogenesis of the disease and directly two types of association: 
direct association is when the SNP under study is thought to be the actual disease causative 
SNP, while the indirect association when SNPs under investigation are not thought to be 
the causative SNPs themselves, but act as a surrogate for SNPs they are in LD with 
(Cordell and Clayton, 2005), however, in practice this is not well known in advance. 
 
4.5 Strategies for association studies 
 
There are four main components to be considered when designing a genetic association 
study: the disease or trait to be studied, a group of individuals in whom traits are examined, 
genetic marker selection and the analytic method to interpret the results.   The most crucial 
elements of any association study are careful sample collection and study design (Newton-
Cheh and Hirschhorn, 2005). 
 
4.5.1 Case – Control Study 
 
This is the most commonly used strategy in association studies for characterizing the 
genetic involvements to disease.  The advantage of case control study is that cases and 
controls are easy to obtain and genotype.  In this strategy, allele frequencies of variants are 
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compared between disease carrier and controls with the assumption that any differences in 
frequencies are associated with disease outcome (Lander and Schork, 1994). 
 
Patients and control groups should be carefully selected and have identical ethnic 
background.  If the control group has not been matched adequately with the patient group, 
one group may contain a subgroup such as a founder population or people from the same 
family, which has different allele frequencies and false associations, might be reported, 
known as population stratification (Healy, 2006).  Popuation stratification refers to a 
situation when there is unidentified population substructure.  Hardy-Weinberg equilibrium 
(HWE) is the binomial distribution of genotypes in a population, when allele (A) and (a) 
are present in that population with frequency of (A)=p and (a)=q, the genotype frequencies 
may be calculated as (AA)=p2, (Aa)=2pq and (aa)=q2.  Then, HWE can be applied when 
there are no factors such as migration or admixture that cause deviation from these 
genotype frequencies.  Also, when these assumptions are true, allele or gene frequencies 
will not change over subsequent generations (Balding, 2006; Hirschhorn and Daly, 2005). 
However, if the genotyped frequencies in the population being studied deviate from this 
ratio and are different at significant level (p<10-3 or 10-4), then the population is said to be 
not in HWE for that SNP (Balding, 2006).  Any systemic allele frequency differences 
between cases and controls may appear to be an association (Cardon and Bell, 2001).  Still 
another way to improve control ascertainment is to use a prospective study cohort that also 
allows monitoring of environmental factors increasing sample size and the finding should 
be validated in another population (Cardon and Bell, 2001).  For example, recent genome 
wide association studies (GWAS) for AE and other diseases have case-control sizes of 
approximately 3000 individuals (Esparza-Gordillo et al., 2009; Harley et al., 2008; van 
Heel et al., 2007). 
 
4.5.2 Study power  
 
The power of a study is the statistical probability to detect a true association if this result is 
true in the underlying population (Zondervan and Cardon, 2004).  In association studies, 
power depends not only on the sample size and density of the markers but also on several 
parameters such as relative risk and the marker allele frequencies, penetrance, underlying 
disease model and the patterns of LD around the causal variation (Schork, 2002; Zhang et 
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al., 2002).  A direct computation of power is not possible; therefore, simulation methods 
providing realistic systems of allele frequencies and LD are commonly used (de Bakker et 
al., 2005; Pe'er et al., 2006).  According to de Bakker, power is defined as the ratio of the 
simulated case-control groups in which the test statistic transcends the significance 
threshold (when an association may be declared) (de Bakker et al., 2005).  A common 
measure of the strength of genetic effect, which is the extent to which a factor affects the 
risk of the condition under study, is the odds ratio (OR).  Odds ratio defined as the odds of 
exposure to the susceptible genetic variant among cases compared to that in controls.  If the 
OR is equal to one, then the exposed individuals are at no increased risk compared with the 
unexposed individuals, an OR is significantly greater than one, then the genetic variant is 
associated with the disease and 0<OR<1 implies a negative association or a protective 
effect (Zondervan and Cardon, 2004).  
 
4.5.3 Association analysis method-Transmission disequilibrium test (TDT) 
 
The transmission disequilibrium test (TDT) was introduced as a test for linkage between a 
complex disease and a genetic marker. It examines whether an allele at a specific locus is 
transmitted more often from the parents to the affected offspring (Spielman et al., 1993), 
provided that disease association with specific marker allele is also present (Spielman and 
Ewens, 1996).  Several variants of and extensions of TDT have been proposed; for 
instance, these can be used in studies of quantitative outcomes, in family studies other than 
case-parent trio and when there are a missing data (Tiwari et al., 2008).  It is a family-based 
design for testing the association that uses genotype data from trios, which includes both 
parents and an affected offspring.  Furthermore, TDT is a non-parametric method and its 
validity does not depend on the proper specification of a disease model or assumptions 
about the distribution of the disease in the population (Laird and Lange, 2006).  It focuses 
only on heterozygous parental genotype and an affected offspring.  The two affected alleles 
inherited to offspring are the case alleles while the other untransmitted alleles from the 
heterozygous unaffected parents are classed as control alleles.  It compares the number of 
alleles that are transmitted with those expected in Mendelian transmission. An over-
transmission of alleles of one type among the affected individuals represents a disease-
susceptibility locus for a trait of interest is linked and associated with the marker locus 
(Laird and Lange, 2006).  Under Mendelian law, all alleles should have a 50% chance of 
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being transmitted to offsprings.  However, alleles associated with disease risk tend to be 
transmitted more often than 50% and the frequency of these alleles should be tested across 
the whole data set (Risch and Merikangas, 1996). 
 
This test, however, have weaker power and thus might require even larger sample size than 
case control studies (Spielman and Ewens, 1996).  Another possible limitation to the TDT 
is its requirement of parental genotype which is difficult to obtain for late-onset disorders 
(Cardon and Bell, 2001).  Extensions to the TDT must maintain robustness to population 
stratification and to potential misspecification of the phenotype distribution, which makes 
the basis for the family-based association test (FBAT) approach (Laird and Lange, 2008). 
 
4.5.4 FBAT approach 
 
This approach implements a broad class of family-based association tests, adjusted for 
population admixture.  The unified approach proposed by Rabinowitz and Laird (2000) and 
Laird (2002), allows any type of genetic models, multi-allelic data, general family design, 
haplotypes, tests with missing parents, different null hypothesis and any phenotypic traits. 
It builds on the original TDT method (Spielman et al., 1993) in which the observed number 
of alleles transmitted to affected offspring are compared with the expected distribution of 
alleles among offsprings.  According to Mendelian inheritance pattern, each parental allele 
has a 50% chance of being transmitted.  Statistical deviation from this expectation indicates 
that the risk allele is not only associated with disease susceptibility locus but also linked to 
it (Laird et al., 2000; Rabinowitz and Laird, 2000).  To motivate this approach, it is crucial 
to consider those aspects of the TDT which make it so robust and powerful.  First, FBAT 
statistic is computed conditionally on parental genotype.  This conditioning helps to 
eradicate any assumptions about the distribution of alleles in the population, such as Hardy-
Weinberg or that allele frequencies are the same in cases and controls under the null.  
Second, the distribution of the test statistic when the null hypothesis is true should then be 
demonstrated so the at valid p-values may be computed.  Finally, the random variable is the 
offspring genotype.  As a result, the validity of the test statistic depends only on Mendel’s 
law of random transmission of each parental allele with equal probability to each offspring.  
The test statistic uses a natural measure of association between two variables, a covariance 
between the traits and the genotypes (Laird and Lange, 2008). 
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FBAT statistic is a two-stage procedure: the first stage involves identifying a test statistic 
which demonstrates association between the marker locus and the trait locus.  The second 
stage involves specifying the distribution of the genotype marker data under the null 
hypothesis (Laird and Lange, 2006).  Family-based designs have distinct advantages: they 
are robust against confounding and variance inflation due to population substructure, and 
they test for both linkage and association (Laird and Lange, 2008). 
 
4.5.5 Case-control designs versus family-based designs 
 
Case-control study design is the most powerful and current method of choice for detecting 
modest risk variants in common diseases although there are many other designs for genetic 
association studies including family-based and cohort (Healy, 2006). Indeed in the last few 
years, there have been numerous case-control genome wide association studies for a whole 
range of common disorders including diabetes, psoriasis, hypertension, celiac disease and 
cancer predisposition. Numerous low risk gene variants have been identified with some 
implicated in quite distinct disorders. The development of array-based high throughput 
genotyping coupled with increased funding in this area (e.g. Wellcome Trust) allows 
hundreds to thousands of individuals to be genotyped.  A typical case-control studies may 
include 3,000 cases (and corresponding controls plus those 10,000 genotyped in the 
Wellcome Trust consortium study) (consortium, 2010). 
 
The case-control and family designs such as case-parent trio (an affected child and his/her 
parents) have apparent advantages and disadvantages when examining the genetic 
association (Infante-Rivard et al., 2009).   For genetic association studies, case-control 
design is the usual option; however, an important concern is the possibility of population 
structure bias, a type of confounding which may occur when genetic ancestry is associated 
with allele frequency as well as with disease incidence.  This can be adjusted using race or 
ethnicity, although, good-quality data catching subtle ancestral admixture is not easily 
available leading to residual confounding (Infante-Rivard et al., 2009).  A number of 
strategies have been proposed for GWAS including using a group of markers to control the 
structure bias in the population (Tiwari et al., 2008).   
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Family design is an alternative to the case-control design which has the major advantage of 
being robust to population structure bias.  This due to the fact that estimation of allele 
transmission within families, build up on parental genotypes, cannot be biased due to a 
variation in genetic background (Infante-Rivard et al., 2009).  Furthermore, family data are 
more benefical when using certain models to test for maternally or paternally mediated 
effects which are of great importance and relevance when studying early-life outcomes or 
pregnancy (Buyske, 2008).  There are other aspects differentiating these designs including 
cost and power.  For the family design (3 individuals), the cost of genotyping is greater 
than that for the case-control design (2 individuals), but it is decreasing due to the rapid 
advances in high-throughput genotyping and new generation sequencing technology.   
 
4.5.6 Interpreting association studies 
 
These studies have become an extremely common strategy to mapping variants which 
affect complex traits but, they are often misinterpreted and therefore, reproducibility can be 
variable.  The analysis is based mainly on a statistical test carried out for each SNP in the 
array, aiming to select those SNPs that present a significant association with the trait 
(Sebastiani et al., 2009).  For each SNP, the null hypothesis that there is no association 
between the SNP and the phenotype is tested against the alternative hypothesis that there is 
an association.  The most common test used to test these hypotheses by the p-value which 
defined as the probability of obtaining a stronger association than that determined from the 
data assuming that there is no association, and refer to a single absolute probability 
(Sebastiani et al., 2009).  For instance, if the association is measured by the OR for the 
disease between exposed individuals (carriers of the risk allele) and unexposed individuals, 
the p-value is the probability of detecting an OR more extreme than that estimated from the 
data, when there is no association (Sebastiani et al., 2009).  Expecting a large OR would be 
unlikely in common diseases, even the well-designed studies, aimed at an OR of 1.3 and 
MAF of more than 0.1 (10%) will have less power than assumed and not reproduced (Wang 
et al., 2005).  If there is a significant correlation between genotypes at a variant and a 
disease, that is, the p-value is 0.05 or lower, this usually analysed as a significant evidence 
of association between the variant and the phenotype.  Historically, such associations were 
not usually replicated, in a review of literature; only 6 out of 166 associations were 
reproduced by at least 75% of subsequent studies (Hirschhorn et al., 2002).  
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Genome-wide association studies on complex diseases conducted recently showed that OR 
of 1.1-1.5 are more likely, for example the OR in several studies to detect variants 
associated with type 1 diabetes (T1D) was less than 1.3 (Cooper et al., 2008; Hakonarson et 
al., 2007; Smyth et al., 2006; Todd et al., 2007).  This due to various causes such as: a false 
positive association which is not corrected, a true association fails to be replicated in an 
underpowered follow-up study (false negative) and a true association in one population that 
fails to be replicated in another population due to heterogeneity in both genetic and 
environmental background. The most popular method for correction p-value is the 
Bonferroni correction, almost equivalent to multiplying the theoretical p-value by the 
number of hypotheses tested in order to avoid the type one error (false positive) (Newton-
Cheh and Hirschhorn, 2005).  Another aspect of failure to replicate association studies was 
likely explained by the modest influences of the causal variants on disease risk and the 
consequent false-negative studies.  Mostly, the causal variant was associated with a small 
increased risk of disease which suggest that sample sizes in thousands are needed to 
achieve a significant p-value <0.05 instead of few hundreds (Hirschhorn, 2005; Ioannidis et 
al., 2001). 
 
Caution should be used when interpreting the results of a genetic association study.  For 
negative results, assessment of power to identify modest effects is vital, while careful 
evaluation of the likelihood of false-positive results in an apparent significant genetic 
association should also be made.  Correction of a nominal p-value for multiple tested 
hypotheses of genetic variants (and combinations), phenotypes, and genetic models is 
crucial.  The importance of such correction is increased dramatically when multiple gene–
gene or gene–environment interactions are tested (Newton-Cheh and Hirschhorn, 2005). 
 




Genetics has clearly been known to play a crucial role in the development of AE.  The 
importance of genetic factors in AE is suggested by the finding that a positive parental 
history is the most significant risk factor for AE; children with one allergic parent become 
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allergic 50% of the time, increasing to 75% if both parents are allergic (Sturgill and 
Bernard, 2004).  Children whose parents have AE show a higher risk of developing AE 
than children whose parents have allergic rhinitis or asthma (Moore et al., 2004; Wadonda-
Kabondo et al., 2004). These observations and the high concordance rate of AE among 
monozygotic twins (MZ) of (0.72-0.86) compared with (0.21-0.23) in dizygotic twins (DZ), 
in combination with the early age of onset, indicate that AE represents a genetically 
complex disease (Larsen et al., 1986; Schultz Larsen, 1993; Wuthrich et al., 2007).  Also, 
AE can occur with increased severity along Blaschko’s lines (Hladik et al., 2005), 
consistent with genetic mosaicism (Moss, 1999).  Twin studies also, have demonstrated 
evidence about the genetic component of other allergic phenotypes including: asthma, 
hayfever, and elevated serum IgE.  These studies showed that the heritability of atopy 
(elevated IgE and positive skin test) as well as other allergic phenotypes lies between (0.60-
0.70) with higher concordance rate for MZ twins compared with DZ twins (Duffy et al., 
1990; Hopp et al., 1984; Koppelman et al., 1999; Los et al., 1999).  The development of 
the disease is dependent on multiple genes and the expression is usually affected by 
environmental factors (Chien et al., 2007) and risk may be mediated through skin-specific 
genes, rather than simple systemic immune risk genes.  This leads to recent focus on the 
important role of epithelial barrier dysfunction in the development of AE, supported by 
evidences from genetic, immunological, and physiological studies (Cookson, 2004; 
Hudson, 2006; Irvine and McLean, 2006; Jakasa et al., 2006; Taieb et al., 2006). 
 
5.2 Strategies for investigating the genetic basis of AE 
 
A tremendous amount of research has been conducted worldwide recently to detect genetic 
factors underlying the aetiology of atopy and AE.  Three main strategies have been used 
including: genome-wide linkage studies, which are hypothesis free and compare the allele 
sharing in families, candidate gene association approach by selecting genes based on a 
hypothesis made from pre-existing knowledge of biological function and GWAS (Brown 






5.2.1 Statistical significance in genome-wide linkage scans 
 
In the context of a modern genome screens for linkage, there are hundered of markers used.  
Lander and Kruglyak (1995) explained that for a genome-wide error rate to be 0.05 or to 
keep the chance of encountering a false positive at no more than 5%, the logarithm of odds 
(LOD) score of ≥3.6 or p=2x10-5 to achieve the recommended genome-wide significant 
level of 5%.  LOD score is the measurement of linkage between loci and refers to the ratio 
of two probabilities, while p-value indicates a single absolute probability.  For example, 
LOD=3 means that the observed data is 103-fold more likely to arise under a specified 
hypothesis of linkage than under the null hypothesis.  The standard may appear stringent at 
first glance, but it is well accepted in historical practice (Lander and Kruglyak, 1995). In a 
classical two-point linkage studies of simple Mendelian traits, the traditional cut off point 
of LOD 3 is equivalent to p=10-4 (Chotai, 1984), for a genome-wide significant level 
corresponds to 9%.  So, in order to achieve the significant level for a genome-wide scan, 
the LOD score need to be increased to 3.3, corresponding to p=5x10-5.  Small p-value 
represents that it is very unlikely the results were due to chance. The lower the p-value, the 
less likely the null hypothesis is true, so the more significant is the result obtained (Lander 
and Kruglyak, 1995).  Thresholds for mapping loci underlying complex traits based on 
specific classifications.  These categories include:  suggestive linkage when the statistical 
evidence that might be expected to occur once at random in a genome scan.  Significant 
linkage, the statistical evidence required to occur with probability of 0.05.  Highly 
significant linkage, the statistical evidence needed to occur 0.001 times in the genome scan.  
Confirmed linkage, the statistical evidence obtained from one or a combination of studies 
that has been confirmed subsequently by other independent groups or in a larger samples 
and a normal p-value should be 0.01 (Lander and Kruglyak, 1995). 
 
In complex traits most linkage studies have little power due to small sample sizes.  Genome 
wide linkage scans have been completed in different populations for AE.  There are only a 
few overlapping regions of linkage in all of these studies (Table 1.3) and this could be due 
to sample size, different marker panels used, statistical methods used or it might be related 




5.2.2 Genome wide linkage scans for AE 
 
Genome-wide linkage studies using microsatellite markers (Table 1.2), have highlighted 
several possible areas of linkage to AE (Figure 1.4) on chromosomes 1q21 (Cookson et al., 
2001), 3q21 (Lee et al., 2000), 3p24-22 (Bradley et al., 2002), 3p26-24 (Haagerup et al., 
2004), 15q21 and 1q24 (Enomoto et al., 2007) as well as 17q25 (Cookson et al., 2001).   
Specific regions on chromosome 3q, 3p, 17q and 18q are indicative of linkage in at least 
two studies.  However, only two of these regions (3p and 17q) have shown linkage to 
asthma or other allergic phenotypes in more than one study (Hoffjan and Epplen, 2005), 
highlighting that different genes may be contributing in the aetiology of AE. 
 
A screen conducted in children of German and Scandinavian families (n=839) individuals 
with at least 2 affected children with AE found evidence of linkage on chromosome 3q21 
with AE (p=8.42x10-6) and allergic sensitization (p=6.7x10-4) (Lee et al., 2000).  In this 
region two genes have been mapped, CD80 and CD86, they are involved in T-cell 
activation (Sansom, 2000).  Another study on British children reported two regions of 
linkage to AE on chromosome 1q21 (p=0.0005) and 17q25 (p=0.0004) as well as AE in 
combination with asthma on chromosome 20p (p=0.0005).  Weaker evidence for linkage 
was observed between the total serum IgE and 5q31 (p=0.004) (Cookson et al., 2001).  In 
Cookson et al., study (2001), results were less significant than the previous scan conducted 
by Lee et al., (2000) although both screens of similar size and power.  This due to several 
factors including: disease severity was classified differently; most of patients are asthmatics 
in Cookson’s screen (60% versus 24%) which may represent different aspect of the disease.  
Also, both studies used different group of markers (Cookson et al., 2001; Lee et al., 2000).  
A study on Swedish adults (n=470) individuals attended at hospital outpatient clinics 
showed linkage of AE to chromosome 3p24-22 (LOD=2.18, p<0.001).  Weaker evidence of 
linkage identified in additional chromosome regions; 5q13 (LOD=1.47, p<0.005), 10p13-
12 (LOD=1.42, p<0.01), and 6q16 (LOD=1.39, p<0.01).  However, when severity score of 
AE was used, more putative loci were identified in chromosome 3q14, 13q14, 15q14-15 
and 17q21 (p<7.4x10-4) (Bradley et al., 2002).  Interpretation of these results according to 
Lander and Kruglyak (1995) criteria, give p<7.4x10-4 as the standard for suggestive linkage 
and p=2x10-5 for a significant linkage (Lander and Kruglyak, 1995).  Several regions in 
chromosome 3, 13, 15, 17, and 18 fulfilled the criteria of suggestive linkage.  The 
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susceptibility region on chromosome 3q14 which is linked to the severity score of AE is 
found just centromeric of chromosome region 3q21, detected in previous scan (Lee et al., 
2000).  The chromosome region 13q14 had been linked to atopy in previous report (Daniels 
et al., 1996).  A study conducted on Swedish and German individuals, also showed linkage 
between AE and chromosome region 13q12-14 (Beyer et al., 2000).  In this region, the 
high-mobility-group protein-1 (HMG-1) gene is an interesting candidate gene, which is 
important in activation of pro-inflammatory cytokine production in human monocytes 
(Andersson et al., 2000).  Another candidate gene is that for the Wiskott-Aldrich protein 
family member 3 (WASF3) (Suetsugu et al., 1999), this is due to that patients with Wiskott-
Aldrich syndrome present with eczema similar to AE.  Although, most genes for this 
syndrome are found on Xp11, which subsequently was investigated for possible association 
with AE (Bradley et al., 2001).  This is consistent with the results obtained when defining 
another qualitative phenotype, extreme AE, which showed stronger evidence for linkage to 
chromosome region Xp11 (MLS=2.64, p<0.005) (Bradley et al., 2002).  Chromosome 
region 18q21 showed suggestive linkage for the phenotype of AE in combination with IgE.  
This region has been reported in another study conducted on a Finnish population with 
evidence in favour of linkage to asthma (Laitinen et al., 2001).  Another chromosome 
region 17q21 has been linked to asthma in previous scan (Ober et al., 1998), which is 
centromeric of the locus 17q25, linked to AE by Cookson et al., (Cookson et al., 2001) and 
to psoriasis (Enlund et al., 1999; Nair et al., 1997; Tomfohrde et al., 1994). 
 
Another scan carried out in Danish affected sib-pair families with AE, reported three 
regions linked with AE (MLS≥2): 3p26-24 (MLS=2.14), 4p15-14 (MLS=2.00), 18q11-12 
(MLS=2.25) (Haagerup et al., 2004).  The region on chromosome region 4p was a novel 
region linked to AE, and the other loci: 3p, 18q and Xp11, demonstrated confirmation of 
previously identified AE regions.  Another eight chromosome regions showed suggestive 
linkage with MLS from 1-2.  This report neither replicated nor excluded the results in two 
previous AE scans (Cookson et al., 2001; Lee et al., 2000).  The most recent screen 
conducted on Japanese families using a high density SNP genotyping assay.  This screen is 
the first screen in an Asian population, showed suggestive evidence of linkage on 
chromosome regions: 15q21 (LOD=2.01, p=0.0012) and 1q24 (LOD=1.26, p=0.008) 
(Enomoto et al., 2007).  The combination phenotype of AE and asthma has also shown 
significant linkage to chromosome 20q (Cookson et al., 2001), while a greater attention was 
66 
given for the loci that overlap with regions for inflammatory skin diseases such as psoriasis 
on chromosome 1q21, 17q25 and 20p (Capon et al., 1999; Tomfohrde et al., 1994; 
Trembath et al., 1997), leprosy on 20p12 (Tosh et al., 2002).  The chromosome region 
17q25 showed linkage to multiple sclerosis (MS) (Kuokkanen et al., 1997; Sawcer et al., 
1996) and rheumatoid arthritis (RA) (Jawaheer et al., 2001).  Based on these evidences, 
shared regions of linkage between AE and psoriasis contain several genes that might be 
involved in dermal inflammation and immunity.  The 1q21 locus is of a particular interest 
as it contains the epidermal differentiation complex (EDC), a family of genes including; 
FLG, loricrin, involucrin, and S100 that are involved in terminal differentiation of the 
human epidermis (Mischke et al., 1996).  Several DNA microarray studies have been 
conducted to analyse chromosome region 1q21.  A large-scale study has demonstrated that 
four genes encoded on that region had variable expression in eczematous skin.  Of these 
genes, S100A7 and S100A8 showed increased expression and FLG and loricrin were 
reduced expression (Sugiura et al., 2005).  The majority of these results showed suggestive 




















Table 1.2: Genome-wide screens reported for AE and other allergic phenotypes in 
different populations.  Note that chromosome regions of highest linkage including: 3q14, 
3q21, 11q13, and 17q21 adapted from (Hoffjan and Epplen, 2005). 
Reference Study population Sample Phenotypes 
Regions of highest 
linkage 
AE 3q21 (p=8.42×10–6) 
Lee et al., (2000) European 199 families with 2 






AE plus asthma 20p (p=0.0005) 
16q-tel (p=0.0007) 
Cookson et al., 
(2001)  British 
148 nuclear families 
recruited via children 




















Bradley et al., 
(2002)  Swedish 
109 families (197 
affected full-sib pairs, 
9 affected half-sib 
pairs) 
Severity score of 
AE 




Haagerup et al., 
(2004)  
 
Danish 23 affected sib-pair families 
AE plus specific 
IgE 
18q11-12 (p0.004) 
Enomoto et al., 
(2007) Japanese 
77 affected sib-pair 
families AE  
15q21 (p=0.0012), 1q24 
(p=0.008) 
Esparza-Gordillo 





4 sets of case-control  AE 11q13.5 (pcombined 
7.6×10–10 ) 
Christensen et al., 
(2009) Danish 










Figure 1.4: Susceptibility loci identified by genome screens in asthma, AE and 
psoriasis.  Loci on chromosomes 3q, 3p, 17q and 18q showed possible linkage to AE in at 
least two genome-wide screens (overlapping circles).  AE loci on chromosomes 1q, 3q, 17q 
and 20p overlap with psoriasis regions (white bars), while there is little overlap with loci 




5.2.3 Whole genome linkage scans in the Bangladeshi population 
 
In collaboration with OXAGEN, a microsatellite whole genome scan (400 microsatellite 
markers evenly spaced throughout the genome) was performed using 60 families with at 
least one family member with severe AE.  This was conducted prior to any work contained 
in this thesis.  Suggestive linkage was identified in a number of chromosomal regions.  
Chromosome 2 (Figure 1.5), 3 (Figure 1.6), and X (Figure 1.7) showed possible regions of 
linkage.  Chromosome 2 had a linkage peak to IgE levels as did the X chromosome, while 
chromosome 3 had a linkage peak with affected status.  Intially linkage analysis was done 
using both parametric and non-parametric analysis.  However, it is thought that non-
parametric analysis is most appropriate for complex trait analysis as a mode of inheritance 
does not have to be assumed which make it more robust with less error.  
 
In comparison between the previous linkage scans for AE which were carried out mostly in 
Caucasian European population and this linkage scan in the Bangladeshi population 
suggests little overlap in these results.  No chromosome 2 or X chromosome regions have 
been reported in previous studies.  However, the region in chromosome three has 




Figure 1.5:  Chromosome 2 linkage.  Maximum likelihood score (MLS) for chromosome 
2 with MLS (>1.5).  LOD scores are computed for all markers using non-parametric 




Figure 1.6:  Chromosome 3 linkage.   Maximum likelihood score MLS for chromosome 3 
with MLS (>1.5).  LOD scores are computed for all markers using non-parametric analysis.  
A linkage peak of around 1.75 can be seen around 70 cM (Prof. D. Kelsell). 
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Figure 1.7:  Chromosome X linkage.  Maximum likelihood score (MLS) for the X 
chromosome with MLS (>1.5).  LOD scores are computed for all markers using non-
parametric analysis.  A linkage peak of around 1.8 can be seen between 50 and 90 cM 
(Prof. D. Kelsell). 
 
Replication of whole genome linkage data is rare, as can be seen in table 1.3.  The power of 
linkage results is mainly linked to sample size, pedigrees versus sibling pair studies and the 
polygentic nature of inheritance.  Furthermore, multiple testing can have a great impact on 
statistical robustness.  There has been few replication of whole genome linkage findings in 
other diseases such as hypertension (Patel et al., 2003), prostate cancer (Xu et al., 2005) 
and osteoporosis (Deng et al., 2002).  
 
5.2.4 Genome-wide association (GWA) studies for AE  
 
Recently, a genome-wide association (GWA) study conducted to test 353,569 SNPs for 
association with serum IgE levels in 1530 individuals showed significant results.  Firstly, 
two variants, rs2251746 and rs2427837, in the gene encoding the alpha chain of the high 
affinity receptor for IgE (FCεR1α) on chromosome 1q23 were significantly associated with 
total IgE levels with a p-value of 1.85x10-20 and 7.08x10-19 respectively.  Another finding 
confirmed signal transducer and activator of transcription 6 (STAT6) as susceptibility locus 
regulating the level of IgE.  Also, variants within the RAD50 gene might demonstrate 
additional factors within cytokine gene cluster on chromosome 5q31 that require further 
assessments of this region.  This gene is a member of the MRE11–RAD50–NBS1 (MRN) 
complex vital for proper maintenance of genomic stability and tumour suppression 
(Weidinger et al., 2008b).  A recent genome-wide association study conducted in two sets 
of European samples; 939 individuals with AE and 975 controls; while the other set 
includes 270 complete nuclear families with two affected siblings.  SNPs associated with 
AE in both sets were then assessed in two additional independent replication sets, and 
highly significant association was found with allele A of rs7927894 on chromosome 
11q13.5 (pcombined=7.6x10-10).  Approximately 13% of Caucasians are homozygous for 
rs7927894[A], and their risk of developing AE is 1.47 times that of noncarriers (Esparza-
Gordillo et al., 2009).  Furthermore, linkage study conducted on Danish families showed 
evidence of linkage with several regions including: 3p24.3 (MLS=1.8, p=0.010) with AE, 
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3q21.2 (MLS=3.2, p=0.013) with IgE-associated AE and 4q22.1 (MLS=3.7, p=0.0001).  
The last region is the most significant linkage obtained for AE severity, suggesting a novel 
AE severity locus (Christensen et al., 2009). 
 
Genome-wide scans for AE and associated phenotypes have revealed different results.  
That might be a consequence of differences in phenotype definition or diagnostic criteria, 
environmental factors, study power, sample size, markers, and different populations.  Also, 
some research groups tend to report only highly significant markers (top SNPs) and exclude 
weaker markers. 
 
5.2.5 Candidate gene association studies in atopic eczema and atopy 
 
This approach addresses specific candidate genes implicated in AE.  They are founded on 
pre-existing knowledge of the underlying pathophysiology (Bonness and Bieber, 2007).  
Approximately nineteen genes have all been previously associated with AE in about 53 
publications with varying results (Kiyohara et al., 2008).  Candidate gene investigation into 
AE has mainly focused on immune system related genes with only few candidate genes 
being involved in the skin barrier. One example is the cytokine gene cluster located on 
chromosome 5q31-33, where the T-helper type 2 cytokines (Th2) such as IL-3, IL-4, IL-5, 
IL-13 and granulocyte-macrophage colony-stimulating factor (GM-CSF) map (Liu et al., 
2003; Rafatpanah et al., 2003).  Other examples include, the β Chain of the high-affinity 
receptor for IgE (FcεRIβ) on chromosome 11q12-13 which showed linkage to atopy but 
inconsistent results in AE (Coleman et al., 1993; Cox et al., 1998; Moffatt et al., 1992; 
Sandford et al., 1993; Soderhall et al., 2001), and mutations that affect the function of the 
promoter region of the lymphocyte-attracting chemokine, RANTES (regulated on activation, 
normally T-cell expressed and secreted) on chromosome 17q11 (Nickel et al., 2000).  A 
number of genes have been associated with AE including those important in the epidermal 
barrier function, such as the serine protease inhibitor Kazal type 5 gene (SPINK5) expresses 
the 15-domain serine protease inhibitor lympho-epithelial Kazal-type-related inhibitor, 
named LEKTI  (Kato et al., 2003; Nishio et al., 2003; Walley et al., 2001), FLG gene on 
region 1q21 (Palmer et al., 2006) and the stratum corneum chymotryptic enzyme (SCCE) 
gene (Vasilopoulos et al., 2004). 
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In the following section, a selection of AE candidate genes that have shown association 
with AE in two or more independent studies will be discussed to find out the evidence for 
their contribution in AE pathology.  
 
5.2.5.1 Mast cell chymase 1 (CMA1) 
 
Mast cell chymase1 (MCC1) is encoded by the gene CMA1, which maps to chromosome 
14q11.2, a region that has shown previous linkage with AE (Soderhall et al., 2001).  MCC1 
is a glycosylated chymotryptic-like serine protease, which is a major constituent of the 
secretory granules of human mast cells.  Mast cells contribute to pruritis and inflammation 
in AE via release of MCC1, histamine and tryptase, which have pro-inflammatory effects 
on release from activated cells.  Experiments that introducted purified human MCC1 into 
the skin or peritoneum of animals such as guinea pigs found increased microvascular 
permeability, and increased accumulation of inflammatory cells such as neutrophils, 
eosinophils, and macrophages (He and Walls, 1998a, b). 
 
Moreover, CMA1 shows a range of features that play a crucial role in tissue remodelling.  
These include the ability to activate interstitial pro-collagenase (Saarinen et al., 1994), to 
convert pro-collagen into collagen and promoting the formation of fibrils (Kofford et al., 
1997) and to release the transforming growth factor beta 1 (TGF-β1) from the epithelial and 
endothelial cells (Taipale et al., 1995). These properties, in addition to abundant expression 
of the protein in the dermis implicated MCC1 (CMA1) as a candidate for genetic 
association with AE.  These observations have been supported by the increased number of 
CMA1-positive cells in chronic AE skin lesions compared with that seen in both psoriatic 
and normal skin (Badertscher et al., 2005), and a possible role of chymase in the promotion 
of skin barrier defects and cutaneous neovascularisation has been suggested (Groneberg et 
al., 2005). 
 
Several studies (Table 1.3) conducted to investigate one promoter polymorphism (-
1903A>G, rs1800875) indicated an association with atopy.  A Japanese study conducted on 
100 controls and 400 individuals with different allergic phenotypes showed a significant 
association between a CMA1 gene promoter polymorphism with and AE (OR=2.17, 
p=0.009) (Mao et al., 1996).  These findings were confirmed in two subsequent studies in 
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Japan; a study conducted on 851 school children showed a significant association 
(OR=2.89, p<0.001) for AE with low level of total serum IgE (<500 IU/mL) (Mao et al., 
1998), also another study on 169 patients with AE showed significant results with low 
serum IgE (p=0.03) (Tanaka et al., 1999).  However, these results could not be replicated in 
another case-control study recruited  from Japanese population (n=201) individuals 
(OR=1.2, p=0.81) (Kawashima et al., 1998a) and an Italian study of 23 families (Pascale et 
al., 2001).  More recent study in Caucasian families confirmed the association between total 
IgE levels in patients with self-reported AE and the polymorphism in the promoter 
(p=0.0032) (Iwanaga et al., 2004).  Furthermore, A large cohort study (n=1875) carried out 
to investigate the association between atopic phenotypes such as AE, asthma, 
rhinoconjunctivitis and total serum IgE with other SNPs, including (-1903A>G) in CMA1 
region.  Results showed significant association between (-1903A>G) and AE (OR=1.91, 
p=0.002), but not with other atopic traits. This supports the significant association between 
AE and this polymorphism which raise the speculation whether this variant change the 
expression of chymase (Weidinger et al., 2005).  These observations require functional 
studies and analyses to clarify the consequences of this polymorphism in the CMA1 gene, 
and possible therapeutic interventions in AE.  Few studies were investigated the association 
between (TG)n (GA)m repeat polymorphism with atopic phenotypes. A case-control study 
in two independent cohorts conducted on Indian population showed significant association 
with atopic asthma (p<0.05) (Sharma et al., 2005), as well as in an Egyptian study (p=0.02) 












Table1.3: Association studies of CMA1 gene polymorphisms and atopic phenotypes. 
Most of these studies confirmed the association between a promoter polymorphism, 
rs1800875, and AE in different populations. 
SNP 
 
Sample size population Phenotype p-value Reference 
Rs1800875 500 individuals Japanese AE 0.009 (Mao et al., 
1996) 
Rs1800875 851 school 
children 
Japanese AE with low 
IgE(<500IU/mL) 
<0.001 (Mao et al., 
1998) 
Rs1800875 169 individuals Japanese AE with low 
IgE(<500IU/mL) 
0.03 (Tanaka et al., 
1999) 
AE 0.002 Rs1800875 
plus 7 more 
variants in 
CMA1 locus 
1875 adults German  
Other atopic 
phenotypes: 

















30 children  
 
Egyptian 
Atopic asthma ≤0.001 
 





The SPINK5 gene is located at Ch5q32, and encodes the protein lymphoepithelial Kazal 
type related inhibitor (LEKTI), a 15-domain serine protease inhibitor.  LEKTI is expressed 
in specific tissues such as skin, thymus and oesophagus (Bitoun et al., 2003).  In the skin, 
expression is mainly in the granular layer where terminal differentiation is taking place 
leading to stratum corneum formation (Deraison et al., 2007).  Recessive SPINK5 
mutations underlie Netherton syndrome (NS) (Chavanas et al., 2000), in which, patients 
have ichthyosiform erythroderma and also a specific hair phenotype-bamboo hair (Judge et 
al., 1994).  Furthermore, patients display high IgE levels, hayfever, asthma and food 
allergies, showing an immune system sensitisation and overlap with symptoms of atopy.  
Several reports have shown SPINK5 gene polymorphisms to be associated with AE in 
different populations (Kabesch et al., 2004; Kato et al., 2003; Nishio et al., 2003; Walley et 
al., 2001).  SPINK5 mutations/LEKTI deficiency causes abnormal desmosome cleavage at 
the granular layer-stratum corneum junction (Descargues et al., 2005; Hewett et al., 2005; 
Ishida-Yamamoto et al., 2005; Tartaglia-Polcini et al., 2006; Yang et al., 2004b).  This 
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result in loss of skin barrier dysfunction which is caused by defective stratum corneum 
adhesion (Descargues et al., 2005; Hewett et al., 2005; Tartaglia-Polcini et al., 2006; Yang 
et al., 2004b).  This gene will be discussed in more detail in chapter 4. 
 
5.2.5.3 Tenascin-C (TNC) 
 
Tenascin-C is an extracellular matrix protein that is expressed during embryogenesis and 
wound healing.  Expression of TNC in normal skin is low but it may be elevated in skin 
tumours and in wound healing (Latijnhouwers et al., 1996).  It is located at Chr9q33 and 
consists of twenty eight exons and spans 97.68 kb (http://www.ensembl.org/accessed on 
27/03/09).  TNC is regulated by cytokines and therefore, could be involved in the immune 
regulation of the skin (Latijnhouwers et al., 1998).  It has been reported that TNC was 
upregulated in lesional skin of AE patients while it was not upregulated in non-lesional skin 
or psoriatic skin.  Also, TNC was upregulated by IL-4 and IL-13 and moderately by IFN-γ 
in cultured keratinocytes (Ogawa et al., 2005).  Upregulation of TNC in lesional skin of AE 
patients suggests its role may be specific to AE and as a result, it may be involved in the 
immune regulation of AE.  This gene has not been investigated in previous AE studies, 
however, in this thesis; it has been investigated as a plausible candidate gene associated 
with AE according to its position and function.  This will be discussed in further detail in 
chapter 5. 
 
5.2.5.4 The cytokine gene cluster 
 
Cytokines have been functionally divided into two groups: Th1 that activate the cellular 
machinery of the immune system, and Th2 cytokines which activate the humoral immune 
system.  The first group, Th1 cytokines consist of interleukin (IL) 2, IL-12, IFN-γ, and 
tumor necrosis factor alpha (TNF-β), while the other group, Th2, consist of IL-4, IL-5, IL-
9, IL-10 and IL-13 cytokines (Funauchi et al., 1998; Mosmann and Coffman, 1989; 
Romagnani, 1997; Viallard et al., 1999).  Disturbance of the balance between Th1 and Th2 
linked to several autoimmune diseases and immune disorders such as allergy.   
 
Genome-wide studies have demonstrated strong linkage between chromosome region 5q31-
33 and atopy as well as other atopic phenotypes (Postma et al., 1995; Xu et al., 2001).  
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However, the evidences of linkage between total serum IgE and this region were not 
consistent (Mathias et al., 2001; Xu et al., 2000).  This region contains several genes 
involved in the IgE-mediated inflammatory reaction including: interleukin-4 (IL4) and 
interleukin-13 (IL13) (Cookson and Moffatt, 2000; Marsh et al., 1994; Niimi et al., 2002).  
These genes reported to show association with AE in two or more independent studies 
(Table 1.4).  IL4 maps on chromosome 5q31.1 and it promotes the switch of to Th2 
immune response and IgE release.  The T allele of (-590T>C) variant was associated with 
an increase risk of AE (p=0.001) in a Japanese study of 88 families (Kawashima et al., 
1998b).  Another study conducted in Caucasian population showed that the T allele of (-
590T>C) variant in the IL4 gene was associated with the development of early onset AE 
(p=0.006) and atopy (p=0.009)  (He et al., 2003).  IL13 gene maps on chromosome 5q31-
33 and it promote B-cell switch to IgE production.  Several reports in different populations 
confirmed the significant association between the Arg130Gln SNP and the increased risk of 
AE (Liu et al., 2000; Tsunemi et al., 2002).  Also, haplotypes consisting of IL-13 
Arg130Gln were associated with AE in Caucasian individuals with AE (p=0.006) (He et 
al., 2003).  However, there were no significant association between two SNPs, -1111C>T, 
704A>C and AE in a Japanse study (Tsunemi et al., 2002).  Interleukin-4 receptor (IL4R) 
gene maps on chromosome 16p11.2-12.1 and is also involved in the Th2 immune response 
and IgE production.  There are several SNPs of the IL4R gene found to be associated with 
AE many of them may have functional significance (Hosomi et al., 2004).  Of these 
functional SNPs, 1727G>A (Gln551Arg), was confirmed to be associated with AE in 
Caucasian children (Callard et al., 2002) as well as in in the Japanese population (Oiso et 
al., 2000).  There was no association of cytokine gene polymorphisms including: IL-4, IL-
13 and IL4R in a Chinese case-control study recruited 94 patients with AE and 185 healthy 










Table 1.4: Studies investigating the association between candidate genes for AE and 
other atopic phenotypes in the cytokine gene cluster.  It shows the significant 
association between cytokine genes polymorphism including: IL4, IL13, and IL4R with AE 
and other atopic phenotypes. 
SNP 
 
Sample size population Phenotype p-value Reference 




Sib-pair, 88 families 
(n=377) 
Japanese AE 0.001 (Kawashima et 
al., 1998b) 
AE 0.03 IL13 
Arg130Gln 
1314 newborns German 
Elevated IgE 0.026 




185 individuals Japanese AE 0.016 (Tsunemi et al., 
2002) 


















Gln551Arg 27 individuals Japanese AE 0.01 (Oiso et al., 
2000) 
Gln551Arg 13988 cohort Caucasians Early onset 
flexural AE 




























Genetic linkage studies of AE and psoriasis have highlighted the importance of 
chromosome 1q21 (Bowcock and Cookson, 2004; Cookson, 2002), a region spanning 2 Mb 
and contains a collection of approximately 45 genes known as the epidermal differentiation 
complex (EDC) (Mischke et al., 1996).  The genes of this cluster are expressed late during 
maturation of epidermal cells in combination with genes encoding calcium-binding proteins  
(Hardas et al., 1996).  There are three gene families recognised within the complex 
including; the small proline-rich proteins (SPRPs), the S100 calcium-binding proteins 
(S100), and the late envelope proteins (LEPs), as well as other small number of additional 
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single-copy genes such as trichohyalin, repetin, FLG, involucrin, and loricrin (Marshall et 
al., 2001).  S100A protein family, is a sub-cluster group of S100 proteins, with low 
molecular weight that increase in different skin diseases especially psoriasis, cancer, and 
inflammatory skin conditions (Eckert et al., 2004).  Furthermore, mutations within the 
loricrin gene were found to cause the ichthyotic form of Vohwinkel Syndrome, an 
autosomal dominant disorder (O'Driscoll et al., 2002). 
 
Genes in the EDC represent good candidates for more genetic studies.   Consistent with this 
assumption, decreased level of both FLG and loricrin and increase levels of S100A7 and 
S100A8 expression have been noticed in skin biopsy specimens of patients with AE 
(Sugiura et al., 2005). 
 
B) Genetic deficiency of filaggrin (FLG) gene is associated with AE 
 
Filaggrin plays a very important role in epidermal differentiation and skin barrier function.  
It is important in keratin cytoskeleton aggregation in order to facilitate the flattening of 
keratinocytes in the stratum conrneum (Manabe et al., 1991).  Also, the degradation of FLG 
produces a mixture of amino acids that involve in barrier function (Rawlings and Harding, 
2004).  When FLG loss-of-function mutations were identified as a major causative for 
icthyosis vulgaris (IV) by Smith et al., (2006), this provided clues to the gene defect 
relevant to another common skin disease, AE, especially that several affected individuals of 
these families with IV also exhibited AE.  In addition to great phenotypic overlap exists 
between IV and AE, both diseases share similar clinical features such as scaly skin, 
keratosis pilaris and palmar hyperlinearity (Oji and Traupe, 2006; Weidinger et al., 2006).  
So, it was logical to examine these null mutations, R501X and 2282del4, in patients with 
AE.  Palmer et al., (2006) sought to analyse the same fifteen families studied for IV and 
found a 13 of 29 patients (44%) with mild type of IV had AE which were heterozygous for 
a FLG null allele.  However, AE was more common in patients with severe type of IV, 16 
of 21 patients (76%) had AE and all were homozygous for FLG null alleles (Palmer et al., 
2006).  Then they confirmed their findings by studying three cohorts in different 
populataions.  Intially, 52 Irish children with AE and controls (n=189), the combined allele 
frequency for the 2282del4 and R501X mutation was 33% compared with only 4.3% in 
controls.  The second step was to compare 604 asthmatic children from a cohort with 1008 
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controls from the same cohort.  When the effect on AE was assessed, 72% of all the 
children carrying a FLG null allele had AE, in comparison with only 46% of those without 
FLG variants. These mutations had a significant association with AE (OR=3.3, p=4.8x10-
11).  Finally, 372 Dansih children with maternal history of asthma were compared with 
healthy controls.  The results showed that FLG variants were more common in children 
with AE compared with controls (p<0.0001).  These two loss-of-function mutations 
(R510X and 2282del4) of FLG gene account for the majority of FLG mutations in 
Caucasians with AE and are major risk factors for AE, and AE-associated asthma (Palmer 
et al., 2006; Weidinger et al., 2006). Furthermore, these mutations in FLG gene are 
predisposing factor for early-onset AE that persists into adulthood.  They sought to study 
adults with onset of AE in childhood to evaluate the role of FLG null mutations in severe 
and chronic AE.  Analyses data showed that 8.8% of the general population carry one or 
more FLG null alleles, while 42% of the AE patients carry one or more of these alleles, 
approximately a six-fold over representation of disease alleles in affected individuals, 
which is statistically significant association.  Also, mutant alleles are found in 8-10% of 
individuals with European origin, and confirm that FLG mutations are a fundamental 
contributor to disease persistence into adulthood (Barker et al., 2007).  
 
Since the initial studies in 2006, at least twenty different loss-of-function mutations in the 
FLG gene have been identified so far in European populations, while in Asian populations 
an additional seventeen mutations have been reported (Table 1.5).  Approximately 9% of 
these null mutations including: R501X, 2282del4, R2447X, 3702delG and S3247X are 
prevalent in the European population.  Other mutations such as: 3763delC, R1474X, 
5360delG are at much lower frequencies and found in European and European American 
populations (Brown and Irvine, 2008) while variants S2554X and 3321delA are common in 
Japanese (Nomura et al., 2007).  The first population study (n=811) reported a less strong 
association between FLG null muatations and mild-to-moderate forms of AE (OR=1.53) 
(Brown et al., 2008), compared with that previously identified in the moderate-to-severe 
AE studies (OR=2.03-13.4) (Barker et al., 2007; Palmer et al., 2006; Ruether et al., 2006; 
Sandilands et al., 2007).  The significant association was found only in children with two 
null alleles suggesting a recessive mode of inheritance (Brown et al., 2008).  Another large 
population cohort (n=3099) coducted on German children support the significant 
association between these mutations and AE (p=2.5x10-4).  Also, it showed a strong 
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association  between FLG null mutations and other atopic phenotypes such as AE in 
combination with asthma (OR=3.49) as well as allergic rhinitis without AE (p=2.5x10-6) 
(Weidinger et al., 2008c).  Furthermore, a birth cohort study (n=6971) support the strong 
association with AE (p=2.5x10-4) as well as suggesting these mutations as a risk factor for 
an early onset AE that tends to persist in childhood and associated with other atopic 
phenotypes (Henderson et al., 2008).   
 
Table 1.5: Summary of some genetic studies conducted to investigate the significance 
of FLG null mutations in AE.  There are at least twenty genetic studies investigating the 
significant of FLG mutations and AE in different populations. The most common variants 
in Caucasians are R501X and 2282del4, while 3321delA and S2554X variants are common 
in Japanese population. 
Study 
population 
Method of  recruitment % AE cases with 
one or more FLG 
null mutation 
P-value, OR Reference 
Ireland 52 children at hospital 
clinic 
56 p=3x10-17 
Scotland 604 children and 
adolescents with asthma 
23 p=4.8x10-11 





(Palmer et al., 
2006) 
Germany 871 birth cohort (189 
AE) 
16.7 p=3.5x10-5 (Marenholz et al., 
2006) 




(Barker et al., 
2007) 
Japan 7 patients with IV and 
143 with AE  
NA 0.0015* (Nomura et al., 
2007) 
England 811 children from birth 
cohort (195 with AE) 
18.4 p=1.2x10-4 
 
(Brown et al., 
2008) 
England 6971 children from birth 
cohort (1445 with AE) 
20.7 p=3.96x10-20 (Henderson et al., 
2008) 
Germany 3099 children from 
cross-sectional 
population study 
15.8 p=2.5x10-14  
(OR=3.115) 
(Weidinger et al., 
2008c) 
*Data related to the 3321delA and S2554X mutations. 
†The analysis was extended to include all 6 common FLG mutations in 186 subjects which showed that 
45.7% of cases had one or more of these mutations (p=1.3x10-28, OR=5.6). 
 
 
The association between FLG mutations and AE have been demonstrated in several studies 
(Hamada et al., 2008; Nomura et al., 2007; Palmer et al., 2006; Sandilands et al., 2006; 
Sandilands et al., 2007).  These mutations may interfere with the transformation of 
profilaggrin to filaggerin that leads to skin barrier dysfunction (Palmer et al., 2006).  
Decreased expression of filaggrin has been found in lesional and nonlesional skin of AE 
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patients (Seguchi et al., 1996).  However, the significance of FLG mutations in the 
development of AE is controversial and can not explain all of AE cases.  Since FLG 
mutations do not account for all patients with AE (Sinclair et al., 2009), genetic variants of 
other genes involved in skin barrier function are possibly to be important in the 
pathogenesis of AE, such as SCCE and SPINK5.  SCCE gene involve in desquamation by 
cleaving proteins of the stratum corneum therefore disrupting function (Vasilopoulos et al., 
2004), while SPINK5 controls skin desquamation and shedding  (Ekholm et al., 2000; 
Komatsu et al., 2002), which will be discussed in more detail in chapter 4.  Also, skin 
inflammation in AE patients is accompanied with upregulation of the cytokines especially 
IL-4 and IL-13, both of which decrease the expression of FLG gene and other proteins in 
keratinocytes (Howell et al., 2007). 
 
6. Human genetics and technology 
 
The enormous advances in human genetic recently, are in part due to enabling technologies 
to achieve conclusive high-resolution genomic analysis.  These new technologies include 
whole-genome sequencing, targeted sequencing of candidate genomic regions, functional 
genetic studies (Morozova and Marra, 2008) and being able to genotype SNPs (105-106) in 
thousands of samples (Grant and Hakonarson, 2008).  Recently, whole-genome sequencing 
have been used in genetic and medical studies, such as discovering cancer-initiating 
mutations of myeloid leukaemia in previously unidentified genes that may respond to 
targeted therapies (Ley et al., 2008).  
 
In the past, investigators generally used two main strategies to identify disease-
susceptibiltly genes including, linkage analysis using a series of consecutive molecular 
markers such as microsatellites or SNPs, and candidate gene approach to identify genes that 
are know to contribute in disease pathogenesis (Hirschhorn, 2005).  Denaturing high-
performance liquid chromatography (dHPLC) have been used for SNP detection based on 
motilities of DNA molecules under partially denaturing (nonfluorescent) in polymerase 
chain reaction (PCR)-amplified regions using double-stranded DNA (Xiao and Oefner, 
2001) and abnormal profiles sequenced for polymorphisms identification.  The 5'-nuclease 
83 
allelic discrimination assay, TaqMan®, is one of many PCR-based assay for genotyping 
SNPs detected (Holland et al., 1991; Hui et al., 2008; Livak, 1999).   
 
The knowledge gained from the HapMap project as well as the tremendous advances in 
high-throughput genotyping technologies using high-density SNP genotyping arrays (Hao 
et al., 2008), result in an expansion of positive whole genome-association studies (WGAS), 
and identification of major genetic factors underlying common diseases such as 
inflammatory bowel diseases (IBD) (Duerr et al., 2006; Hampe et al., 2007; Rioux et al., 
2007), type 2 diabetes (Saxena et al., 2007; Sladek et al., 2007; Zeggini et al., 2007), and 
systemic lupus erythematosus (SLE)  (Harley et al., 2008; Kozyrev et al., 2008; Nath et al., 
2008).  Several technologies have been used including; Invader assays (Mein et al., 2000), 
Affymetrix GeneChips, The Perlegen Genotyping Platform, and Illumina’s Infinium 
Beadchips.  The Affymetrix and Illumina offer the highest marker densities with 1.8 and 
1.2 million assays, respectively (Ragoussis, 2009), and high-density SNP genotyping arrays 
such as Affymetrix 500K (Affx500K) and Illumina 650Y (Ilmn650K) SNP arrays are used 
widely in WGAS (Hao et al., 2008). 
 
7. Genome Database(s) 
 
There are several genomic resources online that are easily accessible and do not require 
special bioinformatic skills to use (Table 1.6).  Information about whether variants occur 
near a gene, in a coding region, in an intron, in an exon or up- or down stream of the gene is 
using many genome resources.  These including: The National Centre for Biotechnology 
Information (NCBI) database (Wheeler et al., 2001), The University of California Santa 
Cruz (UCSC) database and Ensembl, as well as HapMap and database of single nucleotide 
polymorphisms (dbSNP).  Ensemble provide visualisation access and some interpretations 
related to function, based on experiment.  Also, with the sequencing of other species 
genomes, comparative sequence analysis is now possible (Hammond and Birney, 2004). 
Several loci and disease-specific variants databases are integrating additional functional 
information into their annotation sets, such as protein structure.  The Human Genome 
Variation Society provides a comprehensive list of locus-specific information that consists 
of high-quality annotations on variation in specific genes or diseases 
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(http://www.genomic.unimelb.edu.au/mdi/dblist/dblist.html).  The UCSC Genome Browser 
and genome assembly maintain an excellent resource for visualisation of SNP positions and 
other genome interpretations (Kent et al., 2002).  Furthermore, The UCSC website contains 
the genome browser which zooms and scrolls over chromosomes and maps them.  Blat 
allows users to map the sequence of interested genes to the genome.  The gene sorter 
provides information on groups of genes which may be associated together and the table 
browser permits users to access the underlying database. 
 





dbSNP http://www.ncbi.nlm.nih.gov/SNP/ SNPs from the complete 
genome  
Ensembl http://www.ensembl.org Genome database 
GoldenPath http://genome.ucsc.edu/ Genome database 
HapMap Consortium http://www.hapmap.org/ Haplotype block 
information 
 
The other primary genome resource is Ensembl, useful in obtaining DNA and amino acid 
reference sequence for the gene of interest, all reported variants within that gene with their 
data annotations such as location in the gene, type of mutation, possible change in the 
protein and whether this polymorphism is conserved among other species or not.   Another 
powerful resource for SNP analysis is SNPper created at Harvard University (Riva and 
Kohane, 2004) which focuses on SNP selection for genetic studies (http://snpper.chip.org/).  
In this study, I will use mainly UCSC (Figure 1.8), HapMap, Ensembl, and NCBI databases 
because they are easily accessible and provide large collection of comprehensive and 





Figure 1.8: UCSC genome browser page showing the Foxp3 gene.  It demonstrates 
FOXP3 gene structure, as well as visualisation of SNPs positions in the gene and whether 
they are conservated in humans and other species (http://genome.ucsc.edu/ accessed on 
28/06/08). 
 
8. Background to project 
 
AE is a common inflammatory skin disease, which usually develops before the age of 5 
years.  The prevalence of AE and other atopic phenotypes including: allergic rhinitis and 
asthma is increasing in developed countries.   A recent cohort study conducted in the UK to 
determine 18-years prevalence of AE and other atopic phenotypes showed high prevalence 
rate of AE in children (36.5%) (Punekar and Sheikh, 2009).  It is characterized by an itchy 
rash that flares intermittently over many years; skin gets inflamed and may become prone 
to various infections.  Most children arre managed using topical treatments, although a 
small number might require systemic immunosuppressive therapy (Buys, 2007).  The best 
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available immunological marker for the presence of the atopic state is the presence of an 
exaggerated tendency to form IgE antibodies to common allergens, or IgE responsiveness.  
IgE is normally produced by individuals in response to infections such as helminthic and 
gut pathogens. However, in atopic individuals the production of IgE is against common 
antigens, such as the house dust mite, pollens, moulds and animal dander (Droste et al., 
1996).  AE has a strong genetic component as nearly 70% of AE patients reported a family 
history of atopic disease.  The pattern of inheritance is polygenic with a number of genetic 
and environmental susceptibility factors involved (Sturgill and Bernard, 2004).  
Environmental factors are also known to influence the expression of atopic disease 
including month of birth, birth order, animal exposure during the first few months of life, 
maternal atopy, exposure to tuberculosis and viral upper respiratory tract (Harris et al., 
2001). 
 
Genetic linkage and association studies have been undertaken to try to map disease loci 
for AE with linkage to chromosome regions 1q21, 5q31, 11q13 and 17q25 (Cookson, 
2002).  A number of genes have been associated with AE including LEKTI, a-domain 
serine proteinase inhibitor and those important in the immunological response such as 
alpha subunit of interleukin-4 receptor (IL4RA) (Hershey et al., 1997; Walley et al., 
2001).  A significant recent finding in understanding the genetic mechanisms of AE was 
the identification of an association with AE and mutations in the gene encoding the skin 
barrier associated protein FLG (Palmer et al., 2006).  Subsequently, there have been 
numerous studies that have robustly replicated this finding in European and some Asian 
populations (Brown and Irvine, 2008; Brown et al., 2008; Nomura et al., 2007; Rodriguez 
et al., 2009; Sandilands et al., 2007).  However, we found no strong evidence for genetic 
association with AE and FLG in a Bangladeshi family study (Sinclair et al., 2009). 
 
The Bangladeshi community in the East of London is one of the poorest immigrant 
communities in the UK with high rates of unemployment, overcrowding, and poor 
housing (UK Census data, 1991).  In the Pediatric Dermatology clinic at the Royal 
London Hospital, 90% of the children attend the clinic for AE are Bangladeshi.  They tend 
to come from large families with several siblings and, for the majority of cases, originated 
from the same geographical region of Bangladesh, Sylhet, which may makes the gene 
pool smaller than ethnically mixed populations such as the Caucasian UK population.  
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The prevalence of AE in Bangladeshi children born in Bangladesh is approximately 6.5%  
(Kabir et al., 2005), while we estimate that AE occurs in approximately 20% of 
Bangladeshi children born in the UK which is similar to the prevalence observed in other 
migrant groups suggesting that although genetic factors are important in AE, so are 
environmental triggers (Williams et al., 1999). 
 
The atopic eczema project was started in 2001 before the human genome was sequenced 
and the development of cost-effective high throughput genotyping systems to allow WGA 
studies to be performed.  Therefore, a family-based study has been designed in which, 
families with same ethnicity and location in Bangladesh as well as strong history of AE.  A 
microsatellite genome scan was performed and a number of suggestive regions of linkage 
identified including regions in chromosome 2, chromosome 3 and chromosome X.  The 
next step was to target positional genes in the genome (microsatellite) scan plus assessing 
other genes previously associated with AE from other population sets.  A literature review 
was conducted to identify genes which had been previously associated with AE and other 
atopic phenotypes in several populations.  Also, other possible novel candidate genes that 
were identified as being particularly relevant either through biological function or position 
within the genome.  A total of twenty seven candidate genes were screened using Illumina 
Based Array, eleven genes had been previously associated while sixteen genes were novel.   
 
A cohort of 70 Bangladeshi families was recruited with two or more siblings with AE from 
East London, UK as well as all first degree relatives. This means that they are likely to be 
enriched for a genetic component of disease as one affected might be sporadic while several 
affected individuals in same family suggest higher chance of underlying genetic aetiology.  
In addition, this ethnic group have a relatively high incidence of consanguinity and 
originated from the same region of Bangladesh (Syhlet), thus enriching for common 
disease-assocated gene variants within families and between families. We have defined AE 
as eczema symptoms along with IgE sensitivity.  This cohort was used to look for known 
and novel genes linked to AE and other atopic phenotypes including asthma, hayfever, and 
food allergy as well as combined atopic phenotypes such as AE with asthma, AE with 
hayfever and AE with food allergy. 
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9. Overview of aims and objectives of thesis 
 
The aim of this thesis was to investigate the genetics of AE in the Bangladeshi families of 
East London in order to find out possible associations with AE or atopic diseases.  This 
involved investigating previously associated genes and also novel genes according to 
positive findings obtained from the microsatellite genome scan and Illumina based Array 
genotyping.   
 
Three genes have been selected for further investigations in this study; FOXP3, SPINK5 
and TNC.  Suggestive linkage from the microsatellite genome scan was identified to region 
in chromosome Xp11 (LOD score=1.8) that have been previously implicated with IgE 
levels.  In terms of broader relevancy to autoimmunity, this region also has been linked to 
other autoimmune disorders including T1D, multiple sclerosis (MS), RA and autoimmune 
thyroid disease (AITD) (Ban et al., 2007; Cornelis et al., 1998; Cucca et al., 1998; Ebers et 
al., 1996; Orsmark-Pietras et al., 2008), highlighting the presence of common susceptibility 
polymorphism(s).  Furthermore, it gained a lot of attention due to the presence of higly 
plausible candidate gene, FOXP3 which maps the chromosome region Xp11.23.  SPINK5 
gene has been associated with AE in several different ethnic populations (Kabesch et al., 
2004; Kato et al., 2003; Nishio et al., 2003; Walley et al., 2001).  Autosomal recessive 
mutation in SPINK5 underlie the monogenic skin disease NS (Chavanas et al., 2000), 
which has several overlapping symptoms with atopy such as elevated IgE levels and 
predisposition to atopic diseases.  Tenascin-C gene has been found to be upregulated in the 
lesional skin of patients with AE in comparison to non-lesional skin or psoriatic skin 
(Ogawa et al., 2005).  Also, TNC gene has been identified as an important gene in asthma 
pathogenesis as well as other allergic diseases (Laitinen et al., 2004; Orsmark-Pietras et al., 
2008), which make it a possible candidate gene associated with AE.  So, the two main aims 
of this thesis were as follow: 
 
• Assess Forkhead boxp3/forkhead helix transcription factor (FOXP3) gene to 
identify possible AE (and other atopic phenotypes) associated SNPs segregating 
in the Bangladeshi families.  
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• Polymorphism detection of variants in SPINK5 and tenascin C (TNC) genes 
associated with AE and other atopic phenotypes in the Bangladeshi families 
including: asthma, hayfever and food allergy as well as AE in combination with 
other atopic phenotypes such as: AE in combination with asthma, AE with 
























































2.1 Recruitment of subjects 
 
2.1.1 Definition of the Bangladeshi AE family 
 
All families recruited for this study originated from Sylhet in Bangladesh but now reside in 
the borough of Tower Hamlets, London.  At least two children are affected with Atopic 
Eczema (AE) in each family and all available first degree relatives were recruited. 
 
2.1.2 Family ascertainment 
 
We conducted a genetic investigation of 70 Bangladeshi families with two or more siblings 
with AE from East London.  Twenty nine of these families had more than three affected 
siblings with three families having six or more affected individuals.  Probands were 
identified from the Paediatric Dermatology Clinic at the Royal London Hospital and 
phenotyped using the UK Working Party’s Diagnostic Criteria for AE (Appendix A), which 
is a refinement of the Hanifin and Rajka diagnostic criteria for AE (1980) (Table 2.1) 
(Williams et al., 1994a; Williams et al., 1994b; Williams et al., 1994c) .  Diagnosis of other 
atopic phenotypes was obtained through patient’s history in the clinic and questionnaire 
data by asking the parents about the history of asthma, hayfever or food allergy affecting 
the patient or any other family members.  Ethical approval was obtained from the North 
East London and City Health Authority Research Ethic Committee (Appendix B). 
 
Table 2.1:  The UK working party’s diagnostic criteria for AE, adapted from (Williams, 
2000) 
Child must have an itchy skin condition in the last twelve months, plus three or more of : 
1) An early age of onset (below age of two) 
2) A history of flexural involvement 
3) A history of asthma or hayfever (or history of atopic disease in siblings and parents if the 
child under four years) 
4) A history of a generally dry skin in the last year 
5) Avisible flexural dermatitis as per photographic protocol 
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These families have consented (Appendix C) to a genetic and epidemiological study, 
involving a questionnaire, atopic phenotype by IgE levels and blood sampling for genetic 
studies.  A Sylheti-speaking research assistant, trained and validated in using the Diagnostic 
Criteria for AE, visited family members at home to perform phenotyping evaluation of 
other family members and obtain blood samples from consenting individuals.  The main 
strategy of this study have been summarised in a flow diagram (Figure 2.1).   
 
Figure 2.1: General strategy used in this study for disease gene identification in the 
Bangladeshi families with atopic eczema individuals (Prof D. Kelsell). 
 
2.1.3 Questionnaire Data 
 
Epidemiological Information collected via questionnaires (Appendix D) covered a wide 
range of information related to probands and their first degree relatives.  It includes 
personal and family details, child’s immunization and medical history and social history.  
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Also, details have been obtained about other atopic phenotypes such as asthma and hay 
fever as well as possible associated environmental factors which might be contributed to 
child’s eczema such as type of accommodation, paternal smoking, and history of pet 
exposure.  Details of each family, their affection status (eczema, asthma and hayfever) and 
their IgE levels can be found in (Appendix E). 
 




The majority of the Bangladeshi community in the East End of London is from the Sylhet 
region of Bangladesh.  It is one of the poorest immigrant communities in the UK with high 
rates of unemployment, overcrowding, and poor housing (1991 UK census).  A Sylheti 
speaking research assistant (Ruma Choudry) contacted families by telephone and arranged 
home visits for completion of a health questionnaire. The questionnaire collected 
information on medical and social history as well as potential risk and protective 
environmental and familial factors. 
 
B) Subject characteristics 
 
All epidemiological parameters (Table 2.2) including standard deviations (SDs), confidence 
intervals (CI), mean ranges and percentages were performed by Dr. Haitham El Bashir.  Of 
the 70 families studied, the total number of children was 284.  Based on the on the presence 
or absence of AE, the children were divided into 3 groups; 170 are currently affected, 29 
previously affected and 85 non-affected. The mean ages were 7.2 years (C.I 6.4-8.0), 9.9 
(C.I 7.9-11.9) and 12 (C.I 10.6-13.5) for those currently affected, previously affected and 
non-affected respectively.  There was no marked difference in participant’s gender among 
all groups; however, we noticed a mild shift toward male predominance in all affected 
group (55.3%). The majority of affected (currently or previously) children were born in the 




Table 2.2: Epidemiological description of all individuals recruited for this study.  This 
includes mainly birth data such as place, weight, type of delivery and others. 
 




Not affected (85) 
Mean age (CI) 7.2 (6.4-8.0) 9.9 (7.9-11.9) 12.0 (10.6-13.5) 
Male sex (%) 94 (55.3) 16 (55.2) 40 (47) 
UK born (%) 164 (96.5) 27 (93.1) 66 (77.7) 
Mean gestational age 
(range) 
40 (39.4-39.8) 40 (39.2-40.4) 40 (39.3-40.0) 
GA#<37 wks 5 (33-36 wks) 0 0 
Caesarean section or 
assisted delivery (%) 
21 (12.3) 6 (20.1) 9 (10.6) 
Mean birth weight in 
Kg (CI) 
3.1 (3.1-3.2) 3.24 (3.1-3.4) 3.2 (3.1-3.3) 
Birth weight<2kg 2 1 0 
Mean birth order 3 (2.8-3.2) 2.6 (1.9-3.3) 2.6 (2.3-3.0) 
1st child (%) 34 (20) 10 (35) 26 (30) 
Breast feeding 135 (79%) 26 (90%) 70 (82%) 
Mean duration of 
breast feeding (SD) 
7 (7.3) 9 (9.9) 10 (11.3) 
GA: gestational age, CI: confidence intervals, SD: standard deviation 
 
Of the 284 children in the study, 231(81%) were breast-fed. Hundred and thirty five (79%) 
of those currently affected were breast fed compared with 70 (82%) siblings with non-
affected.  The average duration of breast feeding among currently affected and their healthy 
siblings was 7 and 10 months respectively, (p=0.54).  The median age at onset of AE was 3 
months and that at diagnosis was 4 months.  A personal history of other medical conditions 
was reported in 58% of those with a history of AE compared with 23% in the non-affected 
group (p<0.001).  The common conditions were asthma 67%, food allergy 51%, hay fever 
37% and 41% have 2 or more conditions.  Common food allergens were eggs, seafood and 
peanuts.  Solids were introduced at a mean age of 4 months in both groups (Table 2.3).  All 
epidemiological data were obtained via questionnaire; patients were tested only for total 








Table 2.3: Common food allergens among Bangladeshi children with current or 
previous history of AE and food allergy (total number 100). 
Allergen Yes       No Unknown/Unsure 
Eggs 45  51 4 
Sea food  30 67 3 
Peanut 25 66      9   
Citrus fruits 24 73 3 
Food additives  33 59 8 
Cows milk 19  77 4 
 
 
On average, the age of mothers at time of study was 33 years (range 22-54).  All parents 
were born in Bangladesh and immigrated to the UK between 1973 and 1999.  The majority, 
84% (59/70) had only primary or secondary school education.  With the exception of 4 
mothers who were working/ studying, the rest were housewives.  History of atopy was 
common with 9 (13%) mothers have AE, 18 (26%) gave a history of hay fever, 11 (16%) 
have food allergy, and 7 (10%) have asthma.  None of the mothers smoked during 
pregnancy, however, 14 (20%) avoided some food items (mainly fish, seafood and meat). 
Four mothers developed gestational diabetes and were on carbohydrates restricted diet.  
 
The ages of fathers ranged from 24 to 68 years with a mean age of 40 years.  All parents 
were born in Bangladesh and arrived in the UK between 1960 and 2000.  Forty-four had 
primary or secondary school education and 8 were university students.  Twenty-six (37%) 
were unemployed at the time of the study.  Six (9%) have AE, 18 (27%) have hay fever, 5 
(8%) have asthma and 7 (10%) have food allergy. Of the 70 families, 17 (24.3%) gave 
history of parental consanguinity. 
 
Most children in the study lived in flats 58/70 (83%) and 96% had full-carpeted bedrooms. 
Sixty-two (89%) families were living in a council or housing association accommodation, 
7(10%) owned their accommodation and 1 was privately renting.  The average number of 
people per accommodation was 7 (range 3-12) and the average number of rooms was 4 
(range 2-10).  Forty (57%) children with AE (aged 6 months to 14 years) shared the 
bedroom with their parents, compared with only 9 (16%) of the unaffected siblings 
(p<0.001).  Sixteen families have moved house within the last 3 years; 4 felt that their 
children AE got better, 1 became worse and 11 were not sure or there was no change to 
their child’s condition.  Over a 3 months period, one-third (16/48) of children with AE 
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attending a nursery or school reported absence of up to 7 days, 9 were absent for 8-14 days 
and 3 were absent for more than 14 days because of exacerbation.  The Majority (11/12) of 
those absent for 8 days or more were older in age. Indoor smoking by a family member was 
present in 40 (57%) families; in 34 (85%) families, the father was the sole smoker, in 2 
families at was a sibling and in 2 families it was the grandparent.  Two families had the 
father and another relative as smokers.  Of the 170 children with a current or previous 
history of AE, 105 (62%) reported flaring of their eczema mainly in the summer and winter 
seasons.  
 
2.1.5 Collection of Samples 
 
At the beginning of my study (2005), many families were collected by myself and 
Ms.Ruma Choudry (trained in phlebotomy and AE diagnosis).  Families were recruited 
from the Royal London Hospital (paediatric dermatology clinic) and informed of the home 
visit time and date.  This followed by home visits usually at the afternoon when children 
come home from school.  Epidemiological information and history collected via 
questionnaires which performed by myself and blood was extracted by Ms. Choudry from 
the patient and all first degree relatives available.  Also, some families were sent to hospital 
for blood extraction.  All blood samples were collected in 0.25 mM EDTA tubes to prevent 
clotting before DNA extraction. 
2.1.6 DNA extraction from blood 
 
Blood samples were processed immediately or frozen at (-80) ºC.  Genomic DNA was 
extracted from whole blood samples using a commercially available kit (Qiagen).  DNA 
extraction performed using the robotic workstation based in the Genome Centre or at 
OXAGEN. 
 
DNA was extracted from blood samples taken from individuals collected by myself for the 
AE study using the QIAGEN FlexiGene DNA kit at the Genome Centre.  Table 2.4 shows 
a list of reagents used for 10ml of blood.  These were then scaled up or down depending on 
the total volume of blood in each sample.  The protocol was carried out as stated in the 
FlexiGene DNA handbook. 
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Table 2.4: DNA extraction.  Reagents required for processing 10ml Blood samples. 
Reagents 10ml Blood sample 
Buffer FG1 (ml) 25.0 
Buffer FG2/IAGEN Protease (ml) 5.0 
100% isopropanol (ml) 5.0 
70% ethanol (ml) 5.0 
Buffer G3 (ml) 1.0 
 
2.1.7 Measurement of sensitization (atopic phenotyping) 
 
IgE antibodies were quantified in all affected and non-affected individuals at OXAGEN. 
The total IgE was measured in affected and non-affected individuals. Allergen-specific IgE 
assays were done using Pharmacia's CAP System (Pharmacia & UpJohn Diagnostic AB, 
Uppsala, Sweden) which is a sensitive and specific quantitative assay for allergen-specific 
IgE antibodies more than the previous Pharmacia Phadebas Radioallergosorbent (RAST) 
system  (Leimgruber et al., 1993).  The clinical investigations proved its diagnostic value 
and confirmed the relation between the serum concentration of IgE antibodies and the 
severity of the allergic disease (Al Obaidi and Al Samarai, 2008; Benhamou et al., 2008).  
The results were reported as positive if the specific IgE is equivalent to (≥0.35 kU/L)  
(Kotaniemi-Syrjanen et al., 2003), although specific IgE testing is difficult to interpret in 
patients who have very high levels of total IgE (> 1000 kU/L) such as  patients with AE, as 
they may have low-grade reactions to many allergens (Douglass and O'Hehir, 2006).  
 
2.2 Candidate gene analysis 
 
2.2.1 Gene selection 
 
A candidate gene association study was conducted using the Illumina GoldenGate 
genotyping assay and utilizing information from the HapMap project to identify tagSNPs 
for each gene under investigation.  Eleven previously associated genes and sixteen novel 
genes were analysed.  These genes encode proteins that are largely linked with either 
immunological or skin barrier functions. 
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Phenotypic information for other allergic diseases, such as asthma, hayfever and food 
allergies, was also available for this specific population.  Therefore, all the Illumina 
candidate genes were analysed for association to these other allergic diseases.  This analysis 
also allowed combinations of allergic disease to be analysed such as AE with asthma, AE 
with hayfever and AE with food allergy.  
 




The aim of this technique was to genotype many SNPs in large number of samples in a 
rapid and cost effective manner.  The BeadArray technology is an accurate, oligo ligation 
and extension (Fan et al., 2006).  The BeadArray used in this study was the Sentrix Array 
Matrix (SAM) in which, the arrays are made of beads located in microwells of optical fibre 
bundles and further organized into a matrix that matches a 96-well microtiter plate.  A set 
of universal bead types is used for the Illumina GoldenGateTM genotyping assay.  Each 
bead type has a unique oligonucleotide sequence, corresponding to the complementary 
DNA sequences (address sequence) designed into the genotyping assay nucleotides (Fan et 
al., 2006). 
 
B) Genotyping  
 
A 384 SNP custom Illumina GoldenGate genotyping assay was designed and performed.  
Information required has been downloaded as text files from the HapMap website 
containing all of the tagSNPs for each gene.  These are then cut down by using stringent 
cut-offs and design scores received from Illumina for each tagSNP.  An r2 of 0.8 and a 
minor allele frequency (MAF) of 0.15 were used to create the final lists.  HapMap 
information from the Caucasian, Chinese and Japanese population was compared to ensure 
that maximal information from the Bangladeshi population was likely to be achieved.  
Experimental procedure was completed according to the manufacturer’s instructions.  A 
total of twenty seven candidate genes were genotyped by Claire Sinclair and Nadya 
Mahmud at the Genome Centre (Table 2.5) using the Illumina GoldenGate genotyping 
assay. 
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Table 2.5: Candidate genes for AE and other atopic phenotypes genotyped using 
Illumina in the Bangladeshi families.  Candidate genes analyed including: previously 
associated genes with AE and other atopic phenotypes as well as novel genes.   
No.  Gene symbol 
 
No. of SNPs 
per gene 
Gene name Chromosomal 
Location 
1 ABCA12 37 ATP-binding cassette (ABC) transporter, 
family 12 
12 
2 SPINK5 25 Serine protease inhibitor, Kazal-type, 5 5 
3 CARD4 (NOD1) 16 Caspase recruitment domain-containing 
protein 4 
7 
4 IL4RA 14 Alpha-subunit of the interleukin-4 receptor 16 
5 CD86 18 Type I membrane protein of the 
immunoglobulin superfamily 
3 
6 TNC 45 Tenascin C 9 
7 IL1RL1 (ST2) 16 Interleukin 1 receptor-like 1 2 
8 ACVR1 23 activin A type I receptor 2 
9 CCR4 3 Chemokine (c-c motif) receptor 4 3 
10 TIM3 2 T cell immunoglobulin- and mucin 
domain-containing molecule 
5 
11 JAK3 21 janus kinase 3 19 
12 KYNU 53 Kynureninase 2 
13 SLC9A3R1 7 Family 9, isoform 3 regulatory factor 1 17 
14 PTGDS 4 prostaglandin D2 synthase 9 
15 STAT6 8 Signal transducer and activator of 
transcription 6 
12 
16 IL10RA 11 Interleukin 10 receptor 11 
17 FCER1B 8 beta-chain of the high-affinity receptor  11 
18 PTPN22 13 Protein tyrosine phosphatase-22 1 
19 HRF 5 IgE dependent histamine releasing factor 13 
20 CCL5 
(RANTES) 
5 Chemokine (c-c motif) ligand 5 17 
21 CMA1 8 Chymase 1 14 
22 WASIP 15 Wiskott-Adrich syndrome protein 
interacting protein 
2 
23 NRAMP 6 Natural resistance-associated macrophage 
proteins 
2 
24 FAP 7 Fibroblast activation protein 2 
25 COL7A 2 alpha chain of type VII collagen 3 
26 Loricrin 4 Loricrin 1 
27 CCL1 4 Chemokine (c-c motif) ligand 1 17 
 
 
2.2.3 Statistical analysis of genotype data 
 
Genotyped data for individual markers was tested for association with AE using The 
Family Based Association Test (FBAT) package (FBAT, V2.0.2c) at the Genome Centre 
(Dr. Charles Mein).  FBAT compares the genotype distribution found in offspring with its 
expected distribution (Rabinowitz and Laird, 2000).  It handles multiple affected offspring 
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per family and both multi-allelic and bi-allelic markers.  Also, it permits various genetic 
models to be tested such as additive, recessive and dominant models.  The effect of risk 
allele does the following; it increase with its copy number in additive model, it is the same 
for one or two copies in a dominant model, and it presents only with two copies of the risk 
allele in the recessive model (Tang et al., 2007).  FBAT is used to test for association using 
the phenotypes affected status and IgE levels as discontinuous and continuous traits (Laird 
et al., 2000).  Phenotype files were also created documenting all allergic disease of all 
individuals in this study.  Allergic disease phenotypes include; AE, Asthma, Hayfever and 
Food allergy.   
 
Pedigree Based Association Test (PBAT) was used to calculate the expected power of our 
study (Lange et al., 2004).  Families with two or more affected individuals were modelled 
over a range of odds ratios to demonstrate the population’s power to detect dominant and 
recessive effects.   LD maps were generated using the generated genotypes from the 
Illumina study and haploview (Barrett et al., 2005). 
 
2.2.4 Bonferroni correction 
 
The Bonferroni correction is a statistical method for correction when multiple statistical 
tests are being carried out.  Therefore the significance level that a p-value is required to 
meet is more stringent and in theory would reduce the type 1 error or the number of false 
positives.  To calculate the bonferroni correction the significance level (usually 0.05) is 
divided by the number of tests being carried out (for example the number of SNPs being 
investigated).  
 
As discussed in previous sections, there is a need to correct p-values for multiple testing.  
Three genes were studied in this thesis, including; FOXP3, SPINK5 and TNC.  P-values of 
each gene were corrected using total number of markers, phenotypes and models.  This 
means that in order for SNPs to be significant after multiple testing, specific thresholds 





2.2.5 Power calculation and statistical analysis 
 
Power calculations were performed to calculate the expected power of our study population 
(Claire Sinclair and Dr Charles Mein).  This was done using the PBAT (Lange et al., 2004) 
which is an extension of the FBAT (Horvath et al., 2001) software and allows calculations 
of power for studies based on specific assumptions.  The likelihood of detecting major and 
minor effects under dominant and recessive models in the 70 Bangladeshi families with 2 
or more affected individuals was computed.  The results of these calculations are listed in 
(Table 2.6).  The results indicate that, in this family study, major effects (OR=4) with 
common allele frequencies for both dominant and recessive models would be seen and 
minor effects (OR=2) with common allele frequencies in a dominant model would be 
found. 
 
Table 2.6: Power calculation of this study done using the PBAT.   This software permits 
calculations of power based on specific assumptions.  The likelihood of identifying major 
and minor effects under dominant and recessive models in the Bangladeshi families (n=70) 
was computed. The results showed that major effects (OR=4) with common allele 
frequencies for both dominant and recessive models would be seen and minor effects 
(OR=2) with common allele frequencies in a dominant model would be found  











0.05 0.32059 0.4199 0.34382 0.9412 
0.1 0.88209 0.9471 0.49758 0.98733 
0.2 1 1 0.57173 0.99041 
0.3 1 1 0.52021 0.96731 
0.4 1 1 0.41226 0.8804 
 
Statistical analysis was performed using the Illumina Beadstudio package to ensure proper 
clustering of the alleles.  SNP association analysis was performed using the Family Based 
Association Test (FBAT) program (Laird et al., 2000).  This allowed us to generate global 
p-values for each tagSNP and see if there was any association with AE.  Multiple testing 
corrections were also done on a gene by gene level using the total number of SNPs used to 
analyse each gene.  The results of these power calculations indicate that within this 
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population, both major and minor dominant effects and major recessive effects could be 
observed within this population.  However, this population would only be able to find 
common effects, minor allele frequency of over 10%, and not rare variants.  This power 
calculation is quite optimistic as it assumes a p-value of 0.05 and quite a large OR.  Smaller 
p-values have been used in this study to account for multiple testing and also realistic Odds 
are much smaller given that AE is a complex genetic disease.   
 
2.3 Mutation screening-DNA analysis 
 
2.3.1 Sample selection for polymorphism detection in TNC and SPINK5 
 
Patient selection for TNC and SPINK5 has been carried out using haplotype sample 
selection approach based on the Illumina result data and Haploview software (v3.32).  
Using the SNP loader DOTPED program at the Genome Centre, PED files for TNC and 
SPINK5 data have been created.  PED files then uploaded in Haploview software to 
identify the haplotype blocks.  The "ped" file format is a widely-used format for linkage 
pedigree data. Each line describes a single (diploid) individual in the following format: 
family ID, individual ID, father ID, mother ID, gender, phenotype, genotype 1, and 
genotype 2.  If the data lacks pedigree information, such as father or mother ID, it indicated 
in ped file by 0.  Individual’s gender represented 1=male and 2=female.  Phenotype refers 
to the affected status (for association studies) where 0=unknown, 1=unaffected, 2=affected.  
Finally, each genotype is written as two (=diploid) integer numbers (separated by 
whitespace), where 1=A, 2=C, 3=G, 4=T. No header lines are allowed and all columns 
must be separated by whitespace.  
 
2.3.2 SNPs identification 
 
To assess the prevalence of known SNPs and to detect novel SNPs in Foxp3, TNC and 
SPINK5 genes present in the Bangladeshi families.  Individuals representing the major 
haplotypes were screened for sequence variants (using the ensemble and the UCSC 
websites http://www.ensembl.org/ and www.genome.ucsc.edu).  The genomic structure of 
these genes was elucidated using the genome browser at UCSC website 
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(www.genome.ucsc.edu) and primers that flank the coding regions of these genes were 
designed for PCR and subsequent dHLPC/sequence analysis.   
2.3.3 FOXP3 primers 
 
Primers were designed using the Primer 3 website (primer3_www.cgi v 0.2) that covered 
the whole coding region of FOXP3, spanning 12 exons shown in (Table 2.7), 5΄ region, are 
shown in (Table 2.8), and the intronic boundaries are shown in (Table 2.9).  Primers were 
designed according to gene sequence (ENSG00000049768).  These sets of primers were 
ordered through (Sigma Genosys).  
 
Table 2.7: Primers used to screen Foxp3 exons 
Primer name 
 


















































Table 2.8: Primers used to screen foxp3 promoters 
Primer name 
 




















Table 2.9: Primers used to screen foxp3 introns 
Primer name 
 
































Failed  optimization 
 
2.3.4 TNC primers 
 
The intron-exon organization of TNC was determined by an electronic search of the 
genomic DNA using ensemble genome browser web site (http://www.ensembl.org/ 
accessed on 20/07/08).  Twenty eight pairs of primers were designed using Primer 3 





Table 2.10: Primers used to screen TNC gene 
Primer name 
 





























































































































































2.3.5 SPINK5 primers 
 
SPINK5 primer sequences were obtained from a study by Bitoun et al., (2001). Primers 
which failed at the level of optimization (1, 5,12,13,16, 23, 31, 32, 11, 21, and 10) were 
redesigned (Table 2.11).  The introns-exon boundaries of SPINK5 were revealed by an 
electronic search and gene sequence obtained from Ensemble (http://www.ensembl.org/ 
accessed on 20/07/08).  SPINK5 is encoded by 34 exons and spans a region of 61 kb. 
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Table 2.11: primers used to screen SPINK5 
Primer name 
 

















































































































































































2.3.6 Polymerase Chain Reaction (PCR)  
 
Standard PCR reactions were carried out using Biotaq polymerase (Bioline, UK) in a PCR 
reaction with a total volume of 20µl.  These reagents, as well as the concentrations used, 
are shown in (Table 2.12). 
 
Table 2.12: Standard PCR reagents and all concentrations 
Standard 20µl PCR reaction 
4µl 5ng/ µl DNA                                           
2µl (10X) NH2 Buffer 
0.6µl (25mM) MgCl2 
0.2µl (10mM) dNTP mix 
0.2µl Taq Polymerase 
0.2µl (10 pmol/ µl ) Forward primer 
0.2µl (10 pmol/ µl ) Reverse primer 
12.6µl dH2O 
 
All PCR reactions were carried out using engine Tetrad PCR blocks (Bio-Rad, UK).  
Optimal annealing temperature was determined for each set of primers across a gradient 
from 55°C to 65°C.  Cycling conditions were standardized unless otherwise stated with 
initial denaturing at 94ºC for 2 min followed by 35 cycles of 94ºC for 30s followed by the 
specific annealing temperature for 30s and then 72ºC for 1 min, with final elongation stage 
at 72ºC for 5 min in the final cycle. 
 
2.3.7 Agarose Gel Electrophoresis 
 
Agarose gels for the analysis of DNA fragment size were all prepared for a medium size 
tray using 2% of agarose (Sigma, Pool, UK) dissolved in 1 X TBE buffer.  The solution 
was then heated in a standard microwave until boiling, cooled to below 60 ºC before the 
addition of ethidum bromide to a final concentration of 0.5 µg/ml.  After pouring the gel 
and allowing to set, DNA products were loaded onto the gel using 6X loading dye (Bioline) 
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and run in a submarine tank (Bio-Rad, USA).  The size standard used was 1 Kb plus ladder 
(Invitrogen, USA).  Then the samples are electrophoresed through the gel for 40 minutes at 
constant voltage of 120 V.  Products were visualized using an ultraviolet (UV) trans-
illuminator and photographed for reference.  All solutions required for agarose gel 
electrophoresis are shown in (Table 2.13). 
 
Table 2.13: Details of agarose gel solutions 
6X Loading Dye 1Kb Plus DNA Ladder 1X TBE 
0.25% bromophenol blue 10% 1Kb Plus ladder (Invitrogen, 
USA) 
45mM Tris-Borate 
15% Ficoll in H2O 
 
16% 6X loading dye 2mM EDTA 
0.25% xylene cyanol FF 
 
74% H2O  
 
2.3.8 High Performance Liquid Chromatography (HPLC) 
 
Denaturing high performance liquid chromatography (dHPLC) was used to identify SNPs 
distinguishing between homo and heteroduplexes of DNA using the WAVE manufacturer.  
This technique aims to detect heterozygous polymorphisms and it has been shown to be a 
highly sensitive method for the identification of genetic changes comparable to fluorescent 
single strand conformation polymorphism (SSCP) (Ellis et al., 2000).  PCR products are 
denatured and slowly rehybridised allowing non-variant DNA to form a homoduplex.  
Fragments containing a mismatched base pair(s) will form a heteroduplex.  The sample is 
then passed through the resin column that binds the DNA by means of the chemical 
intermediate triethylammonium acetate (TEAA).  The TEAA-DNA molecules have an 
overall positive charge that binds the negatively charged resin column.  The affinity for 
homoduplexes is higher than that of heteroduplexes, so by using an increasingly stringent 
gradient of acetonitrile (ACN) buffer, the homoduplexes and heteroduplexes elute from the 
column at different time points giving rise to distinct profiles.  The precise method used is 
as follow: 
 
After the generation of PCR products, 3-10 µl, DNA fragments in a 96-well plate 
(ThermoHybrid) were heated to 95ºC for 2 min then cooled on a ramping gradient of 
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0.03ºC per sec to a temperature of 40 ºC.  This allows DNA re-hybridization in a random 
manner to ensure formation of heteroduplexes.  In each run, 5µl of PCR product was 
individually injected into the WAVE machine and analysed using the mutation detection 
programmes specific to each sequence. The Wavemaker 3.4 software (Transgenomic, 
France), has been used for each DNA fragment to predict the optimal acetonitrile gradient 
and column temperature for efficient elution of the DNA homo and heteroduplexes.  Each 
sample took approximately 9 min to run, and following each run a wash of the column and 
injection needle was carried out using supplied washing solution buffer C.  With each new 
experiment fresh buffers for each new set of runs as shown in (Table 2.14). 
 
Table 2.14: Transgenomic WAVE buffer details 
Buffer A Buffer B  Buffer C for 75% ACN hot 
wash 
Bufffer D for 8% ACN 
needle wash 
50ml 2M TEAA, pH 
7.0 
50ml 2M TEAA 300ml ACN 32 ml ACN 











2.3.9 DNA Sequencing  
 
All exons for each gene were amplified by PCR and then sequenced in the chosen 
individuals to try and identify any mutation and determine its structure.  Sequencing was 
carried out using a BigDye sequencing protocol, in which the reaction chemistry is based 
on BigDye® terminators, energy transfer dyes (Lee et al., 1997; Rosenblum et al., 1997).  
The dideoxy method for DNA sequencing, developed by Sanger et al., (Sanger et al., 1977) 
uses the advantage of the ability of DNA polymerase to incorporate analogues of 
nucleotides by using a mixture of dioxynucleotide triphosphate (dNTPs) and 2’, 3’-
dideoxynucleotide triphosphate (ddNTP) as substrates.  When dideoxynucleotides are 
incorporated at the 3’ end of the growing chain, it terminates chain elongation.  In BigDye 
terminator method, four different fluorescent dyes are used to label ddNTPs.  Thus, a 
pattern of peaks of different dye, corresponding to fragments of different lengths, is 
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produced.  Sequencing traces, calls bases, and quality value to each called base then 
analysed using Phred Phrap software.  Thermal cycling conditions for the dye incorporation 
thermal cycling are mentioned in section 2.3.9.2. 
2.3.9.1 Clean up of PCR products prior to sequencing 
 
PCR products were cleaned up using Exonuclease 1 and Shrimp Alkaline Phosphatase 
(EXOSAPIT) (Amersham Pharmacia Biotech, Sweden), which contains the two hydrolytic 
enzymes; exonuclease 1 which degrades single stranded DNA including primers and 
shrimp alkaline phosphatise that dephosphorelates unincorporated dNTPs.  1.5µl of 
EXOSAPIT was added to every 3.5µl of PCR reaction and transferred to the thermocycler 
using the following conditions; 37ºC for 15 min, 80ºC for 15 min, and finally 4ºC for 2 
min. 
2.3.9.2 BigDye Sequencing Reaction 
 
In the same Abgene 96-well plate, the following reaction mixes for each sample were made 
up to a total volume of 10µl per reaction.  ABI BigDye® terminator reagents (Applied 
Biosystems, UK) were used as shown in (Table 2.15).  Then the plate was transferred to the 
PCR block again for the thermocycling and the following conditions used: 25 cycles of 
96ºC for 30s, 50ºC for 15s, and 60ºC for 2 min, followed by 4ºC for 2 min. 
 




BigDye Terminator master mix v3.1                                                  1µl 
Better µl Buffer                                                                                  3µl
Primer (5-10 pmol/ µl)                                                                       1µl
Template (approx 200ng/µl)                                                            4µl 
Distilled H2O    1µl 




2.3.9.3 Post-sequencing clean up (removal of unincorporated BigDye) 
 
Reactions were precipitated to remove unincorporated Big Dye using a mix of 60µl of a 
33:1 ratio 100% ethanol and 7.5M Ammonium acetate added to each sample in a 96-well 
Abgene plate.  The sealed plate was inverted several times to mix and then centrifuged 
(Sigma 4K15) with a 09100 rotor at 3100 relative centrifugal force (RCF) at 4ºC for 30 
min.  The supernatant was tipped off immediately and plates drained upside down on tissue 
at 250 RCF for 30 sec.  100µl of chilled 70% Ethanol was added to each well and the pate 
was spun at 3100/RCF 4°C for 2 min and this step was repeated once more. The 
supernatant was tipped off immediately and the plate spun upside down on tissue at 250 
RCF for 30 sec and allowed to air dry for 10 min before being re-suspended in 10µl of 
dH2O.   Abgene plate contents were transferred to 96-ABI plate (Applied Biosystems, UK), 
and 8µl of HiDi Formamide was added to each well.  Then, the plate was sealed with a foil 
seal and pulse-centrifuged to 3000 RCF for 1 min before being placed onto an ABI 3700 
sequencer. 
2.3.9.4 DNA sequence Analysis 
 
Sequence analysis was carried out using Phred, Phrap and Consed software and variants 
were detected using reference sequences found using Ensembl Genome Browser 
(http://www.ensembl.org/) (Ewing and Green, 1998; Ewing et al., 1998; Gordon et al., 
1998)  
 
2.3.10 TaqMan® SNP Genotyping Assay 
 
This technique was used to obtain rapid, cost effective and specific genotype data for each 
SNP for a large number of individuals.  The TaqMan® Allelic Discrimination Assay is a 
single tube PCR assay that uses the 5’ nuclease activity of AmpliTaq Gold® DNA 
Polymerase (Livak et al., 1995; McGuigan and Ralston, 2002).  Each assay consists of two 
primers for amplifying the polymorphic sequence of interest and two allele-specific 
TaqMan® probes.  These probes have a fluorescent reporter dye at the 5’ end (VIC® dye is 
linked to the 5’ end of the Allele 1 probe and FAMTM dye is linked to the 5’ end of the 
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Allele 2 probe), and a non-fluorescent quencher (NFQ) with a minor groove binder (MGB) 
at the 3’ end (De la Vega et al., 2005). 
 
When the probes are intact, fluorescence is quenched due to the physical proximity of the 
reporter and quencher dyes (FRET) (Livak et al., 1995).  A fluorescent signal is produced 
when the intact probe, which is hybridized to the target allele, is cleaved by the 5’ 
exonuclease activity of AmpliTaq Gold® Polymerase during each cycle of the PCR 
reaction.  The PCR primers amplify a specific region on the genomic DNA template, and 
each fluorescent dye-labeled hybridization probe indicates which alleles are present in the 
DNA sample as shown in (Table 2.16).  In each PCR cycle, cleavage of only probes that are 
hybridized to the target generates an increasing fluorescent signals by freeing the 5’ 
fluoropohore from the 3’ quencher.  The advantage of using two probes, one specific to 
each allele of the SNP which labeled with two fluorophores, enables identification of both 
alleles in the same tube (De la Vega et al., 2005). 
 
Table 2.16: Correlation between fluorescence signals and sequences in a sample 
A substantial increase in Indicates 
VIC-dye fluorescence only Homozygosity for Allele 1 
FAM-dye fluorescence 
only 
Homozygosity for Allele 2 
Both VIC- and FAM-dye 
fluorescence 
Allele 1 and Allele 2 heterozygosity 
 
Probes with an MGB enhance allelic discrimination, because it protects the double-stranded 
probe template structure, thus, increasing the melting temperature (Tm) without increasing 
the length of the probe.  Shorter probes result in greater differences in Tm values between 
matched and mismatched probes, producing potent allelic discrimination (Kutyavin et al., 
2000). 
 
All TaqMan primers and probes were designed by Applied Biosystem.  Working DNA 
concentration was 5ng/ul for 2.5 µl reaction.  96-well DNA boxes were selected, defrosted 
and centrifuged. 2µl of sample DNAs were dispensed in 384-well plates and kept 
uncovered at room temperature for three days to allow them to dry out.  Taqman reagent 
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mixes were calculated to a total volume of 384µl as shown in (Table 2.17) using the 
Taqman program on Mendel (Genome Centre).  Then, 2.5µl of reagent mix per sample was 
dispensed into 384-well plates.  Finally, plates were sealed with ABI optical seals, 
centrifuged to 4000 rpm for 1min before transferring to the 7900 (ABI). 
 
For new assays, an absolute Quantification method has been used to determine the reactions 
efficiency followed by an Allelic Discrimination (end point) method.  Genotype calls for 
each sample are made by plotting the normalized intensity of the reporter dyes in each 
sample well on a cluster plot.  A clustering algorithm in the data analysis software (SDS 
2.1) (Applied Biosystems) refers individual sample data to a specific genotype cluster (De 
la Vega et al., 2005). 
 
Table 2.17: Taqman® Master Mix calculations 
Allele Scoring                                                                              Volume 
Reaction Volume                                                                                 2.5µl 
Number Reactions                                                                              384µl 
Primer and probe concentration                                                            40µl 
 
Taqman universal mastermix 2X                                                      192 µl 
Primers and Probes                40X                                                      9.6 µl 
dH2O                                                                                                182.4 µl 
Total                                                                                                    384 µl 
 
2.3.11 Microsatellite markers  
 
2.3.11.1 FOXP3 markers 
Five microsatellite markers; J12, J13, J17, J19, and J26 in FOXP3 gene were examined and 
are the same as that in a study by Zavattari et al., (2004) (Table 2.18).  PCR oligo-primers 
and the probes used to genotype the polymorphisms of interest are illustrated in (Table 






Table 2.18: Polymorphisms analysed in and around the FOXP3 gene.  In the first 
column the 5 polymorphisms are indicated by an internal lab code; column 2 contains 
information relative to the distances between the different loci analysed, column 3 indicate 
the class of polymorphism, while in columns 4 is reported positions relative to the FOXP3 
gene.  




53129 Del3 (TAA) +147from exon -1 
J13 
 
54454 del2 (TT) -4665 from exon 1 
J17 
 
58940 (GT) repeat -150 from exon 1 
J19 
 
61394 (CT) repeat Introns 5-6 
J26 
 
81816 (TG) repeat downstream 
 
Table 2.19: Microsatellite markers used to screen FOXP3.  Details of primer sequence 
and their optimal conditions of annealing temperature and MgCl2 concentration are shown.  
Note that forward primers are fluorescently labelled with FAM, TAM and HEX. 
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2.3.11.2 TNCex19 marker 
 
Primer pairs for the microsatellite were selected in order to have PCR products as small as 
possible.  Reference sequences for short tandem repeat STR marker was obtained from 
(http://www.ensembl.org/).  Fluorescently labeled forward primer (5’-
6CCAGAGGGTAGGAGCAAATG-3’) and unlabeled reverse primer (3’-
AGGCTGAAGGTGAGAAATGG-5’) were purchased from Sigma.  Primers had an 
annealing temperature of 64°C to be used in simultaneous amplification reaction.  
 
2.3.12 Microsatellite Genotyping 
 
This technology was used to obtain genotype data of microsatellites detected within short 
turnaround times and low costs by use of fluorescent tagged primers and a pooling strategy.  
Primers amplifying microsatellite markers were synthesized with a fluorescence-labeled 
dye on forward primers which enabled detection on ABI PRISM 3700 automated 
sequencer.   Alleles from each individual in a family are separated by size. 
 
All PCR products pooled together in 96-well plate using post PCR robot program at the 
Genome Centre (http://mendel/sop/MicroSatellite/96 PCRpool.pdf accessed on 17/03/06).  
A mixture of 1 ml of HiDi and 20µl of GENSCAN 500 ROX added together, and 8µl of 
that mixture dispensed in each well of 96-ABI plate.  Using the post PCR robot again 
(http://mendel/sop/3700/96to96 3700prep.pdf accessed on 17/03/06) 2µl of DNA plate 
added to the ABI plate and denatured at 95°C for 5 min.  Samples loaded via a capillary 
system form 96-well microtiter plate and run on an ABI 3700 automated sequencer.  
Analysis of the images was carried out using ABI software package (Genotyper v.3) from 
Applied Biosystems and allele sizes were recorded.  
 
2.4 Summary of various techniques and interpretations 
 
The aim of various genetic techniques and molecular genetic statistical methods used in this 
study was to detect polymorphisms in candidate genes; FOXP3, SPINK5 and TNC.  These 
genes have been studied for association with a range of atopy-related phenotypes including: 
AE, asthma, hayfever, food allergy, AE with asthma, AE with hayfever and AE with food 
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allergy.  Samples of disease subjects along with their parents and other first-degree relatives 
have been used to study a possible association between atopic phenotypes and specific 
genetic markers.  Such family trios design was used to construct family-based association 
tests (FBATs).  FBAT was used to compute the distribution of various test statistics under 
the null hypothesis, conditioning on the phenotypes.  All data collected on a set of related 
phenotypes that are potentially associated with the marker loci under study.  Statistical data 
interpreted according to the p value indicating; significant p-values at p≤0.05 and not 
significant at p≥0.05.   FBAT mainly evaluate the statistical significance of the smallest 
observed p-value among all the scores.  Due to the special design of this study which is a 
family design, all statistical analysis was carried out using the FBAT software and 
interpreted as p values instead of odds ratio that used extensively in case-control studies.  
Odds ratio was calculated for this study to find out that there is enough power to detect 
common effects and minor frequency of over 10% which was optimistically high for a 





















Analysis of genetic variation at the FOXP3 locus 































Previous to this study, a microsatellite genome scan was performed with a high-density 400 
microsatellite markers and suggestive linkage was identified to a number of chromosome 
regions including the X-chromosome (Figure 3.1), on chromosome 2 and chromosome 3 
(introduction section 5.2.3) (Prof. D. Kelsell).  Some of these regions have previously been 
implicated with eczema and IgE; microsatellite markers in the Xp11 region gave suggestive 
evidence for linkage to high IgE (LOD score: 1.8).  In terms of broader relevancy to 
autoimmunity, human chromosome region Xp11 has also been linked to other autoimmune 
disorders including type 1 diabetes (T1D), rheumatoid arthritis, multiple sclerosis and 
autoimmune thyroid diseases (AITD), highlighting the presence of common susceptibility 
polymorphism(s) (Ban et al., 2007; Cornelis et al., 1998; Cucca et al., 1998; Ebers et al., 
1996).  This position has also gained a lot of attention due to the presence of highly 
plausible candidate gene, forkhead box P3 (FOXP3) which maps to the human 
chromosome region Xp11.23 (Paik et al., 2008). 
 
Figure 3.1: A microsatellite genome scan performed on chromosome X in the 
Bangladeshi AE family cohort showing the position of FOXP3 gene.  It demonstrates 
suggestive linkage with AE and the marker LOD score (> 1-1.5) including; markers 
DXS1214, DXS993, DXS8083 and DXS991 (Prof. D. Kelsell).  
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FOXP3 is considered as the master regulatory gene for the development and function of 
Treg cells (Li et al., 2006).  The identification of FOXP3 as the gene mutated in scurfy mice 
highlighting its possible role in a human disorder with clinical features similar to those 
found in scurfy mice (Ziegler, 2006).  Mutations in the FOXP3 gene have been found to be 
the cause of a fatal autoimmune disease called IPEX (immunodysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome OMIM 304790) (Wildin et al., 2002) 
or X-linked autoimmunity-allergic disregulation syndrome (XLAAD) (Zhou et al., 2008).  
IPEX was first reported in 1982 and mapped to the X-chromosome (Powell et al., 1982), 
lack of T regulatory (Treg) cell function due to FOXP3 malfunction highlighting the 
fundamental role of FOXP3 in Treg cell development and activity (Ziegler, 2006).  
Specifically, CD4+CD25+ Treg cells, are thought to play a key role in the maintenance of 
self-tolerance through limiting autoimmune reactions and inflammatory response (Ziegler, 
2007).  We hypothesised that milder variants in FOXP3 may associate with immunological 
aspects of AE and atopy. 
 
3.2 Structure-function analysis of FOXP3 
 
The human FOXP3 gene has eleven exons plus one upstream non-coding exon (Figure 3.2) 
(Torgerson et al., 2007).  It spans an area of approximately 13.88 Kb, from position 
48,994,354 to position 49,008,232 on the reverse strand of the X-chromosome in FOXP3-


























Figure 3.2: Schematic diagram of the X-chromosome and FOXP3 gene.  It shows the 
position and genomic structure of FOXP3 gene and direction of transcript (right to left).  
Red boxes indicate exons while regions in between represent introns 
(http://www.ensmble.org/).  
 
 FOXP3 codes a 48 KD protein from the forkhead/winged helix transcription factor family 
(van der Vliet and Nieuwenhuis, 2007), and has four distinctive functional domains:  a 
single C2H2 zinc-finger domain (200-223 amino acids), and at the C-terminus, the 
forkhead domain (FKH) (338-421 amino acids) followed by a leucine zipper motif (240-
261 amino acids) (Figure 3.3) (Campbell and Ziegler, 2007).  The most important feature of 
FOX proteins is the 'forkhead box' that forms a DNA-binding motif.  The ability to bind to 
DNA permits FOX proteins to regulate the expression of genes contributing to cell 
















Figure 3.3: Schematic diagram showing functional domains of FOXP3 and their 
proposed functions.  Arrows indicate the location of identified mutations found in patients 
with IPEX (Nik Tavakoli et al., 2008). 
 
Approximately twenty mutations in FOXP3 gene have been reported in patients with IPEX-
predominantly affect the DNA-binding domain of the FOXP3 protein (Le Bras and Geha, 
2006; Lopes et al., 2006; Myers et al., 2006; Ziegler, 2006).  Mutations in the FKH motif 
have been shown to affect its ability to bind DNA, critical to FOXP3 repressor activity, 
whereas mutations in the Leucine-zipper-like domain have been found to affect the 
dimerization, and hence DNA binding (Campbell and Ziegler, 2007; Lopes et al., 2006).  
Functional domains within the amino-terminal domain of FOXP3 have been investigated 
and found to be involved in general transcriptional repression and inhibition of nuclear 
factor of activated T cells (NFAT)-mediated transcription (Campbell and Ziegler, 2007; 
Lopes et al., 2006).  Finally, some mutations may lead to an increase in the length of the 
carboxy terminus (C) of FOXP3 which might decrease the stability of FOXP3 mRNA or 
change the three-dimensional structure and the position of the winged helix (Bennett et al., 
2001a; Bennett et al., 2001b; Ziegler, 2006). 
 
3.3 Factors that regulate FOXP3 expression 
 
FOXP3 transcription factor makes an important contribution to the prevention of 
autoimmune disorders through its expression in Treg cells.  It is highly expressed in 
lymphoid tissues such as spleen and thymus (Brunkow et al 2001).  Peripherally, FOXP3 
expressing Treg cells are of the CD4+CD25+ sub types (Hori & Sakaguchi 2004).  The 
modalities involved in initiating FOXP3 expression and promoting its regulatory 
characteristics in thymic and peripheral Treg cells are of great interest.  Signalling pathways 
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generated by T-cell receptor (TCR), IL-2, transforming growth factor-β (TGF-β) and CD28 
are involved in affecting FOXP3 expression (Zhang and Zhao, 2007; Ziegler, 2006).   
 
FOXP3-expressing Treg cells may be induced by antigen stimulation intra-thymically and 
also in the periphery.  In the thymus, this can proceed in the absence of TGF-β and in the 
presence of a dominant negative TGF-β receptor II (Chen et al., 2003; Huber et al., 2004; 
Marie et al., 2005) which is by TGF-β-independent modalities.  Additionally, TGF-β is 
crucial in peripheral lymphoid tissue to maintain normal Treg cell numbers and to enhance 
the conversion of naïve T cells into Treg cells (Kretschmer et al., 2005; von Boehmer, 
2007).  Conversion of naïve peripheral CD4+CD25- T cells into a regulatory T cell 
phenotype with potent immunosuppressive potential may be achieved through 
costimulation with TCRs and TGF-β (Chen et al., 2003). 
 
3.4 CD4+CD25+ Treg cells 
 
CD4+CD25+ Treg cells represent a small percentage (5-10%) of peripheral cells which 
develop in the thymus.  This subset of cells is characterized by the expression of IL-2 
receptor α-chain (CD25), glucocorticoid-induced TNF receptor (GITR) and cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4).   FOXP3 has been identified as a molecular 
marker of CD4+CD25+ Treg cells, which is involved in immune suppression.  Dysfunction 
of FOXP3 in humans is associated with the absence of CD4+CD25+ Treg cells which result 
in autoimmune diseases (van der Vliet and Nieuwenhuis, 2007). 
 
The modalities mediating the immunosuppressive functions in vivo have not been fully 
understood yet.  Various studies explain immunosuppression to be cell contact-dependent 
while other studies suggest that suppression may also be cell contact-independent via the 
secretion of the immunosuppressive cytokines IL-10 and TGF-β or direct lysis of T cells 
via granzymes and perforin (Kronenberg and Rudensky, 2005; Le Bras and Geha, 2006; 
Ziegler, 2006).  This sub set of T cells is involved in regulating the immune reaction of 
other cells such as conventional T cells.  As in conventional T cells, stimulation of 
CD4+CD25+ Treg cells leads to the induction of the transcription factor NFAT.  Upon TCR 
activation and CD28-mediated co-stimulation, NFAT preferentially binds activator protein1 
(AP-1) in conventional T cells thereby, inducing transcription of genes involved in T cell 
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activation.  Whereas in CD4+CD25+ Treg cells, NFAT binds to FOXP3 results in the 
transcription of a different set of genes which result in immunosuppression (Figure 3.4) 
(Wu et al., 2006). 
 
Figure 3.4: FOXP3 regulates NFAT-mediated gene transcription in CD4+CD25+ Treg 
cells. TCR up-regulates the expression of the transcription factor NFAT, in conventional T 
cells (left) and CD4+CD25+ Treg cells (right).  Upon TCR stimulation and CD28-mediated 
co-stimulation, NFAT binds to AP-1 in conventional T cells but to FOXP3 in CD4+CD25+ 
Treg cells which lead to the transcription of a different set of genes in both cell types (van 
der Vliet and Nieuwenhuis, 2007)  
 
Molecular investigations of human and murine Treg cells are revealing how FOXP3 exerts 
its effect.  FOXP3 protein cooperates with the transcription factor NFAT to produce a set of 
suppressive genes such as CTLA-4 and TGF-β.  Another factor, acute myeloid leukaemia 1 
(AML1)/Runt-related transcription factor 1 (Runx1) which involved in normal 
hematopoiesis and T-cell development in the thymus, interacts directly with FOXP3.  It 
induces IL-2 and IFN-γ gene expression in CD4+ T cells.  The interaction of AML1/Runx1 
with FOXP3 results in Treg cell up-regulation and suppression of both, IFN-γ and IL-2 
production (Ono et al., 2007).  Recently, the transcriptional factor AP-1 has been found to 
interact with FOXP3 and their interaction also suppress IL-2 production by Treg cells (Paik 
et al., 2008). 
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3.5 FOXP3 and common autoimmune disease  
 
Although IPEX represents an extreme autoimmune phenotype, decreased circulating 
numbers of Treg cells have been identified in the commoner diseases such as T1D, multiple 
sclerosis and autoimmune polyglandular syndrome type II (Huan et al., 2005; Kriegel et al., 
2004; Kukreja et al., 2002).   
 
The profound effect of FOXP3 mutations in IPEX patients led to the hypothesis that mild 
FOXP3 variants may promote susceptibility to common autoimmune diseases.  Early 
studies concentrated on T1D.  A study performed by Bassuny and colleagues on (n=199) 
patients with T1D and (n=289) healthy controls to investigated whether the human FOXP3 
gene could be a new candidate gene for T1D.  Results showed an association between 
functional microsatellite polymorphism, (GT)n, in the promoter/enhancer region of FOXP3, 
with T1D (Bassuny et al., 2003).  Subsequently, an extensive and comprehensive haplotype 
study of FOXP3 polymorphisms conducted on two independent sample sets of Sardinian 
population found no association with any variants including the (GT)n promoter/enhancer 
microsatellite previously demonstrated by Bassuny et al., (2003) (Zavattari et al., 2004).  
Another study performed on asthma patients (n=50) showed that the (GT)n allele was not 
associated  with either FOXP3 mRNA levels in peripheral T cells, nor with increased IgE 
levels (Karagiannidis et al., 2004).  Although, they showed that glucocorticoid medications 
given to asthma patients induce the expression of both FOXP3 and IL-10 mRNA, while 
TGF-β1 mRNA which encode TGF-β is unchanged.  Thus, one explanation of the 
immunosuppressive effect exerted by glucocorticoids could be the up-regulation of FOXP3 
and other mediators, which is especially interesting in view of the ineffectiveness of 
glucocorticoid medications in IPEX patients with dysfunctional FOXP3 mutation  
(Karagiannidis et al., 2004).  In addition to these studies, the role of FOXP3 in other 
autoimmune diseases such as primary biliary cirrhosis (PBC), Crohn’s disease (CD) and 
autoimmune thyroid disease (AITD) has been investigated and showed contradictory 
results.  A study performed on patients with PBC (n=82), and CD (n=93) and (n=108) 
controls to using ten SNPs of the FOXP3 gene to assess allele and genotype frequencies.  
Analysis showed three SNPs in promoter region (rs3761548, rs2232365, and rs590234) and 
one intronic SNP (rs2232366) existed in CD patients.  Also, no significant differences were 
found between controls and CD patients regarding allele and genotypic frequencies.  
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However, there was a significant difference in allele frequencies between PBC patients and 
controls in the rs2232366 variant (p=0.001).  These findings suggest cytokine inhibition of 
Treg cell function as a mechanism of immune dysregulation  (Park et al., 2005).  A large 
case-control study recruited Caucasian Spanish (n=1155) patients with autoimmune 
disorders and (n=274) controls to detect possible association of functional (GT)n 
polymorphism with predisposition to various autoimmune disorders. This study 
demonstrated no significant role of FOXP3 gene in autoimmune disorders  (Sanchez et al., 
2005).  Several studies have analysed the possible role of FOXP3 gene in the genetic 
susceptibility to AITD.  A cohort study conducted to investigate the association using four 
microsatellite markers flanking the FOXP3 region.  Study sample was recruited from two 
datasets including: U.S Caucasians (269 patients and 357 controls) and Japanese (377 
patients and 179 controls).  Results showed that polymorphisms of the FOXP3 gene may 
play crucial role in the genetic susceptibility to AITD in Caucasian males (p=0.011) and 
females (p=0.00023) but not Japanese, possibly by altering FOXP3 function and/or 
expression (Ban et al., 2007). 
 
FOXP3 gene is located in Xp11, a known region of autoimmune disease linkage to various 
diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA) and T1D (Cornelis et 
al., 1998; Cucca et al., 1998; Ebers et al., 1996).  This position permits FOXP3 to be 
considered as a putative susceptibility gene in autoimmune disease specifically diseases 
common in females.  One explanation might be related to genes situating on the sex 
chromosome, which in the context of a complex inheritance pattern can change the risk for 
the development of autoimmunity (Barbesino et al., 1998; Lockshin, 2002).  For instance, 
in AITD and other forms of autoimmunity, skewed X-inactivation has been illustrated 
(Ozbalkan et al., 2005; Ozcelik et al., 2006).  In addition, it has been hypothesized that 
skewed X-inactivation in the thymus can lead to inadequate thymic deletion of specific X-
linked self-antigens (Chitnis et al., 2000; Stewart, 1998).  However, several reports 
revealed no differences in the susceptibly of autoimmune disorders between females and 
males and even there is male-female bias (Park et al., 2005; Zavattari et al., 2004).  No 
reports of IPEX-affected females heterozygous for FOXP3 mutations has been published so 
far (Wildin and Freitas, 2005).  Interestingly, heterozygous females seem to be healthy 
although X-inactivation occurs randomly.  A study conducted by Tommasini et al., (2002) 
to investigate X-chromosome inactivation in a heterozygous carrier female in comparison 
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with a child affected by IPEX showed that normal and mutant FOXP3 alleles are equally 
expressed in peripheral blood lymphocytes, thereby concealing the disease by other 
mechanisms (Tommasini et al., 2002).  Females with an IPEX-like syndrome (and with two 
X chromosomes) have been observed.  A report by Owens et al identified one family where 
females and males were affected.  No FOXP3 mutations were found and linkage analysis 
excluded the FOXP3 locus (Owen et al., 2003).   
 
3.6 Genetic approaches to assess FOXP3 association with AE 
 
The association of FOXP3 variants and AE as well as other atopic phenotypes in the 
Bangladeshi families was investigated using microsatellites and SNPs.  All primers were 
designed according to gene sequence (ENSG00000049768) (http://www.ensembl.org/). 
 
3.7 Microsatellite mapping near FOXP3 gene 
 
Five microsatellite markers; J12, J13, J17, J19, and J26 in FOXP3 gene were genotyped in 
the Bangladeshi families.  The positions and the sequence of these markers are mentioned 
in details in the general methods chapter, and were obtained from the Zavattari et al., study 
(Zavattari et al., 2004). 
 
3.7.1 Optimization and PCR amplification of FOXP3 microsatellites 
 
Microsatellites of interest in Foxp3 gene were optimized for the annealing temperature and 
MgCl2 concentration as shown in (Figure 3.5). All of the markers were amplified on 
annealing temperature of 67°C except J13 which failed at the optimization level. The 
concentration of MgCl2 was 3 mM for all of them except J19 with MgCl2 of 1.5 mM.  
Standard PCR was carried out; two samples were tested for each marker to determine the 
product size.  In each set of primer tested on a positive control DNA and DNA from an 
affected sample (Figure 3.6) 
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Figure 3.5: Gel electrophoresis picture showing temperature gradient optimization of 
Foxp3 microsatellites J12, J13, J17, J19 and J26 in 2% agarose gel using a 100bp 
DNA ladder.  The gradient used is (50°C-72°C) and the best annealing temperature 
worked for all variant is 67.3°C (the 8th band from the left).  The product size as follow; 
J12=140 bp, J13=210 bp, J17=220 bp, J19=150 bp and J26=200 bp. 
 
Figure 3.6: PCR amplification of Foxp3 microsatellites J12, J13, J17, J19 and J26.  It 
gives variously-sized DNA products which are separated on gel electrophoresis using a 
100bp DNA ladder and 2% agarose gel.   Two samples were tested for each marker to 




3.7.2 Microsatellite genotyping 
 
Microsatellite genotyping was carried out using five markers on Foxp3 gene.   All markers 
amplified except J13 failed to be genotyped (poor peaks shape) on the 3700.  These variants 
were successfully genotyped using fluorescently tagged PCR primers in all individuals 
(n=384) and allele scoring was performed on the ABI PRISM 3700 automated sequencer 
using the genotyper software (v.3) (Figure 3.7). 
 











2) Genotyping of marker J26 
 
 
Figure 3.7: Genotyping analysis of FOXP3 microsatellites J17 and J26 (1) J17 marker 
showing family (033) with an unaffected father with allele of size 202 (hemizygous), an 
unaffected mother with two alleles of size 208 and 212 (heterozygous) and three children a 
previously affected female with two alleles size 202 and 212 (heterozygous) and two 
affected males with one allele each size 212 and 212 (hemizygous). (2) J26 marker showing 
family (001) with unaffected mother having two alleles of sizes 142 and 164 
(heterozygous), unaffected father with one allele of size 174 (homozygous) and three 
female children (child1=unaffected, child2=previously affected and child3=proband).  Each 
female child has two alleles (heterozygous), two of them having same alleles of size 164 








3.8 Patient selection for FOXP3 polymorphism detection 
 
Patients from different families were randomly selected for polymorphism detection in the 
FOXP3 gene (Appendix.F).  Genetic variations in the Bangladeshi families were looked at 
to identify possible association with AE and/or other atopic phenotypes.  Other phenotypes 
include: asthma, hayfever, and food allergy as well as combined atopic phenotypes such as 
AE with asthma, AE with hayfever and AE with food allergy. 
 
3.8.1 PCR of patients DNA 
 
The entire coding sequence of the gene, flanking introns boundaries, and the promoter 
region were amplified using 11 pairs of primers and the PCR products were verified by 2% 
agarose gel (Figure 3.8). 
 
 
Figure 3.8: Gel picture of exon 2 of FOXP3 gene.  Affected patients samples1-12, (+) 
positive control and the lower set are unaffected samples 13-24, using 100bp DNA ladder 







3.8.2 Polymorphisms detection by WAVE® 
 
Twelve fragments showed an abnormal WAVE profiles with double peaks as listed in 
(Table 3.1).  Direct sequencing analysis of these abnormal WAVE profiles was carried out 
for polymorphism detection. 
 
Table 3.1 Wave results of abnormal profiles (double peaks) in intron 1 mostly and 
exon (5-6). 
Oligo name Number of fragments with abnormal WAVE profile 
FOXP3_intron 1 11 
FOXP3_exon (5-6) 1 
 
3.8.3 Sequence of abnormal WAVE profiles 
 
All abnormal WAVE profiles were sequenced.   Sequence analysis revealed three different 
types of polymorphisms in intron 1; A/C, A/G and insertion of G.  There is also a coding 
polymorphism in exon (5-6) (Table 3.2).  Three known SNPs (rs2232367, rs3761548 and 
rs2232365) and a novel variant; FOXP3I1-1 were identified (Figure 3.9).   
 
Table 3.2: Polymorphisms identified in the FOXP3 gene in the Bangladeshi families.  
In the first column the location of the four polymorphisms according to FOXP3 gene; 
column 2 contains the class of polymorphism and the NCBI identification number except 
for the novel SNP which given a lab internal code (FOXP3I1-1), the 3rd and 4th column are 
reported positions and class of polymorphisms.  The last two columns contain information 
about number of individuals with variant and the percentage of AE among them. 








No. of samples 
with variant  
AE% 
Intron 1 FOXP3I1-1 X:49006917  Ins/G 1/5 100 
Intron 1 Rs3761548 X:49005185 A/C 3/10 100 
Intron 1 Rs2232365 X:49002830 A/G 7/10 100 





Figure 3.9: Schematic structure of the first 6 exons of FOXP3 gene with their intronic 
boundaries.  Variants identified in this study (shown in the upper part), while lower part 
shows all variants identified in the database so far.  The SNP ID (FOXP3I1-1, rs2232367, 
rs3761548 and rs2232365), position in relation to the X-chromosome and the FOXP3 gene 
(http://genome.ucsc.edu/).  Note that black colour ID indicates intronic SNPs, red ID non-




This is a splice site, synonymous coding variant, in exon (5-6), located at X:49000256 and 
found in patient 387 (Figure 3.10), not known to be associated with AE in previous studies.  
This is a C/T variant, in which allele C is the reference allele.  
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Figure 3.10: Wave profiles and sequencing trace of exon (5-6). A) Normal Wave profile 
on the left and the abnormal profile with double peak on the right side, patient 387.  B) The 
sequencing traces of an area of exon (5-6) are showing the heterozygous nucleotide 
substitution C/T.   
 
 B) Rs3761548  
 
This SNP, 3648:A/C, located in intron 1, at chromosome region X:49005185.  Abnormal 
WAVE profile detection in individuals 356, 387, 440 was followed by sequencing which 
showed the substitution of allele A to allele C (Figure 3.11).  Annotations of this SNP in the 
human genome diversity project showing that there is an ‘African/Asian’ bias of ancestral 
allele C in the sense that it reaches its highest frequency in African and Asian population.  
However, In Europeans, Mediterranean and Middle East populations, allele frequencies of 
both alleles (A and C) are approximately equal (Figure 3.12). 
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Figure 3.11: Wave profiles and sequencing trace of intron 1 of FOXP3 gene in 
individual 387. A) Normal Wave profile on the left and the abnormal profile with double 
peak on the right side. B) The sequencing traces of an area of intron 1 showing the 














Figure 3.12:  Annotations taken from the human genome diversity project showing 
different allele frequencies of rs3761548 variant.  There is an ‘African/Asian’ bias of 
ancestral allele C in the sense that it reaches its highest frequency in African and Asian 




This is a novel heterozygous SNP located in intron 1 at the position of X:49006917.  It is an 










Figure 3.13: Sequencing trace of patient 387 showing part of intron 1 with an 




This is a heterozygous SNP located in intron 1, and found in individuals 478,434, 380, 487, 
331, 356, 373.  There is a substitution of allele A with allele G (Figure 3.14).  All 
individuals with this variant found to be affected with AE. 
 
Fig 3.14: Sequencing trace of patient 478 showing part of intron 1 with a heterozygous 
nucleotide substitution A/G. 
 
3.8.4 Taqman® for SNPs at FOXP3 loci 
 
Taqman 5’nuclease assay is a well-established technique for medium-to-high throughput 
SNP genotyping. Both allelic probes are 5’ labelled with FAM- and VIC-dye 
fluorochromes respectively.  Four SNPs identified in this study were genotyped using 
Taqman assay in all individuals in the Bangladeshi family study (n=384) (Figure 3.15).  In 
all experiments, a substantial increase in VIC-dye fluorescence only indicates 
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homozygosity for allele (2) appears in red colour, while the increase in FAM-dye 















Figure 3.15: Taqman assay allelic discrimination scatter graph for FOXP3 variants 
genotypes in the Bangladeshi individuals.  A) RS2232367, B) Rs3761548, C) FOXP3I1-
1, and D) Rs2232365.  In all experiments, a substantial increase in VIC-dye fluorescence 
only indicates homozygosity for allele (2) shown in red color, while the increase in FAM-
dye fluorescence only indicates homozygosity for allele (1), represented by blue cluster.  
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Both VIC- and FAM-dye fluorescence indicates allele (2) and allele (1) heterozygosity, 
shown as green cluster in the middle.    
 
3.9 Genotyping analysis of FOXP3 variants 
 
All SNPs (rs2232367, rs3761548, rs2232365, and FOXP3I1-1) and microsatellite markers 
(J12, J17, J19, and J26) details are shown in (Figure 3.16) and listed in (Table 3.3).  Data 
was analysed using FBAT software at the Genome Centre, mentioned in details in general 
methods section 2.4.  Significant p-values in this study were demonstrated before correction 
for multiple testing.  Allele frequencies differe between FOXP3 markers.   Many of these 
markers have almost equal frequencies in both alleles such as J12, J16, and J17 while 
others are mostly one allele such as J18 and FOXP3I1-1. 
 
Statistics that reflects association between the trait locus and the marker locus was tested, 
and the distribution of the genotype marker data under the null hypothesis was 
computerized (Table 3.4 and 3.5).  These results show a significant association between 
SNP, rs3761548, and AE in the Bangladeshi families in both; dominant (p=0.028) and 
recessive model (p=0.025) (Table 3.4).  Haplotype analysis by FBAT was carried out on all 
markers which show four common haplotypes (a1=38%, a2=7%, a3=5%, and a4=3%) and 
other rare haplotypes (Table 3.6).  One of these, a1 which is the commonest haplotype 
identified in approximately 25 families, found to be common in affected individuals (Figure 
3.17).  Haplotype association analysis showed significant association between haplotype a1 
and AE in the dominant model (p=0.013) (Table 3.7). 
 
Analysis of other allergic phenotypes including asthma, hayfever, and food allergy as well 
as combination of atopic phenotypes such as AE and asthama, AE and hayfever and AE 
with food allergy (Table 3.8) revealed positive association between rs3761548 and all 
allergic phenotypes mainly in recessive model.  This SNP showed significant association 








Figure 3.16: Schematic representation of the chromomsome region containing eight 
polymorphisms in FOXP3 gene analysed in this work. These polymorphisms are 
distributed in a region spanning the whole gene.  FOXP3 is organized into 12 exons (one of 
which, -1 is non-translated).  The positions of all polymorphisms used for analysis of 
association are indicated as stars and circles. Red circles indicate microsatellites and 
deletions, while the green circle represents the novel insertion variant, FOXP3I1-1, detected 
in the Bangladeshi families.  Stars indicate known SNPs.  Note that J14=rs3761548, 












Table 3.3: Summary of eight polymorphisms analysed in and around FOXP3 gene.  In 
the first column the 8 polymorphisms are indicated by an internal lab code; column 2 
contains information about the distances between different loci analysed, in column 3 and 
column 4 we indicated the class of polymorphism and the NCBI code (rs). 
Lab internal 
code 





to the FOXP3 
gene 
J12 53129 Del3 (TAA)  +147from exon -1 
FOXP3I1-1  InsG 
 
-4989 from exon 1 
J14 55862 A/C Rs3761548 -3257 from exon 1 
J16 58217 A/G Rs2232365 -902 from exon 1 
J17 58940 (GT) repeat  -150 from exon 1 
J18 60791 C/T Rs2232367 Base+1 exon 5 
J19 61394 (CT) repeat  Introns 5-6 
J26 81816 (GT) repeat  downstream 
 
Table 3.4: FBAT analyses of FOXP3 SNPs in the Bangladeshi families.  It shows p-
values of both alleles in bi-allelic test affection trait in additive, dominant, and recessive 
models. 




















































Table 3.5: FBAT analyses for FOXP3 microsatellite markers in the Bangladeshi 
families.  It shows p-values in multi-allelic test affection trait in additive, dominant, and 







































































































































































N/A =Not available 




Table 3.6: Details of the most common haplotypes identified in the Bangladeshi 
families.  There are eight markers in each haplotype including; FOXP3J12, FOXP3I1-1, 
rs3761548, rs2232365, FOXP3J17, rs2232367, FOXP3J19, and FOXP3J26. The 
commonest haplotype is a2 found in 25 families. 
Haplotype Number of families with 
haplotype 
Eight marker haplotype frequency 
a1 25 
 
127 1   2   1   209 2   142 199 0.378 
a2 7 
 
124 1   2   2   211 2   164 193 0.074 
a3 1 
 
127 1   2   1   209 2   142 197 0.054 
a4 3 
 
124 1   2   2   211 2   160 193 0.033   
 
 
Table 3.7: Haplotypes association analysis between AE and common haplotypes 
detected in the Bangladeshi families.  Note that there is a significant association with AE 
in the dominant model (p=0.013). 
Haplotype Additive model Dominant model Recessive model 
a1 0.212 0.013† 0.550 
a2 0.221 0.221 0.527 
a3 0.564 0.564 0.564 
a4 0.309 0.309 0.414 










Table 3.8: FBAT analysis of atopic phenotypes in association with FOXP3 variants 
identified in this study. Two SNPs, FOXP3I1-I and rs3761548 found to be significant in 





































































































†The probabilities are shown with this symbol if significant (<0.05) 





Figure 3.17: Pedigree of a Bangladeshi family (009) with AE showing the haplotype 
data of the eight markers identified in FOXP3 gene. These variants includes:  
FOXP3J12 FOXP3I1-1 rs3761548 rs2232365 FOXP3J17 rs2232367 FOXP3J19 
FOXP3J26.  In this pedigree, filled symbols indicate affected individuals; open symbols, 
unaffected individuals; arrow indicate proband, and crossed symbol refer to previously 
affected individual.  Red rectangles represent the informative alleles of the last two markers 
in both parents; the other six alleles above are uninformative because all of them are the 
same in both father and mother.  For example, female number 5, alleles in the upper six 
markers are the same (uninformative markers), while bottom two alleles in the red rectangle 
are informative alleles for these markers because they are different in both parents and it 
tells that the left haplotype inherited from the mother while the right haplotype inherited 








FOXP3 is a transcription factor which controls the development and function of Treg cells, 
primarily of the CD4+CD25+ subsets.  The role of Treg cells has been described widely in 
the suppression of T-cell activation (Torgerson, 2006).  A small study carried out on (n=28) 
individuals suggested a possible role of these cells as well as decreased expression of 
FOXP3 in the dysregulation of allergic rhinitis  (Xu et al., 2007).  An interesting positive 
association observed between SNP, rs3761548, and AE in the recessive model (p=0.025) 
and in the dominant model (p=0.028) as well as all other allergic phenotypes.  This result is 
consistent with other studies suggest an important role of Treg cells and FOXP3 in the 
aetiology of allergic diseases in children. A study conducted in Taiwan to identify whether 
numbers of Treg cells are related to airway allergy in (n=51) paediatric patients with 
allergic rhinitis and asthma versus (n=47) controls.  Results showed that children with these 
phenotypes had fewer Treg cells than controls (p<0.05) (Lee et al., 2007). 
 
In this study, the main aim was to evaluate the contribution of polymorphisms in the 
FOXP3 gene towards AE and other atopic phenotypes susceptibility in a family-based 
association analysis.  Eight markers of FOXP3 gene have been investigated, four markers 
(J12, J17, J19, J26) from the Zavattari et al., (2004) study, and four SNPs (FOXP3I1-1, 
rs3761548, rs2232365, rs2232367) (three in introns 1 and one in exon 6) identified in 
Bangladeshi patients with AE. With these markers, we analysed allele and genotype 
frequencies in families with AE using FBAT which evaluates the statistical significance of 
the smallest observed p-value among all analysed data.  All results obtained for FOXP3 
using FBAT software shown in p-values instead of ORs. The latter is the method of choice 
to display SNP association data particularly for case-control association studies but 
unfortunately we were unable to calculate data within FBAT to display in this format.  Our 
data show significant associations between a variant in the FOXP3 gene and AE in 
Bangladeshi families, and also positive associations demonstrated with other allergic 
phenotypes including asthma, hayfever, and food allergy.  All variants identified are 
intronic except one SNP, rs2232367, in exon (5-6) which is a coding synonymous 
polymorphism.  Haplotype analysis identified four common patterns and many other rare 
haplotypes.  The haplotype association analysis demonstrated a significant association 
between haplotype (a1) and AE in the Bangladeshi families (p=0.013).  The novel rare 
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variant identified in this study, FOXP3I1-1, was not significant in FBAT analysis as was 
found only in one affected individual.  
 
Most of mutations detected in the FOXP3 gene and linked to autoimmune diseases 
including: IPEX, XLAAD, and polyendocrinopathy lie in the forkhead domain.  These 
mutations might disturb the DNA binding activity of the protein that alters FOXP3 protein 
function. The immune disregulation resulting from the loss of protein function suggests the 
important role FOXP3 plays in the regulation of activation-induced T cell proliferation and 
differentiation (Wildin et al., 2001).  A recent study recruited (n=524) patients with 
psoriasis and (n=549) healthy controls, to investigate the hypothesis that upstream SNPs of 
FOXP3 gene were responsible for the suppression of transcription of the gene in psoriatic 
patients (Shen et al., 2008).  Results showed that rs3761548 genotypes were significantly 
higher in psoriatic patients (p<0.05)  than in controls as well as in patients with severe 
forms than that in moderate ones suggested a potent effect on FOXP3 transcription levels.  
Also, there was a certain tendency to other autoimmune diseases such as vitiligo, AITD, 
bullous pemphigoid and T1D concomitant with psoriasis.  This suggest that intronic SNP(s) 
might also be involved in transcriptional regulation of FOXP3 and the development of 
other autoimmune diseases (Shen et al., 2008).  In the Bangladeshi families SNP, 
rs3761548, was found to be significantly associated with AE and other allergic phenotypes 
with p-values ranging from 0.025 to 0.034.  Significant p-values identified for FOXP3 gene 
with AE in the Bangladeshi families have not been corrected for multiple testing in this 
study.  For FOXP3 gene, eight markers, seven phenotypes and three models should be used 
for correction to reach a p-value of (≤0.000298) in order to consisder these associations 
significant.  None of these positive associations remained significant after correction for 
multiple testing, although they may suggest an association with AE which require further 
investigations.  Further investigation of the molecular mechanisms underlying FOXP3 
transcription may determine new understanding into FOXP3 transcriptional regulation 
mechanisms and possible therapeutic strategies.  The genetic epidemiologic observations 
for FOXP3 gene in patients with AE and other atopic phenotypes require careful replication 
in other populations and the availability of large, well-characterised case-control 





Assessment of genetic variations at the SPINK5 



















The serine protease inhibitor Kazal type 5 gene (SPINK5) located on chromosome 5q32 has 
been suggested as a putative susceptibility gene for AE (Walley et al., 2001).  Identification 
of the genetic association of AE with SPINK5 came as a result of the study of a rare 
recessive skin disease, Netherton’s Syndrome (NS), in which atopy is a universal 
accompaniment.  Chavanas et al., showed that NS was caused by mutations in the SPINK5 
gene (Chavanas et al., 2000), which encodes lympho-epithelial Kazal-type related inhibitor, 
named (LEKTI), a 15-domain serine protease inhibitor expressed in thymus, epidermis as 
well as mucosal membranes (Magert et al., 1999).  Subsequent studies revealed an 
association with SPINK5 across different populations with AE (Kato et al., 2003; Nishio et 
al., 2003; Walley et al., 2001).  In this chapter, the possible association of SPINK5 with AE 
has been investigated in the Bangladeshi families of East London. 
4.2 Structure of SPINK5 gene and its encoded protein LEKTI 
SPINK5  is located in a genomic region distal to the cytokine gene cluster (Walley et al., 
2001), from the position 147,423,728 to 147,497,045 on forward strand.  There are seven 
known transcripts in this gene (ENSG00000133710) (Figure 4.1).  It spans approximately 
73.39 kb and consists of 33 coding exons and 32 introns (http://ensemble.org/) and encodes 
a putative serine protease inhibitor LEKTI, a cysteine-rich protein consisting of 15 potential 
inhibitory domains (Bitoun et al., 2002). 
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Figure 4.1: Schematic representation of chromosome 5 and SPINK5 gene.  It shows the 
position and all transcripts of SPINK5 gene.  Note that horizontal red lines indicate exons 
while regions in between denotes introns, adapted from (http://ensemble.org/).  
Serine protease inhibitors include four families; the serpins, the Kunitz, Kazal, and 
leukoprotease inhibitors, which overlap in the range of their specificities but, differ in their 
structures and possibly functions (Roberts et al., 1995).  All serine protease inhibitors 
function to control the action of serine proteases in many physiological contexts.  The 
functional region of these inhibitors is near the C-terminal end at an exposed site which 
permits the appropriate serine protease to recognize and perfectly bind (Hill and Hastie, 
1987).   
Full-length LEKTI consists of 1064 amino acid residues which may be assigned to fifteen 
different domains (Figure 4.2).  Two of these domains (domain 2 and 15) show the classical 
pattern of Kazal-type (KT) inhibitors with six cysteines residues almost exactly.  The 
remaining thirteen domains lack two of the six cysteines in third and sixth position (Magert 
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et al., 1999).  KT inhibitors are defined by conserved motifs in their amino acid sequence.  
In a typical Kazal domain, these six cysteine motifs forming a 1-5/2-4/3-6 disulfide bonds 
that most Kazal domains described belong to this class (Kreutzmann et al., 2004; 
Laskowski and Kato, 1980).  So, two of the fifteen potential inhibitory LEKTI domains 
contain three disulfide bridges while the other thirteen domains have only two of these 
disulfide bonds.   They are possibly involved in the stability and inhibitor activity of kazal 
domains due to the fact that lack of the third disulfide bond might contribute in structural 
and functional changes in KT inhibitor domains (Lauber et al., 2003). 
 
Figure 4.2: Amino acid sequence of LEKTI protein.  The protein consists of 15 
domains; domain 2 and domain 15 represent the typical KT inhibitor domains with six 
cysteine residues.  The other remaining 13 domains represent distinct subset of KT 
sequences, shown in blue, with four cysteine motifs and well conserved proteinase 
inhibitory sequences between the second and the third cysteine residues.  Cysteine residues 
involved in the formation of disulfide bonds are shown in red.  An amino-terminal 
secretory  sequence is shown in green, adapted from (Magert et al., 1999).  
4.3 Function of serine protease inhibitors  
4.3.1 Correlation between LEKTI expression and various biological processes 
Although the biological functions of LEKTI is still unknown, its unique expression in 
highly differentiated sites of lympho-epithelial tissues, together with the clinical 
characteristics of NS patients, suggests crucial roles in several physiological mechanisms 
(Bitoun et al., 2003). 
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LEKTI plays a key role in terminal epidermal differentiation and corneocyte desquamation 
(Komatsu et al., 2002), as predicted in NS due to its impaired keratinization and 
cornification, and restricted expression.  Putative targets for LEKTI expression are the 
stratum corneum trypsin- and chymotrypsin-like enzymes (SCTE/KLK5 and SCCE/KLK7, 
respectively).  Both KLK5 and KLK7 are major regulators of the desquamation through 
proteolysis of intracellular adhesion molecules, such as desmoglein (DSG) (Ekholm et al., 
2000).  The study of NS patients as well as the analysis of mouse model of NS showed that 
LEKTI plays an important role in the control of the desquamation mechanism.  A study by 
Descargues et al., (2006) found that the absence of LEKTI expression in NS patients leads 
to intensified SCTE- and SCCE-like activity with early degradation of conrneodesmosomes 
in the stratum corneum (Descargues et al., 2006).  Other possible targets are membrane-
type serine protease 1 (MT-SP1) (Takeuchi et al., 2000) that might mediate inhibition of 
keratinocyte differentiation through activation of protease-activated receptor-2 (PAR-2) 
(Derian et al., 1997).  These data suggests that LEKTI may be a negative regulator of 
Kallikreins (KLKs) and other proteases.  Also, the balance between serine proteases and 
inhibitors is fundamental for both steady desquamation and normal skin barrier function 
(Komatsu et al., 2008).  In NS, there is a massive desquamation of skin resulting in severe 
barrier dysfunction due to mutations in the SPINK5 (Komatsu et al., 2002).  In this context, 
it may be relevant that AE could be associated with epithelial permeability barrier 
dysfunction. 
Lack of LEKTI expression in NS patients may lead to increase predisposition of these 
patients to cutaneous infections that might be attributed to the severe skin permeability 
barrier dysfunction, facilitating invasion by different microorganisms.  However, their 
recurrent and persistent features, that specific to NS in comparison to other ichthyotic 
conditions, indicates additional impairment to host-defense mechanism in the skin (Judge et 
al., 1994).  Anti-microbial roles have been described for many of serine protease inhibitors 
(Sallenave, 2002), including the antileukoprotease (ALP) (Wiedow et al., 1998) and β 
defemsoms produced by keratinocytes (Liu et al., 1998). 
4.3.2 Role of LEKTI in inflammatory and immune allergic responses 
The high expression of LEKTI in thymus and mucous epithelia (Magert et al., 1999), 
together with the identification of thymus-specific serine protease (Bowlus et al., 1999) 
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supports a role for LEKTI in T cell maturation and antigen processing.  Defective LEKTI 
expression might have a deleterious effect on Th2 response thus; enhance inflammation in 
target tissues.  It raises the possibility that LEKTI might play a role in anti-inflammatory 
and antimicrobial protection of epithelia against different pathogens (Bitoun et al., 2002).  
Several allergens themselves are serine proteases and it is likely that their protease activity 
can stimulate their allergenicity in the absence of stable protease inhibition (Thomas, 1993; 
Thomas et al., 2002).  This includes house dust-mite and pollen (Bagarozzi and Travis, 
1998). 
Furthermore, the extent of atopic manifestations in NS that are not seen in other congenital 
ichthyosis, predicts a role for LEKTI as a down-regulator of inflammatory and immune 
allergic responses (Cookson and Moffatt, 2000).  During the inflammation process, trypsin-
like mast cell tryptase, which is a major mediator of several allergic and inflammatory 
conditions, secreted among other serine proteases (Rice et al., 1998).  It plays a key role in 
mast cell activation (He et al., 1998), induction of inflammatory cytokines cell secretion 
(Hou et al., 1998), and recruitment of eosinophil and neutrophil (He et al., 1997), via  
PAR-2 activation (Schechter et al., 1998).  This suggests that mast cell tryptase may 
mediate an activation mechanism of the inflammatory response.  Thus, lack of LEKTI 
suppression could trigger a chronic allergen-induced inflammation in NS patients, and 
potentially in other common atopic disorders (Bitoun et al., 2003). 
The Th1-Th2 paradigm considered as the main hypothesis to explain the mechanisms by 
which a disturbance in the immune system may result in the development of atopic disease 
such as AE, allergic rhinitis and asthma (Romagnani, 1992).  This model, however, is not 
sufficient to describe the onset and all steps in the development of atopic disease.  Instead, 
the initial step in the development of atopic disease may be due to changes in the barrier 
function of target organs such as skin, nasal and bronchial mucosal layers.  Unbalanced 
interaction of innate and adaptive immune defense mechanisms as well as alteration in the 
genetically contributed forms of barrier proteins may have significant outcomes (Kabesch 




4.4 Literature review of SPINK5 gene variants with AE 
SPINK5 has been implicated as a putative susceptibility gene for AE in several studies 
(Table 4.1).  A study conducted by Walley et al., (2001) to examine association to SPINK5 
using two panels of families; the first panel consists of (n=338) offspring recruited through 
children with AE and other atopic phenotypes and the second panel consists of (n=215) 
children recruited to replicate the significant findings.  Six missense polymorphisms were 
identified in SPINK5; two of these variants were significantly associated with AE and other 
atopic phenotypes. Glu420Lys, rs2303067, polymorphism was significantly associated with 
AE (p=0.009), atopy (p=0.005) and total serum IgE (p=0.005) as well as Asn368Ser, 
rs2303063, variant with AE (p=0.024), atopy (p=0.023) and total serum IgE (p=0.030).  
These results suggest that there is a significant maternal over-transmission of the risk allele 
to their children in individuals affected by AE (Walley et al., 2001).  Another study by 
Kato et al., (2003) showed a significant association between seven polymorphisms and AE 
in a Japanese population (rs2303061, rs2303062, rs2303063, rs2303065, rs2303066, 
rs2303067, and rs2303068).  Also, Nisho et al., reported a significant association between 
Glu420Lys polymorphism and AE (p=0.009) as well as Asn368Ser and AE (p=0.0046) 
(Nishio et al., 2003).  
Glu420Lys variant in exon 14 is located in the HF7665 peptide, which found in peripheral 
blood and has a crucial inhibitory role against serine protease.  The substitution of neutral 
Glu to basic Lys may be functionally significant, but not very well understood yet.  It may 
be assumed that the Glu420Lys polymorphism has a possible effect on the barrier function 
of the epithelia.  Proteolysis of SPINK5 by proteases leads to an intense inhibitory response 
due to the release of the KT domains.  Previous studies reported that protease-activated 
receptors in the epithelium might act as targets for mast cell proteases and SPINK5 could be 
important in inhibiting the protease-triggered activation and as a result balancing the 
inflammation caused by mast cell lysis (Schechter et al., 1998; Walley et al., 2001).  
Moreover, it has been believed that this particular variant adds an extra basic residue into 
the linker sequence between domain 6 and 7 in SPINK5 gene that may act as a cutting site 
for proteases, thus affecting the inhibitory function of the end protein (Walley et al., 2001).  
So, the Glu420Lys variant may be a good candidate for functional analyses in the future. 
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Table 4.1: SPINK5 polymorphisms significantly associated with AE in previous 
studies.  Polymorphisms denoted * or ** show linkage disequilibrium with each other and 
polymorphisms denoted ** were in complete LD. 





Int (12-13) IVS12-26C>T* Rs2303061  AE 0.020 
Int (12-13) IVS12-10A>G* Rs2303062  AE 0.029 
AE 0.029 
(Kato et al., 
2003) 
AE 0.024 




Ex 13 1188T>C* Rs2303065 His396His AE 0.020 
Int (13-14) IVS13-50G>A** Rs2303066  AE NS 
AE 0.023 
(Kato et al., 
2003) 
AE 0.009 









Ex 14 1258G>A** Rs2303067 Glu420Lys 
AE NS (Folster-
Holst et al., 
2005) 
Int (14-15) IVS14+19G>A** Rs2303068  AE NS (Kato et al., 
2003) 
SNPs are numbered according to their position relative to the published cDNA  
NS-Not significant 
Other studies showed association between SPINK5 polymorphisms and other atopic 
phenotypes, while others showed lack of such association.  A large study by Kabesch et al., 
a total of 1611 German children were genotyped for Glu420Lys polymorphism association.  
Result analysis confirmed the association of SPINK5 Glu420Lys variant with asthma 
(p=0.041) and atopic carriers of this variant demonstrated greater risk for asthma (p=0.047) 
(Kabesch et al., 2004).  A study conducted in the population of Northern Germany using 
308 trios for AE to rule out association with SPINK5 polymorphisms.  Eight SNPs were 
investigated in different locations of the SPINK5 gene, four of them are nonsynonymous 
SNPs (Asp106Asn, Asn368Ser (1103A>G) and Asp386Asn (1156G>A), and Glu420Lys 
(1258G>A), Gly463Gly, Val553Val, Leu756Leu and Gly804Gly). Results showed that 
none of them were associated with an increase risk of AE (Folster-Holst et al., 2005).  
 
158 
4. 5 Genetic approaches to assess SPINK5 
4.5.1 Overview 
A 384 SNP custom Illumina GoldenGate genotyping assay was designed and performed at 
the Genome Centre.  Data required was downloaded from the HapMap website which 
contained all of the tagSNPs for each gene including SPINK5 and other genes using 
software written by Richard Dobson and Timothy Nugent (Genome Centre).  These were 
then cut down by using stringent cut-offs and design scores received from Illumina for each 
tagSNP.  An r2 of 0.8 and a minor allele frequency of (MAF) of 0.15 were used to create 
the final lists.  HapMap information from the Caucasian, Chinese and Japanese populations 
was compared to increase the likelihood of tagging the Bangladeshi population.  
Experimental procedure was carried out according to the manufacturer’s instructions. 
4.5.2 Haplotype-tagging SNPs strategy for SPINK5 
Twenty five haplotype-tagging SNPs of SPINK5 gene were genotyped using the Illumina 
platform in the Bangladeshi families along with other candidate genes previously 
associated with AE.  Five affection traits were tested including AE, asthma, food allergy, 
IgE, and hayfever as well as AE in combination with other allergic phenotypes including: 
AE with asthma, AE with hayfever, and AE with food allergy, and considered statistically 
significant when p≤0.05. FBAT (v2.0.2c) analysis revealed positive associations with two 
markers rs9325073 and rs4263489 (Appendix G).  The first SNP, rs9325073 found to be 
significant in affected trait (p=0.008) and under all of genetic models and in different 
allergic phenotypes (Table 4.2).  The second SNP is also significant with AE (p=0.05) as 
well as other allergic phenotypes such as asthma (p=0.01) and hayfever (p=0.02).  These 
significant SNPs were novel and not associated with AE in previous studies. SNPs 
rs17704764 and rs4362936 were found to be significantly associated with asthma (p=0.05) 
and (p=0.02) respectively.  One of these SNPs, rs4362936, was significant (p=0.03) also in 
individuals with hayfever (Table 4.2).  Genetic association was further investigated using 
SNPs to assess the association of SPINK5 variants and AE plus atopic associated 
candidates in the Bangladeshi families.  
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Table 4.2: Positive AE/atopic associated SNPs in the SPINK5 gene by FBAT analysis 
with different genetic models in the Bangladeshi families.  Note that variants, rs9325073 
and rs4263489 are significant in AE and other atopic phenotypes. 
Allergic phenotypes Rs9325073 
 
Rs4263489 Rs4362936 rs17704764 
AE 
FBAT: additive model 














FBAT: additive model 














FBAT : additive model 
            P-value 
 
AE+asthma 
FBAT:  dominant model 


























FBAT: additive model 
           P-value 
 
AE+Hayfever 
FBAT: dominant model 


























FBAT: dominant model 
           P-value 
 
AE+food allergy 
FBAT : dominant model 





























4.5.3 Known variants approach 
Previous studies (see section 4.4) showed that there are several markers in SPINK5 which 
are significantly associated with AE in the Japanese population (rs2303061, rs2303062, 
rs2303063, rs2303065, rs2303066, rs2303067, and rs2303068) (Kato et al., 2003) and in 
Caucasian population (rs2303067 and rs2303063) (Walley et al., 2001).  Variants 
previously associated with AE in other populations (six variants) were genotyped in the 
Bangladeshi families in order to replicate similar results except rs2303067, which failed in 
manufacture.  Analysis of the results using FBAT with AE as a quantitative trait, revealed 
no significant association of the SNPs rs2303061, rs2303062, rs2303063, rs2303065, 
rs2303066, and rs2303068 with AE in the Bangladeshi families was found under all the 
genetic models tested (Table 4.3).  Allele frequencies for all markers were produced using 
the genotype data which found to be almost fifty percent for each allele for the specified 
marker.  Also, no significant association was found when tested for other traits such as IgE 
(Table 4.4). 
Non-synonymous SNPs of SPINK5 gene were checked to see if any in LD with associated 
SNPs (rs9325073 and rs4263489) before embarking on massive mutation hunt.  Markers 
are in LD referes to the phenomenon that alleles which are close together in the genome 
tend to be inherited together.  The hapMap genome browser allows the measurement of LD 
for a given set of markers using the r-squared (r2).  SNPs that have not been separated by 
recombination are in perfect or ‘complete LD, r2=1, while lower r2 values means less 
degree of LD.  Genotype data of these markers were examined using the hapMap genome 
browser to compare the LD pattern through different populations except Yoruban, in order 
to find out if any of them is in LD with our significant SNPs.  Comparing previously 
associated variants with prevalent polymorphisms identified in the Bangladeshi families 
using HapMap LD data (http://www.hapmap.org/), showed that none of SNP pairs had a 




Table 4.3: Allele frequencies of SPINK5 markers previously associated with AE in 
different populations genotyped in the Bangladeshi families.  FBAT analysis shows that 
all alleles found to be almost fifty percent for specific marker.  Also, note that p-value in bi-
allelic test for AE in dominant, additive and recessive models is not significant. 











































































Table 4.4: FBAT analyses of SPINK5 markers for association with serum level of IgE 
in the Bangladeshi families.  Results showed no significant association between IgE level 
and these markers in dominant, additive and recessive models. 













































































Table 4.5: SNP pairs tested for LD using r2 between non-synonymous SNPs of SPINK5 
gene and associated SNPs (rs9325073 and rs4263489).   LD was measured for All SNP 
pairs using r2 in three populations including: Caucasian (CEU), Chinese (CHB) and 
Japanese (JPT) using HapMap genotype data.  When r2≥ 0.8, SNP pairs are in LD. 
Rs9325073 Rs4263489 Markers 
CEU CHB JPT CEU CHB JPT 
Rs17860502 NA NA NA NA NA NA 
Rs2303063 0.387 0.047 0.144 0.118 0.143 0.114 
Rs6892205 0.334 0.047 0.144 0.118 0.143 0.114 
Rs17775319 0.387 0.039 0.071 0.118 0.119 0.066 
Rs2303067 0.387 0.044 0.153 0.118 0.149 0.128 
Rs3777134 0.592 0.047 0.144 0.108 0.143 0.114 
Rs2303070 0.012 0.049 0.144 0.006 0.137 0.114 
Rs28408445 NA 0.008 0.061 NA 0.064 0.009 
Rs3188691 NA NA NA NA NA NA 
Rs17705005 0.016 NA NA 0.005 NA NA 
Rs2303064 0.033 NA NA 0.017 NA NA 
NA-data not available 
4.5.4 Searching for other variants 
4.5.4.1 Sample selection for resequencing and polymorphism detection in the SPINK5 
gene 
 
To follow up the positive associations with these four SNPs identified in the Bangladeshi 
families, twelve samples of unrelated homozygous individuals were selected using Illumina 
genotype data.  Homozygous individual for a particular phenotype trait means that this 
individual has a genotype with two identical copies of alleles affecting a given trait.  
Illumina genotype data of all (n=384) samples using 25 tagSNPs in SPINK5 gene file was 
loaded into the Haploview software (v3.32) in order to identify the major haplotype blocks 





Figure 4.3: Marker check page of Illumina genotype data using the Haploview 
software (v3.32). It shows eighteen markers out of twenty five tagSNPs for SPINK5 gene 
genotyped in the Bangladeshi families. 
 
Three LD measures are D', LOD score and r2.  LD plot used here is the D' plot which is the 
default plot of the raw D' score for a given marker pair from the Haploview software 
(v3.32) page (Figure 4.4).  A value of D'=1 means there is a complete LD, while D'<1 
means incomplete LD.  Configration of LD plots of the genotyped SNPs are denoted as 
‘ticks’ and the marker pairwise data is plotted as ‘boxes’ between these ticks.  The intensity 
of the box colour is equivalent to the strength of the LD characteristic for the marker pair.  
The default colour pattern is similar to the Haploview standard colour pattern (Table 4.6).  





Table 4.6: The standard LD colour scheme using Haploview software (v3.32).  Note 
that the bright red colour indicates complete LD between two genetic markers. 
Standard LD clolour scheme 
 D'<1 D'=1 
LOD<2 White blue 
LOD≥2 Shades of red Bright red 
 
 
Figure 4.4: Linkage disequilibrium (LD) map of the SPINK5.  The map was generated 
using the Haploview software (v3.32) and genotype data of 25 TagSNPs from the 80 
Bangladeshi families.  The top part shows the physicial position of the SNPs.  Each square 
box demonstrates the correlation of two SNPs, and the shades of red indicated the strength 
of the correlation ranging from no correlation (white) to strong correlation (red).  Blue 
squares indicate uncertain situations.  The correlation analysis detects three blocks of LD in 
the Bangladeshi families highlighted by the black outlines.  The variability of each of the 






















Figure 4.5: A diagram showing three major haplotype blocks of SPINK5 in the 
Bangladeshi families. This haploblock represents the most common haplotype 
combinations between the three blocks with percentage of 33% for the first haplotype, 10% 
for the second and third haplotypes while the rest of them are rare haplotypes.  Note that 
alleles are displayed in letters. 
4.5.4.2 PCR of patients in different haplotype groups 
Samples of unrelated individuals have been chosen using haploview software, as mentioned 
before; four samples for each haplotype groups (Table 4.7).  Individuals selected were 
affected and not affected with AE to compare between both panels assuming unaffected 
individuals as controls as all selected subjects are homozygotes.  Three major haplotypes 
have been observed in the Bangladeshi families; representing 33% for the first haplotype, 
and 10% for the second and third haplotypes.  The entire coding sequence of the gene, 
flanking introns boundaries (within 100bp), and the promoters were amplified using 34 
pairs of primers and the PCR procducts were analysed on 2% agarose gel (Figure 4.6).   
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Table 4.7: list of patients representing the three major haplotypes used to search for 
other variants in SPINK5 gene.  Four individuals were selected to represent each 
haplotype, some of them affected while others were not affected. 
Sample ID Family ID Member ID Affection* Sex** 
Haplotype 1 
OAG-ECZ-DNA-000248 38 2 1 2 
OAG-ECZ-DNA-000255 43 2 1 2 
OAG-ECZ-DNA-000113 19 5 2 2 
OAG-ECZ-DNA-000187 29 3 2 2 
Haplotype 2 
OAG-ECZ-DNA-000059 07 4 2 1 
OAG-ECZ-DNA-000174 32 2 1 2 
OAG-ECZ-DNA-000379 60 2 1 2 
OAG-ECZ-DNA-000384 60 3 2 1 
Haplotype 3 
OAG-ECZ-DNA-000213 17 2 1 2 
OAG-ECZ-DNA-000276 30 5 2 1 
OAG-ECZ-DNA-000286 47 1 1 1 
OAG-ECZ-DNA-000434 65 3 2 2 
*Affection: 1 not affected, 2 affected. 




 Figure 4.6: Photograph of PCR products been electrophoresed on 2% agarose gel of 
SPINK5, exon 31 primer.  From left to right, twelve DNA bands representing affected and 
unaffected individuals, one positive control and one negative control with product size of 
325b. 
4.5.4.3 Polymorphism detection by WAVE 
This method was used to detect heterozygous variants of SPINK5 gene in the Bangladeshi 
families.  Twenty five of thirty four primer pairs gave good data (normal WAVE profiles) 
while nine primer pairs were failed.  All samples have been screened by dHPLC to detect 
new heterozygous variants (double peaks), but no heterozygous variants were found. 
4.5.4.4 Polymorphisms detection by sequencing strategy 
Direct sequencing of all exons identified twenty different variants in the SPINK5 gene; all 
of them are known variants (Table 4.8).  Of the total twenty SNPs identified, ten are 
intronic variants, eight are exonic and two are 3’UTR.  Three of them (rs2303066, 
rs2303067 and rs2303068) are known to be associated with AE in Japanese population and 
they are in complete LD with each other (Kato et al., 2003), another study on Caucasian 
population showed also association of rs2303067 with AE (Walley et al., 2001).  Two of 
these variants (rs4263489 and rs9325073) were genotyped before using Illumina and found 
to be significant in the Bangladeshi families as mentioned earlier. 
 
169 
Table 4.8: Summary of twenty different variants identified in the SPINK5 gene in the 
Bangladeshi families. Four of these variants including: rs34482796, rs2303067, 
rs3777134, and rs2303070 were nonsynonymous polymorphisms. Also, two variants 
(rs4263489 and rs9325073) were genotyped before using Illumina and found to be 
significantly associated with AE. 
location SNP Alleles  Amino acid change No. of samples  AE % 
Ex11 rs34482796 C/T Missense, Ala-Val 2/3 50 
Int13-14 rs2303066 G/A Previously associated 3/4 33.3 
Ex14 rs2303067 A/G Missense, Lys-Glu 3/4 33.3 
Int14-15 Rs2303068 G/A Previously associated 3/4 33.3 
Ex15 rs6896303 A/G Synonymous, Gly-Gly 5/7 40 
Ex17 rs880687 C/A Synonymous, Gly-Gly 3/5 0 
Int17-18 Rs41291431 C/T   2/4 50 
Ex18 Rs2303071 C/T Synonymous, Val-Val 2/6 50 
Int20-21 rs56820817 +/tt  insertion 5/8 40 
Ex23 rs3777134 G/A Missense, Arg- Gln 8/12 50 
Int23-24 Rs3764926 T/C   2/3 0 
Int24-25 rs9325073 C/G  3/3 0 
Intr24-25 Rs12518996 G/A   1/3 0 
Ex26 rs2303070 G/T Missense, Glu-Asp 2/3 100 
Int27-28 Rs35129431 +/tt  insertion 8/9 50 
Int31-32 Rs6895434 T/C   8/12 50 
Ex32 rs2400478 T/C Synonymous, Gly-Gly 4/12 50 
Int33-34 rs4263489 G/C  4/12 50 
Ex34 Rs4349706 T/C 3’UTR 2/4 0 
Ex34 rs3088193 C/G 3’UTR 2/4 0 
4.5.4.5 Missense variants in the SPINK5 gene identified in the Bangladeshi families 
Four SNPs (rs34482796, rs2303067, rs3777134 and rs2303070) out of twenty other 
variants detected were nonsynonymous polymorphisms where a single nucleotide is 




Figure 4.7: Physical map of SPINK5 gene exons on forward strand of chromosome 5 
and their flanking introns.  Also, the position of missense SNPs, which genotyped in the 
Bangladeshi families using TaqMan® (http://genome.ucsc.edu/ accessed on 25/07/08) 
A) Rs34482796 
This is a missense SNP in exon11 not known to be associated with AE in previous studies 
(Figure 4.8).  Allele C is the reference allele which changed to allele T.  This nucleotide 
substitution changes Alanine (A), non-polar, hydrophobic and neutral amino acid, into 
Valine (V) which is also a non-polar, neutral amino acid (Figure 4.9).  This variant is 
highly conserved among most species except Rhesus and Tree-shrew (Figure 4.10).  
However, it is unlikely that this change in amino acid will lead to a change in protein 
function due to the fact that the methyl group in alanine (-CH3) is non-reactive. 
      
(A)                                                                     (B) 
Figure 4.8: Electropherograms of an area of exon 11 in two unaffected individuals. (A) 
Allele C in individual 255 substituted by allele T in individual 213 (B) who carries a 
homozygous C/T change (shown by arrow). 
171 
 
Figure 4.9: Schematic representation of the chemical structure of two amino acids: 




Figure 4.10: Conservation of rs34482796 in human and other species.  Alanine (A) is 
highly conserved amino acid substitution among human and most other species while 
Valine (V) is conserved only in few species such as, Rhesus and Tree-shrew (from 








This SNP located in exon 14, Glu420Lys, found in three patients: 286, 379, and 59 (Figure 
4.11).   It is known to be associated with AE in previous studies, and in complete LD with 
variants rs2303066 and rs2303068.  The nucleotide change A/G resulting in an amino acid 
exchange from Lysine (K) polar and basic amino acid to Glutamic acid (E) which is a polar 
and acidic amino acid.   Different folding and structure of both amino acids might lead to 
possible changes in the biological activity of the protein (Figure 4.12).  The Glutamic acid 
is well conserved between most species (Figure 4.13). 
 
        
(A)                                                                       (B) 
Figure 4.11: The sequence traces of Glu420Lys variant in exon 14. (A) Reference allele 
A is observed in unaffected individual 255 while allele G (B) is found in individuals 59, 
379 and 286.  Patient 59 (B) is an affected patient and carries a homozygous A/G change 
(shown by arrow).                                                                                           





                                   (A)                                             (B) 
A)                                             B) 
Figure 4.12: Schematic representation of the chemical structure of two amino acids, 
lysine and Glutamic acid.  (A) Lysine is polar and basic amino acid while Glutamic acid 
(B) is polar and acidic amino acid.  Possible changes in amino acid folding might lead to 




Figure 4.13: Glutamic acid (E) is conserved in most species while in human Lysine (K) 
is more frequent (from http://genome.ucsc.edu/).  In the Bangladeshi families the allele 




 Glu825Asp variant located in exon 26, reported by Walley and colleagues (Walley et al., 
2001) has not previously associated with AE.  Allele G observed in individuals 276, 174 
and control while allele T found in individual 113 (Figure 4.14).  Nucleotide change G/T 
leads to amino acid substitution which changes Glutamic acid (E) into Aspartic acid (D), 
both are polar and acidic, share similar properties and as result its most likely does not lead 
to changes in protein function.  Glutamic acid is highly conserved amino acid substitution 
among human and most other species (Figure 4.15). 
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(A)                                                                    (B) 
Figure 4.14: The sequence fragments of an area in exon 26 representing the position of 
variant rs2303070. (A) G is the major allele observed in unaffected individual, 174 while 
T (B) is the minor allele found in individuals 113.  Patient 113 (B) is an affected individual 




Figure 4.15: Glutamic acid (E) is highly conserved amino acid substitution among 








This variant is located in exon 23 and found in individuals; 59,174, 379, 384, 213, 276, 
286, and 434 (Figure 4.16).  Not known to be associated with AE in previous studies.  
Nucleotide change G/A leads to amino acid exchange from Arginine (R) polar and strongly 
basic amino acid to Glutamine (Q) which is polar and neutral amino acid and this may lead 
to possible change in protein function due to different properties.  Moreover, Arginine is 
highly conserved among human and most species except rat (Figure 4.17). 
 
        
  (A)                                                                  (B) 
Figure 4.16: Sequence traces of rs3777134 variant region in exon 23. (A) Allele G is the 
major allele in wild sequence while allele A (B) is the minor allele found in individuals 59, 






Figure 4.17: Arginine (R) is highly conserved amino acid among human and most 
other species except in rats (from http://genome.ucsc.edu/). 
 
4.5.5 Genotyping of all missense variants in the Bangladeshi families using TaqMan® 
 
Four missense SNPs of SPINK5 gene which are not in LD with the tagSNPs were subjected 
to further investigation using TaqMan genotyping.  These SNPs including: rs34482796, 


























Figure 4.18: Cluster plots from a typical TaqMan allelic discrimination assay of four 
missense SNPs of SPINK5 in the Bangladeshi families.  These variants including: (A) 
rs34482796, (B) Rs2303067 (C) rs2303070 (D) rs3777134.  There are three clusters shown 
in all of these assays; blue cluster representing the homonzygous samples on allele Y, the 
179 
middle heterozygous cluster in green, and the red cluster indicating the homozygous 
samples on allele X. 
4.5.6 Genotyping analysis of SPINK5 variants 
 
Allele frequencies of all SNPs in the Bangladeshi families were presented almost equally in 
both alleles except variant rs2303070 which showed sixty percent for one allele and forty 
percent for the other allele (Table 4.9).  Using the FBAT software (v2.0.2c) at the Genome 
Centre, statistics that reflects association between the trait locus and the marker locus was 
tested, and the distribution of the genotype marker data under the null hypothesis was 
computerized (Table 4.9).   None of the SNPs typed significantly associated with AE or 
other atopic diseases such as asthma and hayfever in the Bangladeshi families using 
different models.  Haplotype analysis for the markers showed several haplotypes; three of 
them are most commonly encountered; a1 (45%), a2 (40%) and a3 (12%), while the rest are 
rare (Table 4.10).  Haplotype association analysis with the disease showed that none of 
them was significantly associated with AE (Table 4.11).  FBAT analysis for association 
between variants detected in this study (rs34482796, rs2303067, rs3777134, rs2303070) 










Table 4.9: FBAT analyses of SPINK5 missense SNPs in the Bangladeshi families. 
Frequencies of alleles showing that both alleles in all markers are presented almost equally; 
fifty percent for each allele except variant rs2303070 in which the allele frequency of the 
first one is sixty percent while the frequency of the second allele is forty percent.  FBAT 
analysis showed also the p-value in bi-allelic test, affection trait in dominant, additive and 
recessive models. 
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Table 4.10: Haplotype analysis of SPINK5 variants (rs2303067, rs2303070, rs3777134, 
and rs34482796).  The first three haplotypes are the most common haplotypes in 
Bangladeshi population with frequency of 45%, 39%, and 12% respectively. 
 
Haplotype Number of families with haplotype Four marker haplotype frequency 
a1 21 
 
2      2       1       1 0.451 
a2 15 
 
1      1       2       2 0.394 
a3 2 
 





Table 4.11: Haplotype association analysis with AE for missense variants identified in 
the Bangladeshi families.  Note that there is no significant association with AE in all 
models.  
Haplotype Additive model Dominant model Recessive model 
a1 0.913 0.913 0.961 
a2 0.455 0.455 0.444 
a3 0.564 0.564 0.274 
†The probabilities are shown with this symbol if significant (<0.05) 
 
Table 4.12: FBAT analysis for association between missense variants of SPINK5 













































































































In this study, 25 haplotype tagging SNPs were genotyped and two markers were 
implicating SPINK5 gene with AE and other atopic phenotypes in the Bangladeshi 
population identified: rs9325073 and rs4263489.  SPINK5 gene was resequenced in the 
Bangladeshi families looking for variants that would explain the association with AE and 
other atopic phenotypes reported in other populations.  Resequencing revealed a number of 
missense SNPs previously associated with AE in other populations. One of them, 
Glu420Lys, G1258A found to be significantly associated with AE in the Japanese 
population (Kato et al., 2003) and Caucasian population (Walley et al., 2001).  A recent 
study by Di et al., showed that the homozygous substitution of Glu420Lys might affect the 
function of LEKTI involved in keratinocyte proliferation, differentiation, and skin barrier 
function (Di et al., 2009).  This suggests that this polymorphism involves in the 
susceptibility to AE.  However, this SNP was not associated with AE in the Bangladeshi 
families which is consistent with the results of a recent large cohort recruited (n>2000) 
individuals to assess previously identified polymorphisms in SPINK5 as well as other genes 
to AE risk (Weidinger et al., 2008a). 
 
Illumina genotype analysis of TagSNPs revealed promising positive associations in the 
Bangladeshi families between AE and two markers: rs9325073 with p-value of (0.008), and 
rs4263489 with p-value of (0.05).  The first marker found to be significant under all genetic 
models and in different allergic phenotypes tested (Appendix G). The second SNP, 
rs4263489, also found to be significant in other allergic phenotypes such as asthma and 
hayfever with p-value of (0.01) and (0.02) respectively.  These interesting associations 
were novel and not associated with AE in previous studies.  Another two SNPs including; 
rs17704764 and rs4362936 revealed significant results in asthma trait with p-value of 
(0.05) and (0.02) respectively.  One of these SNPs, rs4362936, was significant (p=0.03) 
also in affected individuals with hayfever.  Resequencing did not revealed any other 
associated SNPs suggesting that rs4362936 and rs9325073 may be linked with mutation 
outside coding region.  Also, it is possible the associated allele might be in promoter, 
introns or other regulatory sequence. 
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It is reasonable to assume the SPINK5, which is mutated in NS, may be considered as a 
candidate gene for asthma and other atopic diseases because NS exhibit allergic phenotypes 
(Chavanas et al., 2000).  An extensive search for polymorphisms in SPINK5 resulted in the 
detection of several SNPs, including six nonsynonymous SNPs in coding region which 
might affect its immune function.  A study conducted by Walley et al., (2001) on British 
population found significant association between two of these SNPs (A1103G and 
G1258A) with AE, asthma, and high serum IgE levels (Walley et al., 2001).  These results 
were confirmed in a large German population study.  Although, subsequent data on the 
association of SPINK5 polymorphisms with asthma alone are controversial suggesting that 
these polymorphisms can only affect the onset of asthma in patients with AE (Folster-Holst 
et al., 2005; Jongepier et al., 2005).  Thus, it is difficult to explain whether the gene’s 
primary effect is on asthma or AE or atopic condition or in the combination of all of them.  
Larger studies are needed to validate the concept that SPINK5 polymorphism is an 
important prognostic determinant for asthma onset in children with AE.  These findings 
point the mechanism by which a serine protease inhibitor might be involved in diseases 
affecting the airways and the skin.  In vivo, protease inhibitors are important down 
regulators of protease action (Magert et al., 2002).  Also, it plays a significant role in T and 
B lymphocyte maturation.  It is well known that SPINK5 is expressed within the thymus 
and as a result, the gene may have an effect of lymphocyte maturation or antigen 
manipulation within the thymus (Magert et al., 1999). Recently, a case-control study was 
conducted on asthmatic patients and healthy controls confirmed the association between (-
206G>A) polymorphism in the SPINK5 and asthma susceptibility in a Chinese Han 
population. This polymorphism produce a functional promoter element that change the 
transcriptional activity of the gene (Liu et al., 2009).  Asthma in NS patients has not been 
explained sufficiently in many studies, but appears to occur in approximately 30% of NS 
patients (Smith et al., 1995).  A recent case report from Turkey studied an infant with NS 
who presented to the emergency department with symptoms of asthma (Kutsal et al., 2008). 
 
Significant p-values identified in SPINK5 gene with AE in the Bangladeshi families have 
not been corrected for multiple testing in this study.  For SPINK5 gene, twenty nine 
markers (25 tagSNPs and 4 SNPs identified by resequencing), eight phenotypes and three 
models should be used for correction to reach a p-value of (≤7.16x10-5) in order to consider 
these associations significant.  After such analyses, none of these positive associations 
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remained significant after correction for multiple testing.  To exclude low risk SPINK5 
variants (OR below 2) being associated with AE, a larger series of families need to be 
investigated or perform a large case-control study of AE in the Bangladeshi population. 
However, SPINK5 is a previously associated gene with AE in different populations and 
several studies which allow less stringent correction at gene to gene level.  Also, none of 
previously associated SNPs were found to be associated in the Bangladeshi families, which 
may indicate no direct overlap between ethnicities and SNPs found to be associated.  Even 
when comparing the Bangladeshi population and the Japanese population, which are 
relatively close by location, none of these SNPs were replicated.  This implies that even in 
populations which are close by distance there is a certain element of genetic variation in 
























Assessment of genetic variations at the Tenascin C 































Tenascins (TNs) are a family of at least four large multimeric extracellular matrix (ECM) 
proteins; tenascin C, -R, -X and –W expressed in vertebrates (Chiquet-Ehrismann, 2004).  
Tenascin C (TNC) is the founding member of the family, discovered in 1983 as a protein 
abundant in gliomas (Bourdon et al., 1983) and as a myotendinous antigen (Chiquet and 
Fambrough, 1984).  These studies showed the major sites of TNC expression, mainly 
tendons, ligaments and the extracellular matrix of tumour stroma (Chiquet-Ehrismann and 
Chiquet, 2003).  TNC modulates adhesion of cells to fibronectin and may be considered as 
an anti-adhesive or adhesion-modulating ECM protein (Chiquet-Ehrismann et al., 1988; 
Orend and Chiquet-Ehrismann, 2000; Sage and Bornstein, 1991).  It is also, present in the 
central and peripheral nervous system (Joester and Faissner, 2001).  In addition, TNC is 
highly expressed during embryonic development and is temporally expressed during 
organogenesis, and absent or much reduced in the fully developed organs (Chiquet-
Ehrismann et al., 1995).  Expression of TNC in normal skin differs from almost absent 
through patchy areas scattered in vascular endothelia, hair follicles, and eccrine sweat ducts 
(Koukoulis et al., 1991; Lightner et al., 1989; Shikata et al., 1994; Tuominen et al., 1997).  
However, TNC expression might be upregulated in wound healing along the basement 
membrane and upper dermis (Latijnhouwers et al., 1996; Mackie et al., 1988).  In patients 
with AE, TNC is expressed at higher levels in lesional skin compared to non-lesional skin 
(Ogawa et al., 2005). 
 




The human TNC gene is located on the reverse strand of chromosome 9q33 at the location 
of (116822627-116920307) according to Ensemble database (http://www.ensembl.org/ 
accessed on 27/03/09).  Human TNC gene contains a total of 28 exons separated by 27 
introns and the two major TNC mRNAs originate from a single (or very close) start locus 
which indicates that human TNC gene transcription is controlled by a single promoter 
(Gherzi et al., 1995).  The transcript used in this study is annotated in the public database 
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TNC-001 (ENST00000350763) with a transcript length of 7598 bp, and a translation length 




Figure 5.1: Schematic analysis of TNC gene.  The upper diagram shows the position of 
the gene on chromosome 9 at q33.1 while the bottom diagram shows introns/exon 
organization of TNC gene on the reverse strand of chromosome 9 in five different 




5.2.2 TNC protein 
 
TNC is a large extracellular matrix glycoprotein composed of six similar subunits linked at 
their N-termini with disulfide bonds (Gherzi et al., 1995).  Each subunit consists of four 
main parts; the heptad repeats, epidermal growth factors like (EGFL) repeats, a series of 
fibronectin type III domains (FN-III) and a carboxyl-terminal fibrinogen-like globular 
domain (Figure 5.2) (Gulcher et al., 1991).  The size of TNC monomers differs due to 
alternative splicing of pre-mRNA in the FN-III domains.  There are eight conserved FN III 
repeats (identified as 1-8) and, in the case of human TNC, up to nine alternatively spliced 
FN III repeats (identified as A-D) inserted between the conserved domains 5 and 6 (Figure 














Figure 5.2: Schematic diagram of TNC protein. (A) Two electromicrographs of a 
hexameric TNC after rotary shadowing are shown in mouse. (B) Model of the TNC 
hexamer, consists of six arms emanate from a central core of the heptad region (green 
central hub).  Proceeding in a fibrinogen globe direction, a series of cysteine residues with a 
highly conserved spacing that appear in all known TN polypeptides (gray portion).  Ouside 
of that region, the domains are as follows: an array of EGFL repeats (Salmon colored 
ovals), two types of FN-III subunits; those conserved in all isoforms of TNC (light blue 
rectangles) and those that are alternatively spliced (red rectangles).  The last part is the 
yellow FG globe. (C) Schematic analysis of TNC polypeptide sequence represent the 
repeats involved in the main parts: (1) Amino-terminal heptads region (green ovals), (2) 
EGFL repeats (salmon-colored ovals), (3) FN-III repeats and a fibrinogen globe (yellow 
circle).  TNC has 13 EGFL repeats which are found in all vertebrate species (Salmon ovals) 






5.3 Role of growth factors and cytokines in regulating TNC gene expression 
 
Previous studies have reported several cytokines as inducers of TNC expression.  Including: 
platelet-derived growth factor beta (PDGF)-β and angiotesin II induced TNC mRNA and 
protein in rat smooth muscle cells (Sharifi et al., 1992).  IL-1 increased TNC secretion in 
human synovial fibroblasts (McCachren and Lightner, 1992).  TNC synthesis is induced by 
the basic fibroblast growth factor (bFGF) in different cell types, including Swiss 3T3 cells 
(Tucker et al., 1993).  Also, it was found that IL-4 strongly induce TN protein levels (up to 
10-fold), while PDGF and bFGF are less potent but up-regulate TNC synthesis in human 
dermal fibroblasts (Makhluf et al., 1996). 
 
Transforming growth factor-β (TGF-β) has been shown to variably modulate TNC in 
different biological process including proliferation, differentiation, extracellular matrix 
production, and apoptosis (Taylor and Khachigian, 2000).  Verrecchia et al., (2001) 
reported that TNC is one of the target genes of TGF-β and its expression is up-regulated by 
TGF-β in human dermal fibroblasts (Verrecchia et al., 2001). 
 
Recently, a report revealed that the transcription factor GATA-6, is a novel repressor of 
TNC gene expression (position -467~-460 of the TNC promoter) (Ghatnekar and 
Trojanowska, 2008).  GATA-6 belongs to a six member zinc finger transcription factor 
family named according to their recognition motif W-GATA-R (Lindholm et al., 2009).  It 
has been demonstrated that over expression of  GATA-6 in fibroblasts decreased basal 
levels, as well as apparently inhibited IL-4 and TGF-β-induced TNC mRNA and protein 
levels (Ghatnekar and Trojanowska, 2008). 
 
5.4 Matrix metalloproteinases (MMPs) and integrins control TNC 
 
TNC is frequently co-expressed with MMPs, a group of zinc-dependent ECM-degrading 
enzymes (Cowan et al., 1999; Jones et al., 1997; Streuli, 1999).  For example, within 
injured blood vessels, TNC expression and MMP-2 activity are activated before the 
development of occlusive neointimal lesions, which indicating that the expression and the 
effect of these proteins can be inter-related (Bendeck et al., 1994; Zempo et al., 1994).  
Moreover, TNC and MMP-2 are expressed and activated during angiogenesis (Brooks et 
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al., 1998; Tokes et al., 1999), as well as in the calcifying heart valves (Jian et al., 2001) and 
in the tumour stroma (Erickson and Bourdon, 1989; Sternlicht et al., 2000).  Also, during 
adult mammary gland involution in vivo, the appearance of TNC in the surrounding tissue 
plays an important role in MMP-mediated dissolution of the basement membrane and the 
subsequent loss of milk protein synthesis (Jones et al., 1995; Jones et al., 1993). 
 
Several lines of experimental evidence show that MMPs support the production of TNC 
(Thomasset et al., 1998), while suppression of MMP-2 and MMP-9 function in cultured 
vascular smooth muscle cells or hypertrophied pulmonary arteries inhibits TNC expression 
(Cowan et al., 1999, 2000; Jones et al., 1997).  MMPs might induce TNC through MMP-
mediated production or processing of soluble growth factors from the pericellular ECM or 
from extracellular integrin-rich cell adhesion sites (Streuli, 1999; Werb, 1997).  Possible 
factors that may be released or processed by MMPs consists of TGF-β1 and FGF-2 which 
are known to activate TNC expression in specific cell types (Rettig et al., 1994). 
Furthermore, vasoactive peptides such as angiotensin II and endothelin-1 have been found 
to be involved in vascular disease and in up-regulation of TNC expression (Hahn et al., 
1993). 
 
5.5 TNC and the skin 
 
The ECM and its associated cell adhesion receptors such as integrins, are used to by cells to 
interact with the mechanical microenvironment, and they also transmit biochemical signals 
to the cell interior (Shyy and Chien, 1997).  The expression of TNC in adults skin is low, 
although it is present at higher levels in fibrotic tissues and skin tumours (Ogawa et al., 
2005).  In normal skin, TNC expression is restricted to the dermal-epidermal junction of 
hair buds and eccrine glands, and to the inner layer of large blood vessels (Mackie et al., 
1988; Schalkwijk et al., 1991).  Furthermore, TNC expression is absent in normal scars 
after wound contraction while remains in keloidal fibroblasts and hypertrophic scars 






5.6 The genetic role of TNC in allergy-related disorders 
 
TNC gene has been identified as an important gene in asthma pathogenesis as well as other 
allergic diseases (Laitinen et al., 2004; Orsmark-Pietras et al., 2008).  A genome-wide 
linkage study on 97 families linked chromosome region on 9q33, where TNC is located, to 
asthma (p=0.007) (Wjst et al., 1999). A case-control study conducted on Japanese 
individuals by Matsuda et al., (2005) reported a coding SNP, rs2104772, in exon 17 (Leu 
1677IIe) which was strongly associated with adult asthma (OR=1.7, p=0.0001).  In this 
study, sixty two SNPs have been identified in the gene, twenty three SNPs were analysed 
both separately and as haplotypes in a case-control study of asthmatics (n=446) and healthy 
controls (n=658).  The Leu 1677IIe SNP represents a coding amino acid substitution in the 
FN-III domain subunit of an alternative spliced region of the gene which may cause 
instability in a β-sheet domain of the protein.  This could affect the integrity and stiffness of 
asthmatic airways (Matsuda et al., 2005).  The same region has been considered as a 
candidate area for genome-wide investigations searching for linkage to allergic rhinitis (Bu 
et al., 2006; Dizier et al., 2005; Yokouchi et al., 2002) although no candidate genes have 
been studied so far. 
 
The role of TNC in AE is not well understood, it was demonstrated that intradermal 
allergen challenge in atopic volunteers resulted in its up-regulation in fibroblast-like cells in 
and around basement membranes in 24-28 hours.  It accompanied with the infiltration of 
eosinophils that induce the differentiation of fibroblasts to myofibroblasts through their 
release of TGF-β and IL-13 (Phipps et al., 2002).  Another study reported that the 
expression of TNC could be regulated by inflammatory cytokines such as IL-4, TNF-α and 
IFN-γ (Latijnhouwers et al., 1998).  Also, Phipps et al., (2004) showed that, intravenous 
anti-IL-5 monoclonal antibody decreases eodinophil and tenascin deposition in allergen-
challenged human atopic skin (Phipps et al., 2004).  A study conducted by Ogawa et al., 
(2005) investigated the expression levels of TNC gene in the skin of patients with AE 
(n=11), psoriatic patients (n=6), and in healthy controls (n=7), found the TNC gene 
expression level was apparently higher (p=0.0077) in the lesional skin compared to non-
lesional skin of atopic patients while it was not up-regulated in the skin of psoriatic patients 
or healthy controls (Ogawa et al., 2005).  Elevated expression of TNC in lesional skin of 
patients with AE suggests that TNC may be considered as a specific marker for diagnosis 
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or disease activity of AE.  Also it may play an important role in regulating the underlying 
inflammatory reactions in AE.  Larger sample size and further investigations in more 
molecular details are required to clarify the function of TNC in the skin lesions of patients 
with AE.  
 
Neuropeptid S receptor 1 on chromosome 7p was considered as a susceptible gene for 
asthma and related traits (Feng et al., 2006; Hersh et al., 2007; Kormann et al., 2005; 
Laitinen et al., 2004; Malerba et al., 2007; Melen et al., 2005).  The ligand for NPSR1, 
known as Neuropeptide S (NPS), activates signalling via NPSR1 (Gupte et al., 2004; Xu et 
al., 2004) and microarray analysis has identified TNC as a target gene of NPS-NPSR1 
signalling (Vendelin et al., 2006) with an up-regulation of more than four fold.  A case-
control PARSIFAL study conducted by Orsmark-Pietras et al., (2008) on Western 
European populations in different countries, to study the genetic association of TNC in 
asthma and related atopic phenotypes as well as the genetic interaction between TNC and 
NPSR1.  Twelve SNPs have been genotyped in (n=3113) children based on previous study 
of Matsuda et al., (2005) and HapMap database.  The genotyping results revealed several 
SNPs in TNC gene associated with current rhinoconjunctivitis with MAF (0.3-0.4), and the 
most significant associations to SNP rs3789873 in intron10 (p=0.002), rs1330363 intron 15 
(p=0.008), rs2104772 in exon 17 (p=0.014) and rs13321 Gln2008Glu (p=0.006). 
Significant genetic association was found between TNC haplotypes and rhinoconjunctivitis 
with estimated haplotype frequency of (0.29) and p-value of (0.0005).  Also, results 
revealed significant genotype-genotype interaction between TNC SNPs and NPSR1 SNPs 
in either atopic sensitization or asthma.  This study concluded that variations in TNC 
influences, not only risk of asthma, but also for other allergic related phenotypes such as 
allergic rhinitis (Orsmark-Pietras et al., 2008).  Several reports studied the genetic 
association of TNC with atopic phenotypes such as asthma and rhinoconjuctivitis but not 
AE. However, most of the evidences demonstrated were not inclusive for TNC SNPs with 
these atopic phenotypes except rs2104772 variant which reported with significant 
association with asthma in two independent studies (Matsuda et al., 2005; Orsmark-Pietras 





5.7 Genetic approaches to assess TNC gene 
 
5.7.1 Overview  
 
Genetic association was investigated using SNPs and microsatellites to assess the 
association of TNC variants and AE and other atopic disorders in the Bangladeshi families. 
 
5.7.2 Haplotype-tagging SNPs strategy 
 
Fourty five tag-SNPs of TNC were genotyped using a customised Illumina BeadChip (San 
Diego, CA, USA) using the GoldenGate assay in Bangladeshi population (performed by 
Claire Sinclair and Nadiya Mahmud).  Haplotype-customised software (adapted by Richard 
Dobson and Timothy Nugent) using Caucasian, Chinese and Japanese populations were 
used to pick the Tag SNPs.   All genotypes were screened for Mendelian inheritance using 
the FBAT software and tested for bi-allelic and multi-allelic test in different models 
(additive, dominant and recessive).  A p-value was computed for each test.  Five affection 
traits were tested including AE, asthma, food allergy, IgE, and hay fever as well as 
affection trait in combination with other allergic phenotypes, and considered statistically 
significant when P≤0.05.  Results analysis revealed positive associations of four markers 
with AE including: rs11793430 (p=0.011), rs11794797 (p=0.017), rs7029844 (p=0.011), 
and rs3748166 (p=0.0097) under most of genetic models (Table 5.1).  Also, these four 
SNPs were significantly associated with most of atopic phenotypes tested (Appendix H).  
One variant, rs12555312 was significant in IgE additive model only (p=0.012).  These 











Table 5.1: Analysis of TNC markers associated with AE/atopic phenotypes using 
Illumina genotyped data generated from 384 samples.  It shows significant p-values 
under different genetic models, revealing positive association between various allergic 
phenotypes and TNC markers in the Bangladeshi families.  Significant variants show p-
value of ≤0.05. 
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FBAT: dominant model 
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5.7.3 Searching for TNC gene variants 
  
5.7.3.1 Sample selection for polymorphism detection in TNC gene 
To follow up the interesting positive associations of these four SNPs identified using 
Illumina in the Bangladeshi families.  Illumina genotype data generated for all (n=384) 
samples using 45 tagSNPs in TNC gene was used to select individuals for polymorphism 
detection.  Genotype data of 45 markers in TNC was downloaded into the Haploview soft 





Figure 5.3: Marker check page used to test forty five markers genotyped at the TNC 
locus using the Haploview software (v3.32). 
 
The LD plot was used to demonstrate the LD pattern between two genetic markers, with a 
cut-off point of r2>0.8 or D'=1.  A value of D'=1 means there is a complete LD, while D'<1 
means incomplete LD.  The intensity of the box colour is equivalent to the strength of the 
LD characteristic for the marker pair.  The default colour pattern is similar to the 
Haploview standard colour pattern (v3.32) (Figure 5.4).  There are three major haploblocks 




Fig 5.4: Linkage disequilibrium (LD) map of the gene TNC analysed in this study.  The 
map was generated using the Haploview software (v3.32) and genotype data of 45 SNPs 
from 384 samples of the Bangladeshi families.  The top part shows the physicial position of 
the four associated SNPs according to the gene.  Each square demonstrates the correlation 
of two SNPs, and the shades of red indicated the strength of the correlation ranging from no 
correlation (white) to strong correlation (red). Blue squares indicate uncertain situations. 
The correlation analysis detects three blocks of LD in the Bangladeshi families highlighted 
by the black outlines.  The variability of each of the three blocks can be captured by a small 







Figure 5.5 A diagram showing three major haplotype blocks of TNC in the 
Bangladeshi families.  These haploblocks were used for selection, and the thick lines link 
these haploblocks represents the most common haplotype combinations between the three 
blocks. 
 
5.7.3.2 Patient selection to detect polymorphisms in TNC gene 
Samples of unrelated individuals have been chosen using haploview software, as mentioned 
before; four samples for each haplotype groups (Table 5.2).  Individuals selected were 
affected and not affected with AE to compare between both panels assuming unaffected 









Table 5.2: list of patients representing the three major haplotypes used to search for 
other variants in TNC gene 
Sample ID Family ID Member ID Affection* Sex** 
Haplotype 1 
OAG-ECZ-DNA-000005 2 5 1 1 
OAG-ECZ-DNA-000091 
6 3 2 1 
OAG-ECZ-DNA-000075 
14 1 2 1 
OAG-ECZ-DNA-000140 
25 1 1 1 
OAG-ECZ-DNA-000007 
2 1 1 1 
Haplotype 2 
OAG-ECZ-DNA-000134 
22 3 2 1 
OAG-ECZ-DNA-000182 
29 2 1 2 
OAG-ECZ-DNA-000321 
40 6 1 2 
OAG-ECZ-DNA-000309 
62 2 1 2 
OAG-ECZ-DNA-000485 
78 3 2 2 
Haplotype 3 
OAG-ECZ-DNA-000058 
7 5 2 2 
OAG-ECZ-DNA-000057 
7 6 2 2 
OAG-ECZ-DNA-000124 
20 8 1 2 
OAG-ECZ-DNA-000353 
55 3 2 1 
OAG-ECZ-DNA-000437 65 6 1 1 
*Affection: 1 not affected, 2 affected. 
**Sex: 1 male, 2 female. 
5.7.3.3 PCR of patients in different haplotype groups 
The entire coding regions (28 exons), introns-exon boundaries, the promoter and 5’-and 3’-
flank regions of the TNC gene were amplified with annealing temperature of 60°C for most 
of them.  Primers used for each PCR reaction are shown in general methods (section 2.3.4).  
Then, the PCR products were analysed on 2% agarose gel (Figure 5.6). 
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Figure 5.6: Photographs of PCR products electrophoresed on a 2% agarose gel from 
two different TNC primers.  (A) Gel picture of TNCex6 showing from left to right, fifteen 
DNA bands representing patients, one positive control and one negative control with 
product size of 326bp.  (B) Gel picture of TNCex7 showing also fifteen samples, positive 
control and negative control with a product size of 456bp on a 100bp ladder. 
5.7.3.4 Polymorphisms detection by WAVE® 
16 fragments showed abnormal WAVE profiles with double peaks (Table 5.3).  Direct 
sequencing analysis of these abnormal profiles was carried out to identify each 
polymorphism. 
Table 5.3: Results of abnormal WAVE profiles in exon 10, introns (9-10), introns 19, 
exon and introns 24.   Fragments with abnormal WAVE profiles showed double peaks, 
mainly in exon 24 and introns (19-20) 
Gene location Number of samples with abnormal variation 
Exon 10 2 
Intron (9-10) 3 
Intron (19-20) 5 
Exon 24 5 
Intron (24-25) 1 
5.7.3.5 Sequence abnormal WAVE profile 
All exons including those with abnormal WAVE profiles were sequenced and revealed ten 
different sequence variants in the TNC gene.  Eight of these are annotated in public 
databases, such as Ensemble or UCSC (http://genome.ucsc.edu/cgi-bin/hgTracks), whereas 
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the other two are novel (Table 5.4, Figure 5.7).  Of the total ten variants identified, one is a 
microsatellite, six are intronic, and four exonic variants.  Three of them (rs13321, 
rs3748166, and rs1617917) were previously genotyped as Tag SNPs using Illumina, and 
one of them, rs3748166, showed significant results in all models and tests with AE and 
other atopic phenotypes in the Bangladeshi families (Table 5.1).  
 
Figure 5.7: Schematic representation of the 3’-5’ of TNC gene analysed in this study.  
Twenty eight exons are depicted by red boxes and non-coding regions as blue boxes.  The 
position of the ten SNPs and one microsatellite of the TNC gene detected in the 
Bangladeshi families.  The SNP ID, polymorphism, position in relation to the gene are 
detailed below.   Known variants are written by rs code while novel variants are represented 









Table 5.4: Details of ten variants identified in TNC gene in the Bangladeshi families.  
Of these; three were genotyped by Illumina (rs3748166, rs13321 and rs1617917) and two 












Alleles No. of 
samples  
% AE 
Intron  1 Rs3748166* 116919970  C/T 2/5 50 
 




Rs1757095 116888215 Non- synonymous, 
coding 
T/C 3/8 33.3 
 
Intron 3 Rs1617917* 116887933  A/T 3/8 33.3 
 




Rs45602433 116875720 Non-synonymous, 
coding  
G/A 2/7 50 
 
Exon 15 Novel 116859337  C/T 1/8 0 
 











Rs13321* 116832404 Non-synonymous, 
coding 
C/G 5/9 60 
 
Intron 25 Novel  116832295  G/C 1/8 100 
 






5.7.3.6 Missense variants in the TNC gene identified in the Bangladeshi families 
There are three missense SNPs including rs1757095 in exon 3C, rs45602433 in exon10, 
and rs13321 in exon 24.  A novel SNP in exon 15 was also analysed as well as a TG-repeat, 
rs35141770, insertion polymorphism located in the beginning of introns 19.  These variants 
were selected as markers in order to be genotyped for further association analysis using 
Taqman® genotyping assay for SNPs and microsatellite genotyping on an ABI 3700 
automated sequencer.  Two variants detected in this study were genotyped including: 
rs45602433 and rs35141770. Two SNPs were excluded, rs13321 and rs1757095: the first 
one was genotyped before in the Bangladeshi families by Illumina and it was not significant 
and the second SNP failed to be genotyped which showed low signal quality due to high 
fluorescent background or noise.  The variant in exon 15 was found only in one not affected 
individual and not genotyped in the rest of the families.  
A) rs45602433 
This is a missense SNP in exon 10 (Figure 5.8) with two individuals having this variant, 
unaffected female and affected female. Allele G changed to allele A.  This nucleotide 
substitution changes Arginine (R) into Histidine (H), both are polar amino acids with 
positive side chains (Figure 5.9).  The polarity of the side-chain of an amino acid affects its 
hydrophilic or hydrophobic character (Creighton and Thomas, 1993).  Differences in these 
properties play an important role in protein structure and protein-protein interactions.  For 
example, both Arginine and Histidine are more likely to bind to negatively charged 
molecules due to their surfaces rich with positive charges.  However, it is possible that this 
change in amino acid is unlikely to affect the protein function due to the fact that both 
amino acids have similar properties.  Functional studies would need to be performed.  This 
variant is conserved among humans and most species (Figure 5.10). 
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Figure 5.8: Sequence traces and WAVE profiles of an area of TNCex10 in two 
unaffected individuals.  (A) Sequence trace of individual 124 representing the wild type 
with normal WAVE profile. (B) Sequence trace of abnormal WAVE profile with a triple 
peak in individual 321, showing a heterozygous G/A change (shown by arrow). 
 
Figure 5.9: Schematic representation of Arginine (R) and Histidine (H) amino acids.   
Both are polar amino acids with a basic side chains.  The positive charge on these side 
chains makes them hydrophilic and they are probably found at the protein surface. 
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Figure 5.10: Arginine is well conserved amino acid among most species.  
B) TNCex15 
This is a novel heterozygous SNP in exon 15 was identified by abnormal WAVE profile 
(double peak).  Only one unaffected male (sample 7) has been found to have the C/T 
variant (Figure 5.11).  After sequencing, this change leads to a substitution of proline (P) 
which is a non-polar and neutral amino acid by Serine (S), polar and neutral amino acid 





Figure 5.11: Sequence traces and WAVE profiles of an area of TNCex15 in two 
unaffected individuals.  (A) Sequence trace of individual 124 representing the wild type 
with normal WAVE profile. (B) Sequence trace of abnormal WAVE profile with a double 
peak in individual 7 showing a heterozygous C/T change (shown by arrow). 
 
Figure 5.12: Schematic diagram of the chemical structure of two amino acids: Proline 
(P) and Serine (S).  Proline is a non-polar hydrophobic amino acid changed to Serine, a 




This is an insertion polymorphism and was found in individuals: 134, 353, 321, 58, 124 
with an abnormal WAVE profiles (multiple peaks).  It is an insertion heterozygous repeat 
of +/TGTG on the reverse strand (Figure 5.13).   
 
Figure 5.13: Wave profiles and sequence traces of introns 19 of TNC gene. A) Normal 
Wave profile of unaffected male (sample 5) and the sequence trace with nine TG repeats.  
B) Abnormal Wave profile with multi peaks of unaffected female (sample 321) and the 
sequence trace showing the insertion of +/TGTG (underlined). 
5.7.3.7 Genotyping of variants in TNC gene 
Ten variants were identified in the Bangladeshi families with two of them more plausible 
functional SNP variants; rs45602433, and rs35141770.  The first one is a nonsynonymous 
polymorphism leading to the substitution of Arginine for Histidine amino acid.  The last 
variant is an intronic insertion type polymorphism +/TGTG.  These variants were 
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successfully genotyped in 71 probands and all available first degree relatives (n=384) using 
Taqman assay for SNPs (Figure 5.14), and a fluorescently labelled primer for the insertion 
variant using the ABI PRISM 3700 automated sequencer and genotyper software (v3), 
(Figure 5.15). 
 
Figure 5.14: cluster plot of 384 DNA samples from a typical Taqman allelic 
discrimination assay of a missense SNP, rs45602433, of TNC gene in the Bangladeshi 
families.  It shows two main clusters; VIC indicates homozygousity of allele G and the 
green heterozygous cluster of both alleles.  There is one sample representing homozygous 









Figure 5.15 Genotyping analysis of TNCex19 microsatellite. This is family (006) 
consists of : a mother with two alleles of size 382 and 386, a father with one allele size 386 
and three affected children; two females and one male. 
5.7.3.8 Genotyping analysis of TNC variants 
Genotype analysis was performed using the FBAT software (v2.0.2c) at the Genome Centre 
as mentioned in the general methods (section 2.4).  Association between these markers and 
AE was analysed under different tests and models (Table 5.5).  Furthermore, other allergic 
phenotypes (asthma, AE and asthma, hayfever, AE and hayfever, food allergy, and AE in 
combination with food allergy) were considered for association analysis.  Results of the 
association test showed significant association between rs35141770 and most of other 
atopic disorders including asthma (p=0.045), AE and asthma (p=0.054), hayfever (p=0.02) 
and AE with hayfever (p=0.022) (Table 5.6).   
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Table 5.5: FBAT analysis of association between TNC variants (rs45602433, 
rs35141770) and AE.  Results revealed no significant association between AE and TNC 
markers in the Bangladeshi families. 
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Table 5.6 FBAT analysis showing the association between TNC markers and other 
allergic phenotypes.  These phenotypes including: asthma, asthma and AE, hayfever, 
hayfever and AE, food allergy, and food allergy in combination with AE.   
Marker Asthma AE+asthma Hayfever AE+Hayfever FA AE+FA 
rs45602433 




















































Various genome scans conducted world wide to search for candidate genes associated with 
different skin conditions such as psoriasis (Sun et al., 2007) and allergic phenotypes such 
as asthma (Wjst et al., 1999),  presented suggestive evidences for linkage in region 9q33.   
The TNC gene appears as one of the best positional and functional candidate genes lying 
within this region and could be associated with AE.  The TNC gene was chosen as a 
positional candidate gene for AE.  Forty five tag SNPs were selected based on the genotype 
data of the HapMap database, spread across the TNC gene.  Result analysis revealed 
positive associations of four SNPs with AE and other allergic disorders in the Bangladeshi 
families including: rs11793430, rs11794797, rs7029844, and rs3748166. These results in 
accordance with the data presented in previous studies that linked TNC variants with a 
range of atopic diseases including: asthma and hayfever (Laitinen et al., 2004; Orsmark-
Pietras et al., 2008).  One variant, rs3748166, was found to be more significantly associated 
with AE than other SNPs in the Bangladeshi families with a p-value of (0.0097), as well as 
other atopic phenotypes such as hayfever (p=0.004), and food allergy (p=0.006).  The other 
two variants, rs11793430, and rs11794797 showed significant association with IgE with p-
value of (0.0098) and (0.0099) respectively.   
Following position association, the TNC gene was resequenced to detect possible 
variations.  A panel of fifteen Bangladeshi subjects were screened for variations in the 28 
exons, and eleven polymorphisms were identified (Table 5.4). Two polymorphisms 
(rs35141770 and rs45602433) were used to further delineate the relationship between TNC 
and AE and other atopic diseases in the Bangladeshi families.  Result analysis showed that 
none of these variants found by resequencing were statistically significant with the AE 
indicating that non-coding variants may be linked with the AE at the TNC locus.  However, 
SNP rs35141770 found to be significant in other allergic phenotypes including: asthma 
(p=0.045), AE and asthma (p=0.054), hayfever (p=0.02), and AE with hayfever (p=0.022).  
To follow up the interesting findings; functional studies and replication studies could be 
conducted in other populations with AE. 
Six of variants identified in Bangladeshi population; rs13321, rs35141770, rs2104772, 
rs45602433, rs1757095, rs3748166 were evaluated previously for association with 
Spondyloarthritis in Caucasian population that revealed no association (Zinovieva et al., 
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2008).  A study conducted by Matsuda et al., (2005) on asthmatic patients found an 
association with a coding SNP, rs2104772, in exon 17, an amino acid substitution 
(Leu1677Ile) within the FN-III domain of the alternative splicing region.  This substitution 
occurs at the outer part of the beta-sheet in FN-III domain and causes instability of this 
sheet.  As a result of the structural changes in that domain, the integrity and the stiffness of 
the airways may be affected.  Thus, Leu1677Ile, may be important marker for assessing the 
risk for developing asthma and plays a role in its pathogenesis.  However, the genotype 
analysis of this polymorphism showed no association with AE or other atopic phenotypes 
in the Bangladeshi families. 
 
Similar to other inflammatory disorders of the barrier organs such as asthma, inflammatory 
bowel disease (IBD), and psoriasis, there are environmental, immunologic, and genetic 
factors that play a fundamental role in the predisposition to AE.  Various studies 
demonstrated evidence suggests that AE risk genes work in a context-dependent manner, 
i.e. gene-gene interactions or gene-environment interactions (Brown and McLean, 2009).  
A study examined the genetic interaction between TNC and NPSR1 in allergic disease 
found that Leu1677Ile variant and Gln2008Glu (rs13321) in exon 24, were associated to an 
increased risk of childhood rhinoconjunctivitis (Orsmark-Pietras et al., 2008).  Also, 
polymorphisms within other genes located in close proximity with TNC might affect the 
association of TNC with different conditions such as polymorphisms in TNC gene and the 
gene encoding for a subunit of type V collagen (COL5A1), have previously been reported 
to be associated with Achilles tendon injuries (September et al., 2008).   
 
Hardy-Weinberg analysis of the allelic discrimination assays was appropriate and no 
outliers were detected indicating the genotyping assay was likely to be accurate. Significant 
p-values identified in TNC gene with AE in the Bangladeshi families have not been 
corrected for multiple testing in this study.  For TNC gene, forty seven markers (45 
tagSNPs and 2 variants identified by resequencing), nine phenotypes and three models 
should be used for correction to reach a p-value of (≤4.43x10-5) in order to consider these 
associations significant.  None of these positive associations remained significant after 






































Historically, the vast majority of research into genetic causes of atopic diseases and AE has 
concentrated on the systemic immune response that shows Th2 predominance and elevated 
IgE levels.  As, AE and asthma did not appear to share the same genetic loci (Cookson, 
2004; Hoffjan and Epplen, 2005; Veal et al., 2005) more recently interests has concentrated 
on skin-specific genes involved in cutaneous immunity, infection, and inflammation as well 
as epidermal barrier function.  Candidate genes can be categorized according to their 
primary functional location, although there is considerable overlap between systemic and 
cutaneous immunity and the epidermal barrier function (Brown and McLean, 2009).   
 
This study was conducted on the Bangladeshi families (n=70) with a strong family history 
of AE to evaluate the contribution of polymorphisms in FOXP3, SPINK5 and TNC toward 
AE susceptibly in a family-based association analysis.  Prior to this study, information on 
the genetic susceptibility to AE and atopy, strong and conclusive genetic determinant was 
lacking.  However, the epidermal barrier protein filaggrin (encoded by FLG)  has now been 
reported as a strong candidate gene associated with AE in more than 15 separate 
publications, many of them include more than a single within-study replication (Brown and 
Irvine, 2008; Rodriguez et al., 2008).  The group that identified the two FLG mutations 
underlying ichthyosis vulgaris (IV) subsequently found them to be significantly associated 
with AE and asthma in Caucasian populations. These variants were carried by 
approximately 9% of people of European origin (Palmer et al., 2006).  Also,  Weidinger et 
al., (2006) in collaboration with this group concluded these loss-of-function mutations are 
associated with AE and allergic sensitization in a German Cohort, as well as with adult AE  
(Barker et al., 2007).  Association of FLG null genotype with AE has been replicated in 
several case-control studies (Novak et al., 2008; Sandilands et al., 2007; Stemmler et al., 
2007; Weidinger et al., 2007), family studies (Ekelund et al., 2008; Morar et al., 2007), and 
population-based studies (Brown et al., 2008; Henderson et al., 2008; Weidinger et al., 
2008c).  These mutations are carried by up to 10% of people, and represent a strong genetic 
predisposing factor for AE, asthma and other allergic phenotypes.  It provides a strong link 
between a defect of the epidermal barrier that is hypothesised to provide easier penetration 
of pathogen/allergen through the skin leading to a systemic hyperactive immune response 
to it (Sandilands et al., 2009). 
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In order to identify susceptibility genes for AE in the Bangladeshi families, twenty seven 
candidate genes have been genotyped using Illumina (General methods).  These genes 
grouped into two main categories; novel genes and genes previously associated with AE in 
other populations.  Novel genes were selected according to their possible biology functions 
implicated them in the pathophysiology of AE.  Analysis of the Illumina results revealed a 
number of significant p-values in novel and known genes in association with AE and other 
allergic phenotypes (Claire Sinclair, PhD thesis). 
 
Significant results were identified in most of previously associated genes (Table 6.1) with 
AE and other allergic phenotypes in the Bangladeshi families including: SPINK5, STAT6, 
NOD1 ST2, TIM3 and IL4RA.  Three of these genes showing association remained 
significant after multiple corrections, IL4RA, ST2 and TIM3.  IL4RA showed a significant 
association between rs2239346 and AE (p=0.000509), asthma (p=0.000466) as well as AE 
with food allergy (p=0.0019).  This gene has been assessed by Hosomie et al., (2004) and 
found that seven SNPs had functional significance in association with AE (Hosomi et al., 
2004), one of them, Gln551Arg was also significantly associated with AE in the Japanese 
population (Oiso et al., 2000).  This SNP found to be more frequent in Caucasian children 
with flexural eczema, especially in the first sixth months of life (Callard et al., 2002).  
SNPs on ST2 gene including: rs13019081, rs1921622 and rs3821204 were significantly 
associated with AE in the Bangladeshi individuals as follow; p=0.00107, p=0.00989, and 
p=0.00205 respectively.  Two of them; rs13019081, and rs1921622 also were significant in 
other atopic phenotypes.  This genes maps on chromosome 2q12, with SNP -226999G/A 
significantly associated with AE in Japanese population (Shimizu et al., 2005).  
Furthermore, TIM3 gene showed a significant association between rs6861025 and AE 









Table 6.1: Summary of association found in the previously associated candidate genes. 
Note that significant association when p-value ≤0.05 
Gene Associated with AE Best AE p-value Other association? 
SPINK5 Yes 0.0076 Asthma, Hayfever, Food Allergy 
CARD4/NOD1 Yes 0.016 Asthma, Hayfever, Food Allergy 
IL4RA Yes 0.000509 Asthma, Hayfever, Food Allergy 
ST2 Yes 0.00107 Asthma, Food Allergy 
STAT6 Yes 0.048 Food Allergy 
TIM3 Yes 0.0075 Asthma, Hayfever, Food Allergy 
CMA1 No 0.126 - 
Loricrin No 0.063 Asthma, Food Allergy 
CCL1 No 0.223 - 
CCL5/RANTES No 0.214 - 
FCεR1B No 0.065 Hayfever, Food Allergy 
 
Novel genes genotype analysis revealed strong and promising association between several 
candidate genes such as JAK3, PTGDS, CD86 and TNC and AE as well as other atopic 
phenotypes (Table 6.2).  One of the associated genes remained significant after correction 
for multiple testing JAK3.  JAK3 showed a significant association between polymorphism 
rs722429 and AE (p=0.0001) and other allergic phenotypes.  Furthermore, two other SNPs; 
rs10421916 and rs2286662 were significant in AE, p=0.0039 and p=0.0024 respectively, as 
well as other allergic phenotypes.  Other genes such as PTGDS, HRF, CCR4, and NRAMP 
showed significant association between several variants and AE as well as other allergic 
phenotypes.  These interesting and encouraging findings may act as a starting point for 
additional future genetic and functional studies.  They outline the possible next steps which 
allow the progression from genetic studies to biological pathways or mechanisms that may 








Table 6.2: Summary of association found in the novel candidate genes.  Note that 
significant association when p-value ≤0.05 
Gene Associated with AE Best AE p-value Other association? 
CD86 Yes 0.01 Asthma, Hayfever, Food Allergy 
TNC Yes 0.0097 Asthma, Hayfever, Food Allergy 
KYNU No 0.000067 (artefact) Asthma, Hayfever, Food Allergy 
ACVR1 Yes 0.011 Asthma, Food Allergy 
CCR4 Yes 0.022 Asthma, Hayfever, Food Allergy 
JAK3 Yes 0.0001 Asthma, Hayfever, Food Allergy 
IL10RA Yes 0.031 Asthma, Hayfever 
PTGDS Yes 0.026 Asthma 
SLC9A3R1 No 0.114 - 
HRF No 0.222 Asthma, Food Allergy 
COL7A No 0.365 - 
PTPN22 No 0.097 Asthma 
WASIP No 0.114 - 
FAP No 0.243 - 
NRAMP No 0.108 Asthma, Hayfever, Food Allergy 
 
In this thesis, three genes have been assessed in more details: FOXP3, SPINK5 and TNC to 
identify an association between polymorphisms in these genes and AE in the Bangladeshi 
families.  Previous to this study, a genome scan was performed and suggestive linkage was 
identified to Xp11, a region has also been linked to other autoimmune diseases, 
emphasising the presence of common susceptibility polymorphism(s) (Ban et al., 2007; 
Cornelis et al., 1998; Cucca et al., 1998; Ebers et al., 1996).  This position has also gained 
a lot of attention due to the presence of highly plausible candidate gene FOXP3 which 
maps to the human chromosome region Xp11.23 (Paik et al., 2008).  Genetic association 
was investigated using microsatellites and SNPs to identify the association of FOXP3 
variants and AE as well as other atopic disorders.  In addition, sequence analysis revealed 
three different types of polymorphisms in intron 1 including: A/C, A/G and insertion of G.  
There is also a coding polymorphism in exon (5-6). Three known SNPs were identified 
(rs2232367, rs3761548 and rs2232365) available in public database, and a novel variant 
FOXP3I1-1.  All SNPs and microsatellites (J12, J17, J19 and J26) from the Zavattari et al., 
(2005) study were genotyped.  Interesting positive association observed between SNP, 
rs3761548, and AE in the recessive model (p=0.025) and in the dominant model (p=0.028) 
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as well as all other allergic phenotypes such as asthma (p=0.034), hayfever (p=0.034), and 
food allergy (p=0.034). 
Illumina results of the 27 genes revealed significant results with SPINK5 and TNC genes 
(Table 6.3).  Haplotype-tagging SNPs using 25 common allelic variants of SPINK5 were 
genotyped using the Illumina platform in the Bangladeshi families. Analysis showed 
positive associations with two markers: rs9325073 and rs4263489. The first SNP 
rs9325073 found to be significant in AE (p=0.008) and under all of genetic models and in 
different allergic phenotypes such as asthma (p=0.004), hayfever (p=0.002), and food 
allergy (p=0.0099).  The second SNP is also significant in AE with p-value of (0.05), as 
well as other allergic phenotypes including: asthma (p=0.01) and hayfever (p=0.02).  These 
significant SNPs were novel but not found to be in LD with previously associated SNPs 
(rs2303061, rs2303062, rs2303063, rs2303065, rs2303066, and rs2303068) and AE in other 
populations.  Previously associated SNPs with AE were genotyped in the Bangladeshi 
families and the results analysis revealed no significant association.  Fifteen unrelated 
individuals were chosen representing each major haplotype group for polymorphism 
detection.  Twenty different variants were identified in SPINK5 gene using direct 
sequencing all of them are known variants.  Of the total twenty SNPs identified, ten are 
intronic variants, eight are exonic and two are 3’UTR.  Three of them (rs2303066, 
rs2303067 and rs2303068) are known to be associated with AE in the Japanese population 
and they are in complete LD with each other (Kato et al., 2003), another study on 
Caucasian population showed also association of rs2303067 with AE (Walley et al., 2001). 
All nonsynonymous SNPs rs2303067, rs2303070, rs3777134, and rs34482796 of SPINK5 
gene were genotyped in the Bangladeshi families using TaqMan.  FBAT analysis showed 
that none of the SNPs tested was significantly associated with AE in Bangladeshi families 







Table 6.3: P-value of Illumina result analysis on TNC and SPINK5 polymorphisms 
associated with AE or/and other atopic phenotypes.  Susceptibility SNPs with 
significant association are shown in pink (p≤0.05) and borderline p-values in blue.  Note 













rs11793430 0.011 0.084 0.021 0.056 0.046 0.022 0.056 
rs11794797 0.017 0.066 0.022 0.049 0.041 0.018 0.056 
rs7029844 0.011 0.123 0.030 0.032 0.053 0.038 0.059 
rs3748166 0.0097 0.029 0.025 0.0036 0.018 0.0058 0.029 
SPINK5 
rs9325073 0.0076 0.0035 0.0069 0.0023 0.005 0.0099 0.033 
rs4263489 0.051 0.010 0.121 0.020 0.169 0.245 0.381 
rs4362936 0.101 0.020 0.199 0.029 0.268 0.424 0.527 
rs17704764 0.063 0.046 0.374 0.107 0.297 0.311 0.284 
TNC is one of the novel genes showing a positive association with AE in the Bangladeshi 
families from the Illumina analysis. Candidate gene analysis of four SNPs: rs11793430, 
rs11794797, rs7029844 and rs3748166, were significantly associated with AE and most of 
allergic phenotypes tested.  Sixteen fragments of abnormal WAVE profile were sequenced 
and yielded ten different sequence variants in the TNC gene.  Eight of these are annotated 
in public databases, whereas the other two are novel.  Of the total ten variants identified, 
one is a microsatellite, six are intronic, and four exonic variants.  Four of them (rs13321, 
rs3748166, rs2104772, and rs1617917) had been genotyped as Tag SNPs using Illumina.  
One of these SNPs, rs3748166, showed a very significant association with AE (p=0.0097), 
hayfever (p=0.0036), and food allergy (p=0.0058) in the Bangladeshi families.  In this 
study, one SNP rs45602433 in exon10, and a TG-repeat insertion polymorphism, 
rs35141770 located in the beginning of introns 19 were selected as markers in order to be 
genotyped for further association analysis.  Result analysis showed that none of these 
variants found by resequencing were statistically significantly associated with the AE, 
indicating that non-coding variants may be linked with the AE and atopic phenotypes at the 
TNC locus.  However, SNP rs35141770 found to be significant in other allergic phenotypes 
including: asthma (p=0.045), AE and asthma (p=0.054), hayfever (p=0.02), and AE with 
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hayfever (p=0.022).  To follow up the interesting findings, functional studies and 
replication studies could be conducted in other populations with AE. 
However, after correction for multiple testing, none of the above SNPs in TNC, SPINK5 
and FOXP3 showing evidence for association were significantly linked to AE and/or other 
atopic phenotypes (see 6.6) 
6.2 Interpretation of genetic data in order to explain the association between variants 
and atopic disease phenotype 
There are two main concepts in explaining the association between polymorphisms and 
atopic disease phenotypes, either positive association or negative association.   Few points 
should be highlighted when discussing positive association.  These include; the causal link 
if the polymorphism tested directly influences gene expression or protein function leading 
to increase susceptibility.  Alternatively, when the polymorphism tested is in LD with an 
adjacent polymorphism that is directly causal.  Population stratification which may lead to 
false-positive associations when case and controls are not matched adequately.  This results 
in type I error especially in studies of multiple markers and disease phenotypes which will 
require p-value correction according to the number of statistical tests performed.   
Key concepts when considering negative or no observed association include; 
polymorphisms assessed do not contribute to the disease phenotype however, that does not 
exclude the encoded protein from contributing in the pathogenesis of the disease.  Negative 
or no association may occur because of lack of power. 
6.3 Potential confounder factors 
As described in the introduction, failure to replicate associations between genetic markers 
and a complex trait in different populations may be due to many factors such as 
misclassification of disease phenotype, small sample size, population stratification and 
environmental factors (Colhoun et al., 2003; Hirschhorn et al., 2002; Ioannidis et al., 
2001).  Another factor, population diversity, considered as a key factor contributing to 
inability to replicate associations.  It is possible that specific genetic markers might involve 
in disease risk in a certain population but not in others, due to differences in allele 
frequencies or risk alleles or due to gene-gene interactions.  At present, it is difficult to 
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examine the influence of ethnicity on genetic associations of AE because most of these 
studies have been conducted in population with relatively little diversity.  Most of 
association studies have been performed in European populations followed by populations 
of Asian descent and none of these studies have been done in groups considered minorities 
such as Bangladeshis, African Americans or Middle Easterns.  The best example of a 
candidate gene for which ethnic diversity may affect the extent to which a variant confers 
risk is FLG.  There is currently no indication that FLG contributes to AE in the Bangladeshi 
population, however, it is involved in IV with variable penetrance (Sinclair et al., 2009).  
On the other hand, most of association studies conducted so far on Northern European and 
Asian populations suggested a strong association between AE and FLG null mutations 
(R501X and 2282del4).  This further advances the knowledge of variation within ethnic 
gene association variation with AE. 
There is an increasingly important role for gene-environment interactions.  The challenge in 
the genetic epidemiology is to identify environmental factors that might account for a major 
proportion of AE expression.  Several studies focused on the effect of exogenous 
substances such as irritants, HDM and drugs on patients with AE with genetic changes in 
skin barrier genes function.  Only few genetic studies have considered evidence of 
association between genetic predispositions in the context of exposure to specific 
environmental factors.  To our knowledge, this is the first study to report on the 
environmental and familial factors in AE in children of Bangladeshi origin who are resident 
in the UK. These factors may have a role in the aetiology of AE as well in disease 
exacerbation and remission.  Perhaps, further examination of epidemiological consideration 
in the Bangladeshi families will highlight the interrogating gene-environment interactions. 
6.4 Limitations of this study 
This thesis was conducted before high-throughput genomewide SNP association and DNA 
sequencing technologies were available commercially.  In 2006, the Illumina Goldengate 
genotyping assay performed as part of this study but not a GWAS which was due to 
funding and as a new technology it was expensive to run.  However, the targeted candidate 
gene study has its benefits.  Utilisation of the same data from the Human Genome Project 
(HGP) and HapMap project and technology for GWAS, but on a lesser scale, allowed 
validation of the Bangladeshi population that has been used in this study through the use of 
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previously associated genes.  Although, there are few potential confounding factors which 
would affect the statistical analysis employed in the study, for example, the FBAT output 
did not allow data to be outputted with respect to ORs and relative risk. This suggests that 
low risk AE variants may be present in the candidate genes tested.  In addition, family 
history and genotyping data (Prof D Kelsell, personal communication) indicate that many 
of of the Bangladeshi families are related.  Our statistical analysis in FBAT has not added 
in this factor. Other genetic studies would include exome sequencing of probands from 
such related families (particular those with multiple affecteds n=5+ affecteds) looking for 
identical mutations or sequence variants associated with AE. This approach shares 
similarities with homozygosity mapping with consanguineous families with recessive 
disease.  Also, all epidemiological data were obtained using questionnaires, a subjective 
self-reporting approach which is not the best strategy to obtain such parameters. 
Several polymorphisms in FOXP3, SPINK5 and TNC showed association (uncorrected p-
value) with AE and other atopic phenotypes.  When these gene associations are corrected 
for multiple testing there are no more positive association.  It is important to remember that 
the power in this study is low due to a small sample size.  This means that realistically sized 
effects are perhaps not being detected not because they are not there but because the power 
in the population is too small.  This is true for the majority of studies that examine complex 
diseases (ORs, <1.5).  However, variants genotyped in this study may not contribute to the 
heritability of the disease phenotype tested but that do not exclude the encoded protein from 
playing a role in the pathogenesis of the disease.  Also, failure to replicate previous report 
of significant association might be due to several reasons.  Several studies represent a false-
negative or false-positive associations.  It is crucial to determine whether these studies truly 
replicate each other; populations of similar genetic ancestry, same variants tested in the 
gene, same disease phenotype and similar environmental factors. 
This gene study into both previously associated and novel genes has greatly increased the 
knowledge in AE within the Bangladeshi population but also emphasises the variation of 
genetic association between different ethnicities.  It also lays the foundation for a whole 
genome association study within this population. 
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6.5 New genetic technologies 
Novel fields and applications of high-throughput DNA sequencing have grown beyond 
genomic sequencing as the original development target.  This includes transcriptome 
sequencing which has been used for applications ranging from gene expression and 
alternative splicing, transcript annotation, and discovery of transcribed somatic or SNPs 
mutation to non coding RNA discovery and quantification.  To date, these technologies 
have been applied in different epigenomic areas, including the identification of DNA 
methylation patterns and posttranslational modifications of histons, and nucleosome 
positioning (Morozova and Marra, 2008).  Furthermore, it can be used to study chromatin 
structure in genome-wide mapping of protein-DNA interactions, micro RAN profiling, 
large-scale polymorphism discovery and targeted genomic polymorphism and mutation 
discovery (Shendure and Ji, 2008). 
 
In the last few years, through genome wide association (GWA) studies using commercially 
available new technologies, several loci involving in disease risk have been identified for 
common diseases.  These studies mapped many novel associated loci including diseases 
and quantitative traits such as cancer (Easton and Eeles, 2008), Crohn’s disease (Lettre and 
Rioux, 2008), type2 diabetes (Mohlke et al., 2008), and also normal variation in adult 
heights (Gudbjartsson et al., 2008; Lettre et al., 2008; Weedon et al., 2008).  GWA studies 
have successfully identified multiple loci with associated common variants for many 
different common diseases.  These loci rarely encompass previously-mentioned candidate 
genes, which showed that previously unsuspected biology is important in leading to 
disease.  However, only a small fraction of the known genetic contribution to phenotype 
has been explained by these associated variants.  Further GWA studies in large samples and 
diverse populations will lead to new discoveries in the risk accounted for by identified 
genetic variants.  Evaluation of these novel variants or loci may identify additional alleles 
which demonstrate additional variance in phenotype, allow identification of associated 
gene(s) and provide better molecular and clinical resources for assessing function and 
mechanism of disease.  Also, coordinated assessment of environmental exposures and 
disease outcomes in large cohorts will improve the understanding of human disease biology 
especially atopic diseases.  The most leading goal is to translate all the information of 
genetic predisposition into a greater understanding of molecular process in the pathogenesis 
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of AE in order to facilitate the development of primary prevention and treatment regimes 
for this common disease.  Identification of the candidate genes reported has not been 
translated yet into therapeutic modalities for AE patient although FLG insufficiency has 
theoretical potential as a therapeutic target.  As a result of recent improvement in DNA 
sequencing technologies as well as genetic research, the 1000 Genome Project 
(http://www.1000genomes.org/), has been launched to create a new map of the human 
genome that will present a view of biomedically relevant DNA variations.  The goal of this 
project is to uncover the genetic variants that are present at a frequency of one percent or 
more in the human genome (Biesecker et al., 2009).  
 
6.6 Final discussion and future work 
 
Susceptibility to AE and other atopic diseases is likely to result from the inheritance of 
different mutant genes rather than just a single gene.  As in many other complex diseases, 
in allergic diseases any defects at the cellular or chemical level that cause the disease are 
unknown, inspite of enormous knowledge of molecular pathways involved in disease 
pathogenesis.  By undertaking research into the genetic basis of these diseases, these 
mutant genes and their abnormal gene products may be detected entirely by the specific 
phenotype they cause.  Identifying these genes has provided a greater understanding of the 
crucial mechanisms of these diseases in several ways.  Firstly, identification of 
environmental factors that interact with patient’s genetic makeup to produce atopic diseases 
and confirmation of the role of these factors through Mendelian randomization.  This 
knowledge might help in disease prevention through environmental modification.  The 
second concept is to have greater understanding of the disease pathogenesis.  It is possible 
to put the genes identified in this study as contributing to atopic diseases into four groups 
including; genes that are directly contribute in modulating response to environmental 
exposure, genes that regulate the immune response, other genes involved in determing the 
tissue response to chronic inflammation and finally a group of genes appear to be involved 
in maintaining the integrity of the epithelial barrier after environmental insults.  Also, there 
are various clinical benefits of greater understanding of atopic disease genetic such as 
identification of susceptible individuals at risk and targt them through early life screening 
and preventive therapies.  Moreover, targeting of therapies based on genetic data that allow 
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subclassification of diseases in order to find out specific therapies based on this 
categorisation. 
 
The majority of genetic experiments in common complex diseases such as AE, rely on 
large scale case control studies and integrating the knowledge gained in the present study 
with case control association studies would be of great value.  This thesis has focused on 
the replication and discovery of genes involved in AE in the Bangladeshi families of East 
London.  In order to confirm that, the findings are indeed true, replication is required.  
Another population is needed to screen for associated variants, especially in the novel genes 
such as TNC, JAK3 and KYNU.  As has been observed from previous studies reviewed in 
the first chapter, there is massive variation in associated genes between different ethnic 
populations, thus even if these results were not replicated in different populations it is 
difficult to dismiss that these genes are not involved in AE in the Bangladeshi families.  As 
aresult, a resequencing project would be ideal using the next generation sequencing 
technologies.  This would permit screening of large regions of sequence around and 
encompassing the gene in question and would facilitate the identification of any potential 
causative variants.  Also, exome sequencing might be conducted in a large number of 
individuals.  These methods would hopefully detect any causative variants and help to 
confirm the associations identified in this study.  This would then allow continuation of 
study into functional studies, such as the influence of any identified mutations in cells that 
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GP telephone No. ………………………………………………………….. 
 
Father’s name ……………………………………………... DOB ……./……./……… 
 




 Name    DOB   Sex         Place of Birth 




2/  ………………………………  ……./……./………  ………
 ……………………….. 
 
3/  ………………………………  ……./……./………  ………
 ……………………….. 
 
4/  ………………………………  ……./……./………  ………
 ……………………….. 
 
5/  ………………………………  ……./……./………  ………
 ……………………….. 
 
6/  ………………………………  ……./……./………  ………
 ………………………..  
 
7/  ………………………………  ……./……./………  ………
 ……………………….. 
 
8/  ………………………………  ……./……./………  ………
 ……………………….. 
 
9/  ………………………………  ……./……./………  ………
 ……………………….. 
 






















   Mother Father 
 
 
    








Date of Visit: ........../........./........ 
 
Pregnancy and Birth Details: 
 
Date of Birth: ........../........./........ Sex:   Male         Female        Place of 
Birth:…………………… 
 
Gestation at delivery: |__|__| Weeks  
 
Mode of delivery:   Normal    Assisted (eg. ventouse, forceps)    Caesarian     
 
Birth Weight:  |__|__|. |__|kg         Birth order (i.e. 1st child, 2nd child, 
etc):………………………………. 
 
Did mother smoke during pregnancy?  Yes      No  
                               
Avoid any food /drink during pregnancy? Yes      No  
               





Child’s Medical History 
       
Age at the time of diagnosis of atopic dermatitis:   |__|__| Years 
 
Does the child have any other medical illnesses apart from Atopic dermatitis?   Yes       
No  
      
If yes, please 
specify………………………………………………………………………………………. 
 
Has your child ever had measles infection?   Yes      No  
              
If yes, at what age?: |__|__| Months/Years* 
*delete as appropriate 
 
Family History  
 
Mother:          Age |__|__| Years                     Ethnic origin:  Bangladeshi  Other  
………………….. 
 
Date of moving to UK: ........../........./........   
 
Level of education: Illiterate     Primary school     Secondary school     University     
Postgraduate     
 
Occupation:………………………………………… 
Mother’s medical history:  Hayfever      Asthma      Atopic dermatitis      Food allergy 
   Other        
Father:          Age |__|__| Years                            Ethnic origin:  Bangladeshi  Other  
………………….. 
Date of moving to UK: ........../........./........ 
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Level of education: Illiterate     Primary school     Secondary school     University     




Father’s medical history:  Hayfever      Asthma      Atopic dermatitis      Food allergy 
   Other      
 
 
Parents history of consanguinity:  Yes      No  
  
Sibling/s born in UK:  
   
DOB         Hay fever         Asthma          Food allergy AD       
(tick if affected)  
                                                
 ........./........./........         
 
 ........./........./........         
   
 ........./........./........         
 
 ........./........./........         
 
 ........./........./........         
 
 ........./........./........         
 
Sibling/s born outside UK:  
 
 DOB         Hay fever         Asthma          Food allergy AD           




 ........./........./........         
 |__|__| Years 
 
 ........./........./........         
 |__|__| Years 
   
 ........./........./........         
 |__|__| Years 
 
 ........./........./........         
 |__|__| Years 
 
 ........./........./........         
 |__|__| Years 
 
 ........./........./........         
 |__|__| Years 
 
                                                                                                                                                                                
AD=Atopic Dermatitis 
Nutrition & Diet  
 
Was the child breastfed? Yes      No  If Yes, for how long?      |__|__| 
Months 
      
At what age were solids introduced?     |__|__| months 
Is your child allergic to the following:   




Milk Yes      No  ………………………………………………………
  
   
  
Dairy products Yes      No      
………………………………………………………  
    
  
Eggs Yes      No      
………………………………………………………  
     
Peanuts Yes      No      
………………………………………………………  
        
Fruits Yes      No     
………………………………………………………  
      
Cereals Yes      No     
………………………………………………………  
       
Fish & seafood Yes      No     
………………………………………………………   
         
Other  Yes      No  Please specify: 
……………………………………… 
   
Results of any food allergy test:……………………………………………… 
 
Social History  
 
Type of accommodation: 
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Flat    Detached House    Semi-detached house   Terrace house    Bungalow    
Other  please specify …………….. 
 
Does the family have access to a car?   Yes      No        
 
If yes, how many? |__|__| 
 
How many people live at this address? |__|__| 
 
How many rooms do you have? |__|__| 
 (Not including toilet, bathroom or rooms used for storage) 
 
Of these rooms how many are carpeted? |__|__| 
 




Type of heating:                
   
Central           Electric fire          Wood burner  
              
 Gas fire           Coal fire               No heating                 
 
Other (Please specify) ………………………………… 
Have you moved houses over the last 3 years?      Yes      No                    
 




How did the severity of eczema change after moving?    Got better    Got worse     No 
change  
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Pets 
 
Do you have any pets at home? Yes       No         
 





Name of school/ Nursery :……………………………………………………………... 
 
If in school, what year (e.g. year 4): |__|__| 
 
During the last 3 months, how many days has your child missed school/ Nursery because of 
atopic dermatitis? 
                                                 
  None   1-3 days    4-7 days    8-14 days      15-30 days       more than 
30 days                           
 
                      
Immunisation history 
 
Has the child had the following immunisations?: 
 
Age   Immunisation    If no, reason why: 
Birth  BCG   Yes       No         flares eczema:  other:  
…………………... 
2 months D/T/P + *  Yes       No         flares eczema:  other:  
…………………... 
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3 months D/T/P + *  Yes       No         flares eczema:  other:  
…………………... 
4 months D/T/P + *  Yes       No         flares eczema:  other:  
…………………... 
12 months MMR   Yes       No         flares eczema:  other:  
…………………... 
3 years  D/T/P + MMR Yes       No         flares eczema:  other:  
…………………... 
10-14 years Heath/BCG/Rubella Yes       No         flares eczema:  other:  
…………………... 
15-18 years D/T + polio  Yes       No         flares eczema:  other:  
…………………...  
   
DTP= Diptheria, Tetanus, Whooping Cough 
* = Polio, Hib, Meningitis C 
  If child has been vaccinated against BCG: 
 
At what age?:  Birth      or    |__|__| months     or    |__|__| years 
          
Does the child have a BCG scar?     Yes       No         
 
If child has been vaccinated against MMR: 
At what age?: |__|__| years   
 
What happens to your child’s atopic dermatitis? 
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                                                   Gets better Gets worse No change 
During school exams        
    
During school holiday       
  
During his/her illnesses       
   
During family crises        
 




Does anyone in the family smoke?  Yes       No         
If yes, who? 
 
 Father  Mother   Sibling       Grandfather       Grandmother   
 
Relative who lives with you  Relative who does not live with you   
Seasonal variation 
 
Does your child’s atopic dermatitis change with seasons? Yes       No         
If yes, in which season(s) is it worse?  
 
Spring      Summer      Autumn      Winter     
  
 
In which season(s) is it better?  
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Spring      Summer      Autumn      Winter     
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List of patients selected from different families to search for 





























Sample ID Family ID Member ID Affection* Sex** 
OAG-ECZ-DNA-000337 52 3 2 2 
OAG-ECZ-DNA-000356 55 4 3 2 
OAG-ECZ-DNA-000331 56 4 2 2 
OAG-ECZ-DNA-000380 60 7 2 2 
OAG-ECZ-DNA-000387 61 3 2 2 
OAG-ECZ-DNA-000072 14 6 1 1 
OAG-ECZ-DNA-000306 62 5 2 2 
OAG-ECZ-DNA-000373 64 4 2 2 
OAG-ECZ-DNA-000434 65 3 2 2 
OAG-ECZ-DNA-000440 66 4 2 2 
OAG-ECZ-DNA-000496 80 4 2 2 
OAG-ECZ-DNA-000108 18 7 1 1 
OAG-ECZ-DNA-000487 79 3 2 2 
OAG-ECZ-DNA-000710 71 3 2 2 
OAG-ECZ-DNA-000465 73 4 2 2 
OAG-ECZ-DNA-000485 78 3 2 2 
OAG-ECZ-DNA-000179 32 4 1 1 
OAG-ECZ-DNA-000475 75 3 2 2 
OAG-ECZ-DNA-000704 72 3 2 2 
OAG-ECZ-DNA-000370 58 4 2 2 
OAG-ECZ-DNA-000314 49 5 1 1 
OAG-ECZ-DNA-000457 69 6 2 2 
OAG-ECZ-DNA-000715 70 3 2 2 
OAG-ECZ-DNA-000478 76 3 2 2 
*Affection: 1 not affected, 2 affected, and 3 previously affected 
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P-values for Illumina genotype analysis of TagSNPs in SPINK5 






























Key – AE – Atopic Eczema, FA – Food Allergy.  Blue numbers indicate borderline p-
values.  Pink numbers indicate significant p-values at p ≤ 0.05.  Green numbers 
indicate significant at a gene by gene level.  Red numbers indicate significant at 





SNP Chr:5 AE 
affected 
Asthma AE+Asthma Hayfever AE+Hayfever FA AE+FA 
rs17107705 147419006 0.326 0.178 0.496 0.243 0.601 0.565 0.717 
rs10069070 147420083 0.888 0.865 0.468 0.926 0.563 0.692 0.251 
rs12514503 147426782 0.297 0.391 0.788 0.506 0.656 0.673 0.718 
rs1423001 147430048 0.674 0.733 0.390 0.713 0.639 0.548 0.213 
rs4519912 147431205 0.888 0.865 0.468 0.926 0.563 0.692 0.251 
rs7445392 147431644 0.333 0.417 0.792 0.540 0.615 0.679 0.726 
rs17718511 147431765 0.716 0.411 0.466 0.594 0.443 0.327 0.456 
rs4472254 147433830 0.446 0.311 0.374 0.505 0.656 0.447 0.199 
rs6580519 147454832 0.446 0.311 0.374 0.505 0.656 0.447 0.199 
rs6870820 147455346 0.260 0.312 0.773 0.517 0.493 0.514 0.766 
rs11948406 147455783 0.260 0.285 0.735 0.479 0.453 0.468 0.716 
rs1422987 147466552 0.439 0.429 0.955 0.528 0.898 0.774 0.906 
rs3777142 147467712 0.859 0.785 0.911 0.809 0.944 0.847 0.944 
rs17704764 147468847 0.063 0.046 0.374 0.107 0.297 0.311 0.284 
rs1862442 147469463 0.661 0.626 0.865 0.511 0.759 0.786 0.975 
rs2287768 147471725 0.921 0.755 0.337 1.00 0.424 0.260 0.425 
rs3815735 147474064 0.886 1.00 0.514 0.779 0.636 0.763 0.254 
rs1422986 147474298 0.393 0.243 0.597 0.283 0.650 0.616 0.775 
rs9325073 147478845 0.0076 0.0035 0.0069 0.0023 0.005 0.0099 0.033 
rs1422993 147484013 0.223 0.144 0.439 0.272 0.427 0.116 0.219 
rs4263489 147496388 0.051 0.010 0.121 0.020 0.169 0.245 0.381 
rs7443321 147496516 0.729 0.595 0.893 0.909 0.936 0.905 0.870 
rs4362936 147498582 0.101 0.020 0.199 0.029 0.268 0.424 0.527 
rs4642357 147499563 0.552 0.709 0.752 0.955 0.449 0.415 0.740 
rs12332183 147500903 0.554 0.708 0.738 0.908 0.426 0.467 0.611 
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rs1888221 116818176 0.658 0.653 0.863 0.533 0.867 0.544 0.869 
rs4452883 116819395 0.774 0.785 0.556 0.996 0.739 0.964 0.889 
rs12555312 116819475 0.801 0.921 0.907 0.725 0.944 0.733 0.950 
rs11787664 116821477 0.967 0.882 0.987 0.907 0.968 0.898 0.984 
rs7035322 116826994 0.975 0.952 0.916 0.964 0.991 0.941 0.995 
rs13321 116832404 0.557 0.444 0.743 0.486 0.823 0.488 0.833 
rs10759752 116843541 0.099 0.168 0.309 0.210 0.321 0.139 0.290 
rs1411456 116843703 0.389 0.403 0.607 0.651 0.722 0.464 0.685 
rs7021589 116844488 0.520 0.698 0.791 0.860 0.550 0.825 0.636 
rs11793430 116847941 0.011 0.084 0.021 0.056 0.046 0.022 0.056 
rs2104772 116848606 0.116 0.111 0.261 0.125 0.329 0.084 0.276 
rs2297181 116849857 0.706 0.968 0.420 0.685 0.737 0.637 0.736 
rs2297180 116849979 0.259 0.193 0.493 0.231 0.545 0.191 0.479 
rs11789268 116851026 1.00 0.803 0.876 0.793 0.869 0.793 0.869 
rs1854707 116851617 0.201 0.351 0.489 0.405 0.503 0.276 0.509 
rs11794797 116855094 0.017 0.066 0.022 0.049 0.041 0.018 0.056 
rs4460459 116857147 0.303 0.427 0.475 0.641 0.438 0.475 0.438 
rs1330368 116860847 0.295 0.607 0.571 0.514 0.525 0.261 0.513 
rs7865462 116862935 0.276 0.557 0.562 0.426 0.542 0.195 0.371 
rs16932160 116869808 0.200 0.285 0.419 0.256 0.404 0.180 0.470 
rs955450 116872927 0.318 0.392 0.636 0.576 0.658 0.385 0.619 
rs1330351 116880743 0.872 0.633 0.848 0.756 0.962 0.528 0.592 
rs2989519 116884060 0.724 0.572 0.748 0.679 0.919 0.696 0.936 
rs1757106 116885154 0.888 0.551 0.712 0.808 0.948 0.523 0.576 
rs1755639 116886271 0.629 0.509 0.703 0.747 0.907 0.613 0.515 
rs2274836 116886391 0.599 0.463 0.719 0.716 0.895 0.547 0.491 
rs1617917 116887933 0.749 0.811 0.825 0.926 0.919 0.831 0.965 
rs3827816 116888018 0.182 0.513 0.308 0.297 0.408 0.248 0.411 
rs1757096 116889462 0.663 0.887 0.716 0.777 0.931 0.629 0.916 
rs1271449 116892343 0.793 0.785 0.870 0.919 0.944 0.861 0.977 
rs1330360 116896698 0.566 0.163 0.316 0.330 0.676 0.309 0.596 
rs2988578 116900116 0.795 0.335 0.439 0.498 0.773 0.439 0.699 
rs10982532 116903235 0.695 0.584 0.855 1.00 0.785 0.915 0.717 
rs10982533 116903732 0.538 0.321 0.664 0.314 0.653 0.388 0.755 
rs2183701 116907779 0.409 0.347 0.438 0.609 0.752 0.525 0.275 
rs2482080 116909505 0.849 0.657 0.824 0.860 0.967 0.678 0.766 
rs7029844 116918732 0.011 0.123 0.030 0.032 0.053 0.038 0.059 
rs7030031 116919033 0.929 0.527 0.532 0.655 0.833 0.465 0.564 
rs10118040 116919235 0.974 0.569 0.420 0.658 0.592 0.782 0.845 
rs3748166 116919970 0.0097 0.029 0.025 0.0036 0.018 0.0058 0.029 
rs2071520 116920613 0.851 0.545 0.650 0.668 0.775 0.838 0.912 
rs1537015 116923292 0.787 0.719 0.564 0.859 0.874 0.966 0.879 
rs10982546 116923481 0.929 0.401 0.441 0.382 0.443 0.360 0.334 
rs1335332 116923836 0.625 0.515 0.492 0.647 0.665 0.632 0.608 
rs4246907 116924730 0.929 0.366 0.383 0.321 0.378 0.332 0.304 
Key – AE – Atopic Eczema, FA – Food Allergy.  Blue numbers indicate borderline p-
values.  Pink numbers indicate significant p-values at p ≤ 0.05.  Green numbers 
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